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Colorectal cancer is a major clinical and public health problem.Early stage colorectal cancer
is amenable to surgical intervention with a high cure rate. Screening for the disease has now
been rolled out throughout the UK, although current screening modality of faecal occult
blood testing (FOBT) is suboptimal. Specific genetic alterations found in primary tumours,
including mutations in proto-oncogenes, microsatellite instability and loss of heterozygosity
(LOH), have been shown to be detectable in the host plasma. Colorectal cancer is an
excellent paradigm in which to investigate the application of assays to detect tumour-related
plasma DNA. There is substantial data regarding specific mutations and their frequency in
colorectal cancer tissue and adenomas. The ability to detect early stage colorectal neoplasia
using DNA plasma assays holds considerable promise as a non-invasive screening modality.
Materials and Methods:
Assay performance was assessed using colorectal cancer cell lines and archived material from
genetic studies. Assays were then applied to a prospective cohort of 124 colorectal neoplasia
cases and controls. Plasma DNA was quantified using a sensitive DNA binding fluorescent
dye and detection platform. A well-characterised tumour-specific mutation was used as the
target for the first assay. This mutation was in a poly A tract of the transforming growth
factor beta receptor II (TGFpRII) gene and was assessed using a restriction fragment length
polymorphism (RFLP) assay. Microsatellite analysis was performed using 3 polymorphic
markers relevant to colorectal neoplasia in matched tumour, normal and plasma DNA
samples. A novel assay was developed exploiting real-time fluorescent PCR amplification of
single nucleotide polymorphisms in the adenomatous polyposis coli (APC) gene as a means
to detect tumour-specific allelic imbalance. Assay performance was determined in spiking
experiments, and performance assessed in clinical samples. A further iteration of the assay
was developed to quantify tumour specific alleles in plasma by counting individual alleles
PCR amplified from plasma DNA of cases and controls.
Results:
Quantification of total plasma DNA revealed a significant difference between cases and
controls (area under the receiver operator curve: 0.7). Despite intensive efforts to overcome
the problem, the TGFpRII RFLP assay was affected by technical difficulties when applied to
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plasma DNA. The required high number of PCR cycles introduced artefact and limited its
applicability. Microsatellite analysis demonstrated LOH in matched tumour and plasma
samples with maximal sensitivity of 67% but specificity was only 32%. The quantitative PCR
assay to detect APC LOH was able to detect 3-5ng of homozygous DNA introduced into 1 ml
of heterozygous plasma, and accurately quantified LOH in tumour tissue. However, it was
not able to discriminate cases from controls by assessment of plasma DNA. Counting of
alleles in plasma DNA from a test case demonstrated matching LOH to that seen in the
primary tumour. Allele counting of a further cohort suggested that this approach has a low
false positive rate.
Discussion:
Analysis of plasma DNA is technically challenging due to a low abundance of partially
fragmented mutant DNA sequences admixed with normal DNA in plasma with DNAases and
PCR inhibitors. However total quantity of plasma DNA was higher in cancer cases compared
to controls with good specificity for cancer at high DNA concentrations. Fluorescent
microsatellite analysis of plasma DNA demonstrated encouraging overall sensitivity but poor
specificity that waslikely at least partly a reflection of low DNA abundance and hence
sampling error within aliquots of plasma DNA. A quantitative PCR approach was developed
and validated with relevant levels of in vitro sensitivity, and improved discrimination of LOH
in some clinical samples. Adaptation of this approach to count alleles individually is labour
intensive and expensive but appears to address issues of sampling error due to abundance and
hence improves specificity. These data, whilst highlighting some of the technical challenges






1.1.1 Colorectal Cancer Epidemiology and Environmental Risk factors
Colorectal cancer (CRC) is a leading cause of cancer death in Western populations. The
World Health Organisation (WHO) estimates 945 000 new cases occur annually worldwide,
with 492 000 deaths (i). In the UK there are around 30,000 new cases and 20,000 deaths
annually from the disease (2)(Cancer Research Campaign, Cancer Stats: Incidences—UK
March 2005).In Scotland in 2003 there were 3,365 incident cases of colorectal cancer and
1,582 deaths from the disease (3). 5 year survival rates in the period 1997-2001 were 40.8%
for males and 40.7% for females (3). As a result, colorectal cancer is the third commonest
cause of cancer behind lung and breast cancers, and second only to lung cancer as a cause of
cancer death for both sexes combined. More than 50% ofWestern populations will develop
an adenomatous polyp by the age of 70, and around 1 in 10 of these will develop cancer (4).
Therefore around 5% ofWestern populations will develop colorectal cancer in their lifetime
(5).
Survival rates from colorectal cancer have improved marginally over a number of decades,
and improvements are attributable to a number of factors including improved peri-operative
care and detection modalities as well as the development of adjuvant treatments. Despite
these modest improvements, CRC remains a common and lethal disease with considerable
clinical and public health impact.
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However, the incidence and impact of colorectal cancer is dramatically lower in under
developed countries (6), and the high incidence in developed countries has been suggested to
be partly due to factors in Western diets.
There is conflicting evidence from epidemiological studies as to whether high fibre diets have
a protective effect against the development of colorectal neoplasia. High fibre diets might be
protective by bulking the stool and reducing intestinal transit time hence diluting dietary
carcinogens and reducing the time that the colorectal mucosa is exposed to them. Case-
control studies have suggested a protective effect of high fibre diet (7) which has not been
bourne out in other studies (8:9). High vegetable consumption has also been associated with
reduced colorectal neoplasia risk (10). particularly brassica vegetables (11). Conversely it has
been suggested that high fat diets are implicated in increased risk of colorectal cancer
although again reports have generated conflicting results. Whilst some data have suggested
an association (12) this may be due to confounding lifestyle factors associated with a high fat
diet. Interventional studies utilising low fat diets have failed to demonstrate alterations in the
rate of colorectal neoplasia (13). Increased levels of alcohol consumption have also been
linked with increased colorectal cancer risk, particularly in conjunction with associated
dietary deficiencies (14).
Various other associations between colorectal neoplasia risk and dietary factors have been
postulated including vitamins, salts and trace elements (15) and it seems likely that dietary
risk is a function of complex interactions of multiple interrelated ingested substances, along
with attendant lifestyle factors.(16;17). A summary report of diet and lifestyle factors was
published by the world cancer research fund in 2007 highlighting the relative contributions of
the above factors, as well as other parameters including abdominal fatness and height
(http://www.dietandcancerreport.org/cup/cuiTent_progress/colorectal_cancer.php)
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There is evidence that secondary bile acids may be carcinogenic, and as such the altered
enterohepatic circulation following cholecystectomy may result in prolonged exposure to
carcinogenic stimuli. Metaanalyses of the rate of colorectal cancer following colocystectomy
have indeed shown a mildly elevated risk of colorectal cancer (18), although a cause and
effect relationship has not been demonstrated.
1.1.2 Clinical Aspects of Colorectal Cancer
a) Presentation. Investigation and Staging
The clinical presentation of colorectal cancer is diverse and results in symptoms requiring
attention either electively or as an emergency. Emergency presentation and operative
intervention may be indicated on the basis of tumour obstruction, perforation or bleeding,
whereby surgical management is associated with poorer outcomes both in short and long
terms (19) and particularly with respect to the ageing population with this disease (20). The
cardinal symptoms and signs of CRC that present electively include rectal bleeding, change
in bowel habit, abdominal pain, anaemia and the finding of an abdominal mass, with the
symptomatic picture being dependant on the anatomic site of the tumour. The relative
frequencies of colorectal cancer sites are demonstrated figure 1.1 .Figure 1.1
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Figure l.l legend: Distribution frequency of colorectal cancer at different anatomic sites.
The gold standard diagnostic test for colorectal cancer is direct visualisation and biopsy at
colonoscopy, which is also able to exclude the presence of synchronous tumours.
Investigation of lower gastrointestinal symptoms is also performed using double contrast
barium enema, as well as an increasing role of computerised tomography (CT) colonography,
discussed further in section 1.3.3.
Following a diagnosis clinical pre-operative disease staging is performed with imaging
modalities, most commonly by CT scanning of chest and abdomen, although there remains a
place for plain chest radiography and liver ultrasound to look for distant metastasis. There is
an increasing role for magnetic resonance imaging (MRI) particularly in the assessment of
local extent of rectal cancer to inform the use of neoadjuvant therapy
(http://www.sign.ac.uk/pdf/sign67.pdf).
Surgery remains the mainstay of colorectal cancer treatment and provides the only
opportunity for cure. Excision of the affected portion of bowel along with its arterial supply
(21)
16
and attendant lymphatic drainage with appropriate oncological margins is coupled to
technical considerations regarding restoration of intestinal continuity where appropriate. The
ability to resect all macroscopic evidence of tumour and detailed histological examination of
the resection provide fundamental information relating to prognosis.
Classical staging of colorectal cancer remains the most important predictor of survival
following resection, and informs the role of adjuvant therapy discussed below. The initial
staging described by Dukes (22) remains valid with more recent modifications or
alternatively TNM (tumour, node, metastasis) classification given below in figure 1.2.
Figure 1.2:
Table 7.1: Staging of colorectal cancers
UICC/TNM Modified Dukes'
Stage 0 Carcinoma in situ A
Stage I No nodal involvement, no distant metastasis
Tumour invades submucosa (T1, NO, MO)
Tumour invades musculans propria (T2, NO, MO)
Stage II No nodal involvement, no distant metastasis B
Tumour invades into subserosa (T3, NO, MO)
Tumour invades into other organs (T4. NO. MO)
Stage III Nodal involvement, no distant metastasis C
1 to 3 regional lymph nodes involved (any T. N1, MO)
4 or more regional lymph nodes involved (Any T, N2, MO)
Stage IV Distant metastasis (any T, any N, M1) D
Figure 1.2 legend: AJCC 5th edition TNM staging of colorectal cancer.
http://www.cancerstaging.org/products/ajccguide
A fundamental problem in impacting on the poor outcomes of colorectal cancer is that the
disease commonly becomes symptomatic after the disease is no longer localised, reducing the
possibility of surgical cure. For example in the non-screened arm of the Nottingham faecal
occult blood test (FOBT) screening trial 11, 37, 23 % of cancer cases had Dukes A, B and C
stage cancers respectively, with a further 24% have distant metastasis at presentation (23).
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English data, from the national cancer intelligence network, are given in the table below
along with the 5 year survival following diagnosis of each stage of disease.
Number of cases (1996-2006) and five-year relative survival of















































100.0 100.0 50.7 50.4 - 51.0
b) Adjuvant treatment
Over recent decades an increasing role has developed for non surgical treatment modalities.
These treatments are aimed at reducing the chance of tumour recurrence after potentially
curative surgery, or at symptomatic control where surgery cannot effect potential cure and is
not considered the most appropriate method of palliation. The widespread introduction of
adjuvant chemotherapy has occurred following many randomised controlled trials analysing
subsets of pathological stage disease with various treatment regimes. Several studies have
demonstrated a survival benefit for 5-fluoruracil based regimes in combination with other
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agents (e.g. levamisole(24), folinic acid (25:26)) in patients with lymph node metastases. The
role of adjuvant chemotherapy in patients without lymph node metastasis is less clear. This
has resulted in national guidelines recommending that adjuvant chemotherapy should be
available for patients with lymph node metastasis but not for those without
(http://www.sign.ac.Uk/guidelines/fulltext/67/section9.html#refl65). It is necessary to select
patients that are most likely to benefit from adjuvant chemotherapy, which may result in an
overall survival benefit of around 5-10%, whilst not exposing those who will not benefit from
it to treatment toxicity. Currently the best selection is via classical disease staging, although
biological parameters and biomarkers hold promise for more accurate selection of patients
that need and will respond to chemotherapy. There is also compelling evidence to support the
use of neo-adjuvant radiotherapy in selected cases of rectal cancer, which in conjunction with
the surgical technique of total mesorectal excision results in reduced local recurrence rates
(27). Recently an increasing role of surgical resection of liver metastases has evolved with 5
year survival rates of over 30% in carefully selected populations (28). (29)(30)
c) Approaches to Improving Colorectal Cancer Outcomes
There are several strategies with potential to impact on colorectal cancer mortality in the
future. Primary disease prevention provides an ideal approach by reducing disease incidence
to some degree. To this end there is substantial research activity into substances, such as
aspirin, that reduce rates of colorectal neoplasia (31-33). Similarly identification of further
dietary risk factors and altering ingestion rates in the general population may reduce the
incidence of colorectal cancer, although clearly this is a very large public health undertaking.
Secondary prevetion of colorectal cancer is already well developed with compelling evidence
for colonscopic surveillance of patients who have previously developed colorectal cancer as
well as groups ofpatients at high risk of the disease (34). There is further potential to develop
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this approach by identification ofmore at risk groups with the discovery of additional risk
alleles and modifier genes(35)-
An alternative approach is to detect disease at an earlier stage when more amenable to
surgical cure. To this end there is a wealth of evidence regarding preclinical detection of
colorectal neoplasia by screening and the development of clinical biomarkers that are
discussed further in sections 1.4 and 1.5, and are the basis of this thesis.
Additionally there are continuing efforts to improve the efficacy of treatments following a
diagnosis of colorectal cancer including the evaluation of further chemotherapy agents and




Colorectal cancer is a disease caused by genetic mutation. Alteration of genetic sequences
that code for essential cellular components and control mechanisms result in dysregulation of
these genes and associated pathways. As such cellular processes are altered, resulting in the
affected cell behaving abnormally and ultimately in exhibiting a cancerous phenotype. The
stimulus for genetic mutation causing a change in cell phenotype is exposure to time and
environmental risk factors. However the cells of different individuals are at greatly varying
risk of the mutational stimulus resulting in genotypic and phenotypic alteration. As such the
aetiology of colorectal cancer is multifactorial, with major contributions from genetics and
environment. There is a large body of evidence highlighting the importance of genetics in
CRC from descriptive data on cancer occurrence in relatives of affected individuals, and from
cohort studies ("36). However the relative contribution of genetic susceptibility to the entirety
of colorectal cancer remains difficult to fully elucidate. A Scandinavian twin study
demonstrated that 35% of all colorectal cancer could be attributed to genetic predisposition
(37). Approximately 20% of all colorectal cancer cases occur in individuals with more than
one first or second degree relative also affected (38). Within this proportion there exist
subgroups of patients with an identifiable genetic mutation conferring greatly elevated CRC
risk, constituting hereditary colorectal cancer syndromes. During the expansion ofmolecular
genetic research over recent decades, these subgroups have been subject to extensive
investigation. As such many genotype-phenotype characterisations have been identified,
allowing tailoring of clinical management aimed at improving outcomes. Investigation of
hereditary colorectal cancer syndromes has partially elucidated the pathogenesis of the
totality of colorectal cancer, by identifying important genes in colorectal cancer and
examining their relative frequencies and phenotypic correlations. Analysis of genetic
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sequences from tumour tissue of colorectal and other cancers has identified a number of
genes demonstrated to be important in carcinogenesis including oncogenes, tumour
suppressor genes and mismatch repair genes discussed further below. Additionally genome
wide association studies have identified susceptibility alleles, which engender a less marked
degree of risk, and are the basis for cancer genetic variance.
Cancer genetic variance
1.2.1 Adenoma-carcinoma sequence:
There is considerable indirect evidence that colorectal cancer develops from adenomas, with
a morphological progression from normal epithelium through small early adenomas, large
dysplastic adenomas and frank carcinoma. This evidence includes the observation that the
prevalence of adenomas precedes carcinomas by around 5 years (39) and adenomas are found
at different colonic sites at similar relative frequencies to cancers (40). The benign adenomas
of familial adenomatous polyposis (FAP) have almost identical morphology to sporadic
colorectal adenomas and adenomas in FAP have an almost 100% rate ofmalignant
transformation by the fourth decade of life. Also incidental benign polyps are frequently
found within colonic specimens resected for cancer (41). and cancers are often surrounded by
benign adenomatous tissue, from which they are thought to have arisen. A proportion of
polyps have been shown to enlarge at serial follow up, and cancer shown to develop at the
site of index polyp in a smaller proportion (42). Furthermore large adenomas are more
commonly dysplastic (39). and have a higher malignant potential (43). Significantly removal
of benign polyps has been shown to decrease CRC incidence in high risk populations (34:44).
and in average risk individuals undergoing screening (45). whilst patients with demonstrated
polyps have a higher colorectal cancer mortality rate (46).
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1.2.2 Multistep theory of colorectal carcinogenesis
In the late 1980s Vogelstein (47) proposed a genetic mechanism for the development of
colorectal neoplasia involving sequential mutation at a series of genes, and correlating with
the morphological progression of colorectal adenomas. This group examined the frequencies
of mutations at different stages of colorectal neoplasia, for four common genetic aberrations,
namely Kirsten ras (K-ras) mutation and allelic deletions of chromosomes 5,17 and 18. They
demonstrated that whilst K-ras mutations and chromosome 18 allelic losses were common in
cancer and late stage adenomas, these alterations were rare in early adenomas. They
concluded that these results suggested a model of colorectal carcinogenesis where the steps
required involved the mutational activation of oncogene(s) coupled with the loss of function
of tumour suppressor genes(47). Each mutation is postulated to confer an advantage to that
cell, resulting in a disproportionate excess of the offspring of that cell and its subsequent
generations; clonal expansion. Acquisition of further mutations at different loci within these
cells result in development of further abnormal phenotype, such as uninhibited cell growth,
loss of adhesion and ultimately the ability to metastasise, i.e. a malignant phenotype (48-50).
This multi-step process involving mutational events on both oncogenes and tumour
suppressor genes has been termed chromosomal or genetic instability. Genetic instability is a
defining molecular signature ofmost human cancers (51). and is characterised molecularly by
allelic imbalance, representing losses or gains of defined chromosomal regions (52). and is
now generally accepted worldwide for the development ofmost cancers, with evidence that
genetic instability occurs at an early stage of colorectal tumourigenesis (53). The fundamental
genetic change of LOH occurs where one allele is contained in a chromosomal segment that
is deleted due to mutation, resulting in only the other allele being functional and detectable.
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With respect to the deleted region containing a tumour suppressor gene, function of the gene
is lost when a further mutational event affects the remaining allele.
1.2.3 Tumour Heterogeneity
A controversial feature of colorectal neoplasia is the existence of intratumour heterogeneity.
The multistep theory of carcinogenesis postulates that the step wise accumulation of mutation
results in a progressive survival advantage for the affected cell or clone, and results in tumour
progression and proliferation of that clone. As such early mutational events would be
expected to be observed in all the subsequent clones, and hence a degree of tumour
homogeneity(54)- However there is evidence that intratumour heterogeneity exists in
colorectal cancer. Studies analysing multiple portions of microdissected tumours or
metastases have identified differing genetic aberrations from different portions of the same
tumour. Whilst the extent of this phenomenon remains to be clearly elucidated, its potential to
affect results of analysis ofDNA extracted frombodily fluids which may be derived from any
or all tumour clonesare clear and are discussed further in following sections.
1.2.4 Mutator phenotype pathway
Approximately 15% of colorectal cancers demonstrate an alternative molecular phenomenon
ofmicrosatellite instability (MSI) or replication error positivity (RER+), whereby the
integrity of short repetitive tracts ofDNA (microsatellites) is not maintained (55-57). This is
due to dysfunction of the mismatch repair system, which has a role in the recognition,
excision and repair ofDNA replication errors. Hereditary MSI-H colorectal tumours are due
to an inherited germ-line mutation in mismatch repair genes, whereas sporadic MSI-H
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tumours result from acquired mutations in the same genes, with promoter methylation an
important mechanism. However there is convincing evidence that the classical model of
progression of adenoma to carcinoma is applicable to hereditary non polyposis colon cancer
(HNPCC) CRC. Adenomas predate carcinoma in young HNPCC kindreds, and have also
been shown to demonstrate similar molecular characteristics to HNPCC carcinomas,
including MSI. Importantly surveillance with colonoscopic polypectomy reduces cancer
incidence and improves survival (58), this being the rationale underpinning the identification
of germline mutation carriers. Conversely sporadic MSI-H CRC has been suggested to occur
from precursors other than the classical adenoma. These include hyperplastic and serrated
polyps as well as aberrant crypt foci, on the basis of several factors including the absence of
mutations in sporadic MSI-H CRC which are abundant in adenomas, and the occurrence of
mutations associated with sporadic MSI-H in the above precursors 159:601. The ability to
identify and treat premalignant precursors has been robustly shown to affect colorectal cancer
survival.
When microsatellite stable (MSS), MSI-L and HNPCC MSI-H have been stringently
excluded from analysis, the resultant sporadic MSI-H tumours have been shown to have
reduced frequencies of genetic aberrations in genes including APC, K-ras and TP53, as well
as less frequent LOH of chromosomes 5q, 17p and 18q (61-631. However the differential
frequency of these mutations has not been demonstrated in other studies (641.
1.2.5 Promoter Methylation
Gene promoter regions may undergo aberrant methylation on CpG islands causing
dysregulation of gene transcription. This process can result in epigenetic silencing of genes,
and has been implicated in the pathogenesis of cancer (651. Many tumour suppressor genes
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show evidence ofmethylation silencing, providing a pathway for tumour suppressor gene
inactivation (66)-
There is evidence that promoter methylation is an important mechanism in colorectal cancer,
most specifically in sporadic MSI cancer (67), although aberrant methylation has been
associated with left sided tumours and stage 4 disease (68). with additional evidence of
relevance to prognosis since promoter methylation of genes involved in apoptosis ,such as
hMLHl, can occur in tumour models of resistance to chemotherapeutic drugs (69) There is
also increasing amounts of evidence that promoter methylation is involved more diffusely in
carcinogenesis. For example P 16 methylation is a common feature in neoplasia (70).
including as an early event in lung carcinogenesis (71). and 5' CpG island methylation is
associated with transcriptional silencing of the tumour suppressor pl6/CDKN2/MTSl in
human cancers (72).
Abnormal methylation can be detected using methylation specific PCR, which is sensitive to
in vitro dilution to between 1 in 500 and lin 1000 (73;74). Treatment ofDNA with bisulfite
results in the conversion of unmethylated cytosine residues to uracil, whilst methylated
residues remain unchanged. Therefore following bisulphite treatment the methylated and
unmethylated sequences are different, allowing the design of specific primers that amplify
only one or the other (75).
This technique allows assessment of the methylation status across a broad range of important
genes, dysfunction of which have been implicated in carcinogenesis, and hence provides an
attractive target for the development ofmolecular biomarkers.
1.2.6 Alternate Molecular Pathways
Since the completion of the work presented in this thesis there has been considerable further
progress in understanding the molecular pathways of colorectal cancer. Whilst this largely
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relates to the increasing understanding of the importance of CpG island methylator phenotype
(CIMP), it has also clarified the interrelations of this phenomenon with the pathways
indicated above. As such Jass proposed a new molecular classification of colorectal
cancer(76), which characterises 5 molecular classes , and is presented in the table below with
suggested relative frequencies of each class for the totality of colorectal cancer
Group CIMP MSI Kras APC BRAF Frequency
1 ++ ++ - - + 12%
2 + + or - - - + 8%
3 - + or - + - - 20%
4 - - - + - 57%
5 - ++ - - - 3%
From the above table it can be seen that upto 20% of colorectal cancers may demonstrate
mutation in the B type Raf kinase gene, however this was not appreciatated until after the
completion of this work hence there was no attempt to develop an assay to this marker
1.2.7 Specific Genes in Colorectal Cancer
In relation to colorectal cancer there is a large body of evidence supporting the multistep
model of carcinogenesis and illustrated by mutations observed in genes important in
colorectal cancer described below.
It is apparent that mutational rates at different loci vary, both in relation to patient
demographics (age, sex, site) and also according to stage of disease, a consideration of direct
relevance to biomarker discovery and performance
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a) APC
Studies of affected families identified the APC gene, responsible for the FAP phenotype. The
gene was localised to the region 5q21(77-81). and encodes a 312 kDa protein (82). The APC
protein is multifunctional but primarily interacts with the intracellular protein (3-catenin
which transcriptionally activates downstream genes such as c-myc and cyclin D1. These
pathways are implicated multiple processes including cellular adhesion and chromosome
stability.
APC protein phosphorylates p-catenin (83) resulting in its ubiquitination and degradation,
hence inhibiting cellular proliferation and promoting apoptosis (84). Dysfunction of this
system therefore generates neoplastic cellular characteristics.
Inactivating mutations are classical of those of a tumour suppressor gene, with mutations of
one allele and allelic loss of the other allele commonly found in colorectal tumours of FAP
and sporadic neoplasms. Mutations frequently result in protein truncation, and whilst there is
a relative excess ofmutations in exon 15(85), they may occur at any point of the gene,
making mutation detection laborious.
Aberrations of the APC gene are among the earliest genetic events in colorectal neoplasia
(86). and has been postulated as a gatekeeper mutational event, resulting in adenoma
formation (48). APC mutations have been observed in the earliest histological lesions
associated with colorectal neoplasia (87). and are common in early adenomas (~50%)(48).
APC mutations per se are clearly however not a universal event with some studies
determining mutation rates of between 60-80% in colorectal cancers (85;88). and much
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lower rates of 5q LOH in other reports (89). However the pathway is dysregulated in nearly
all colorectal cancer with epigenetic silencing implicated as an alternative mechanism.
The biological importance of APC is great both in sporadic and familial colorectal cancer and
is highlighted by the familial cancer syndrome FAP. FAP is an autosomal dominant
syndrome, with very high penetrance, caused by germline mutation of the APC gene.
Affected individuals develop multiple colorectal polyps at a young age with inevitable
development of cancer without intervention, as well as a number of clinically important
extracolonic manifestations. One inactivated APC allele is inherited from the affected parent,
and phenotypic changes occur when the function of the second allele from the other parent is
lost by somatic mutation. The inherited mutant allele has relevance to the phenotypic
expression of disease, and provides one of the clearest examples of genotype-phenotype
correlation. For example mutations between codons 1250-1464 produce profuse polyposis
(90). whereas associated desmoid tumours occur with mutations between codons 1403-1578.
b) P53
The p53 gene is located on chromosome 17p, and is one of the most characterised tumour
suppressor genes, having been called the guardian of the genome (91). p53 protein acts as a
transcription factor, influencing multiple genes, and effects G1 cell cycle arrest (92). allowing
either DNA repair or induction of apoptosis (93). Transcription and translation ofwild type
p53 is induced by cellular stress through the protein MDM2 (94). As such p53 helps to
safeguard against the propagation ofmutations to the next generation of a cell's offspring
(95). Mutation of p53 can therefore result in genetic instability, increased cell survival and
inappropriate cell growth, and has long been associated with the development of a variety of
cancers. Germline p53 mutation is responsible for the neoplastic Li-Fraumeni syndrome, and
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examples of sporadic p53 mutation are described for most human cancers, although the
precise mutations may vary according to primary tumour site (96)
Detectable p53 mutations are common in colorectal neoplasms. It has been proposed that p53
mutation occurs at a relatively late stage of the adenoma-carcinoma sequence on the basis
that mutation is relatively rare in early adenomas, but common in carcinomas. Mutations
have been demonstrated in around a quarter of adenomas, in half of adenomas with high
grade dysplasia, and upto three-quarters of colorectal cancers (47:97). In addition to p53
mutations occuring in 70% of advanced colorectal cancer the presence of the mutation has
been reported as an adverse prognostic factor (98).
The mutations of the p53 gene observed in colorectal cancer are classical of those associated
with a tumour suppressor. Therefore it is common to detect allelic loss of 17 p and mutation
in the remaining allele of the p53 gene. Allelic deletions of the short arm of chromosome 17
are observed in around 75% of colorectal cancers, and the region of allelic loss has been
mapped to that containing the p53 gene (99). In the same study the remaining alleles were
shown to contain mutations in a highly conserved region of the p53 gene. Multiple p53
mutations have been observed and whilst there is not a specific mutational 'hotspot',
alterations are commonly located in exons 5-8 of the gene (82)
Allelic deletions are also commonly observed on the long ann of chromosome 17 (17q) in
colorectal cancer having been described in around 40-50% of colorectal cancers (100), and
are commonly been assessed using surrogate analysis with the microsatellite marker
D17S250.
c) Deleted in Colon Cancer (DCC)
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Early landmark studies of colorectal cancer genetics identified that a region on the long arm
of chromosome 18q underwent allelic loss in over 70% of cases (97;101). This region was
subsequently shown to contain a gene, termed deleted in colon cancer (DCC), which encoded
for a protein with similarities to known cell adhesion molecules. Expression was shown to be
decreased in colorectal cancer, with mutations including point mutations and insertions,
which coupled with the high prevalence of allelic loss intimated the presence of a tumour
suppressor gene (49).
DCC appears to be important late in the adenoma carcinoma sequence, mutation occurring
infrequently in small adenomas (13%), but commonly (73%) in cases with carcinoma (47).
DCC loss has also been associated with poorer prognosis (102)
d) Ras
The Kirsten Ras gene is located on the chromosome 12p and encodes a 21 kDa protein, the
function ofwhich is involved in intracellular signalling and hence control of cellular
processes such as proliferation (103). K-ras is primarily involved in GTP signalling by
binding and allowing hydrolysis ofGTP resulting in GDP that in turn inhibits ras protein
activity. GTP initiated intracellular cascade is an integral step in the transmission ofmany
mitogenic signals and effects transcription factors such as c-myc, whose dysregulation results
in abnormal cellular proliferation (104). K-ras mutation results in overactivity of the protein,
allowing continued or inappropriate signal transduction and a hyperproliferative cellular
state. K-ras mutations are also associated with up regulation of other factors thought to be
important in colorectal carcinogenesis such as cyclin D1 (105).
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The frequency of K-ras mutations in colorectal neoplasia specimens has been shown to vary
according to the stage of neoplasia, such that 47% of colon cancers, 58% of large adenomas
but only 9% of small adenomas exhibit mutations (47). As such K-ras mutation is thought to
be important in the transition from an early to a late adenoma, with the initial development of
neoplasia being dependent on other genetic events. Clinically this is an important step as
small adenomas are common and only a proportion are thought to undergo malignant
progression, whereas late adenomas have high malignant potential and detection is
considered a positive endpoint in screening tests.
The relative frequency ofK-ras mutations in colorectal neoplasms and the restricted number
of common mutational sites has made this gene an attractive marker to study. As such the
marker is potentially informative in substantial proportion of cases using a limited number of
molecular assays. K-ras is hence one of the most characterised potential biomarkers in the
putative non-invasive molecular detection methods described in sections 1.4 and 1.5.
e) TGFBRII
An important example ofMSI being implicated in tumour development is TGF-|3 receptor II.
Transforming Growth Factor-(3 (TGF-|3) is a cytokine growth factor that exhibits a negative
effect on epithelial cell growth. TGF-|3 binds to receptors TGF-(3RI and TGF-|3RII at the cell
surface, although the different receptor types may initiate the same intracellular messages or
act as a complex such that mutation of either subunit can result in dysregualtion of signal
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transduction (106). TGF-|3 signalling is transmitted from the cell surface to the nucleus via
the SMAD family of signal transducer proteins. Activated TGF-[3 receptors phosphorylate
pathway restricted SMADs, which then oligomerise with SMAD4 and translocate to the
nucleus and effect transcription and hence the cellular response to TGF-(3(107).
Dysfunction of this system has been shown to result in epithelial carcinoma progression
since:
1) TGF-|3 suppresses the growth of some epithelial cell lines
2) Certain cell lines can become unresponsive to TGF-|3
3) Inhibition of TGF-|3 enhances the tumourigenicity ofweakly tumourigenic cell lines.
(JL08)
However it has been suggested that TGF-|3 has multiple roles in tumourigenesis, acting as a
tumour suppressor at an early stage, but promoting invasion and metastasis in later stage
neoplasms (109).
Of particular interest in colorectal cancer is the existence of a poly A tract within the coding
region of the TGF-(3 RII gene. This poly A tract is a 10 base pair adenosine repeat (Aio) at
codons 125-128 of its 565 codon open reading frame. In the presence of defective mismatch
repair this repetitive tract is subject to short insertions or deletions, resulting in a frameshift
mutation and hence truncation of the encoded protein, rendering it non-functioning. Analysis
of mutations in this Aio repeat in tumour samples from microsatellite unstable colorectal
cancers has shown a high mutational frequency. In one study of 111 MSI tumour cells, 100
(90%) demonstrated mutation of the Ai0 tract of the TGF-|3 RII gene (110). As such analysis
of TGF-(3 RII is an attractive marker for analysis ofMSI tumours.
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1.3 Clinical Screening Modalities
Wilson and Jungner proposed criteria for disease screening in 1968 (111). These remain the
relative requirements to be fulfilled for screening in asymptomatic populations for a given
disease, and are outlined below along with their implications in colorectal cancer.
1) The disease must be important in clinical or public health terms. Clearly colorectal
cancer meets this criterion on the basis of the evidence presented in the previous
section.
2) There should be an available diagnostic test. The gold standard for diagnosis of
colorectal cancer is visualisation at colonoscopy with histological confirmation by
biopsy. Colonoscopy is widely available and routinely practised in first world
healthcare systems, and has high levels of sensitivity and specificity. With regard to
screening tests of the asymptomatic population, colonoscopy has yet to be evaluated
by way of randomised controlled clinical trials. There are a number of alternative tests
in this context, with differing sensitivity, specificity and other performance indicators,
the evidence for which is presented in the following section.
3) The test should be acceptable to screened individuals. The acceptability of proposed
screening modalities is again considered in the following section.
4) There should be an accepted treatment for disease once detected. Resectional surgery
remains the mainstay of colorectal cancer treatment. Long-term survival is related to
disease stage at presentation, and adjuvant treatment may be offered accordingly.
5) Diagnostic and treatment facilities should be available. Westernised societies have
systems for disease management by necessity of the high disease incidence that
becomes clinically apparent without screening. Screening for colorectal cancer has
implications for the demand on these systems and their organisation, discussed under
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each of the proposed screening modalities below. Developing countries with less
advanced health care systems have lower incidence of colorectal cancer, shifting the
cost to benefit ratio, and hence impacting on the rationale and practicalities of disease
screening in these populations.
6) There should be a recognisable latent phase of the disease. There is a large body of
evidence supporting the concept of the adenoma-carcinoma sequence, discussed in
section 1.2. As such benign adenomas or polyps may be considered as pre-malignant
neoplasms, and hence constitute a latent phase of disease. Endoscopic treatment of
polyps is less invasive than resectional cancer surgery, has superior survival, and
additionally may reduce subsequent cancer incidence (34)
7) The natural history of the disease should be known. Much remains to be elucidated in
the detail of the adenoma carcinoma sequence, particularly in terms ofwhich polyps
progress to cancer and the time frame in which this occurs. However the principle of
the adenoma-carcinoma sequence is widely accepted, and the clinical course
following the development of frank malignancy is uniformly poor without surgical
intervention.
8) There should be a consensus on treatment. There is uniformity in the principle of
resectional surgery for non-metastatic colorectal cancer, and also in the application of
endoscopic polypectomy for adenomas. The survival advantage of adjuvant treatment
for lymph node positive colorectal cancer has been clearly demonstrated.
9) The cost of case finding and treatment must be economically balanced. The health
economics of colorectal cancer screening is complex, and is considered in evaluating
current screening modalities below.
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10) Case finding should be a continuous process. This is the case within a defined age
range in the UK FOBT screening programme, but not with proposed once off flexible
sigmoidoscopy.
Other factors that are important when considering screening modalities are the safety of
both the screening test and the action taken on the finding of a positive result, and also the
accuracy of the test which affects the risk benefit analysis of screening.
Screening for CRC has been proposed by the following methods:





These approaches are based on various premises, and each present problems in addressing the
balance of safety, sensitivity, specificity, acceptability and cost effectiveness. The rationale
and available data for proposed forms of colorectal cancer screening are given in the
following section. In addition there are some developmental approaches, based on knowledge
of the molecular genetics of colorectal cancer, which are discussed subsequently.
For any screening programme to be effective, it must be embraced by the populations it is
offered to. Lack of awareness of disease and or a screening test will result in its poor uptake,
and hence limitation of its potential benefits and cost-effectiveness. A survey of knowledge
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and attitudes has been performed in Europe (JT2). This highlighted a lack of knowledge of
the risk factors for CRC, and of the existence of screening tests. Three quarters of over
20,000 people surveyed expressed interest in FOB screening if it were provided free,
although this was a selected population, sufficiently motivated to undergo a health
questionnaire interview. Perceived problems to screening were lack of awareness of risk
(31%), youth (22%) and fear of a painful test (19%). Cultural factors are likely to play a role,
in particular in relation to bowel symptoms, and this heterogeneity was demonstrated with
91% having a reluctance to discussion in Finland compared to 39% in Iceland. As with many
diseases, those most at risk of poor outcomes may constitute those with the least knowledge
of disease and motivation to be screened. These issue remain a major consideration in
contemplating the implementation of CRC screening.
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1.3.1 Faecal Occult Blood Testing (FOBT)
It has been known for a long time that colorectal neoplasms tend to bleed, although the rate of
loss may be sufficiently low that blood is not detectable macroscopically in the faeces, and
for many years attempts have been made to detect lesser degrees of, or occult, blood loss. A
fundamental difficulty in detecting occult blood loss is that colorectal neoplasms may bleed
only intermittently, or not at all, hence limiting the sensitivity of this approach fl 131.
However the approach was popularised in the 1960's with the use of guaiac tests, which
detect pseudoperoxidase activity present in haem. In an early study of 8 patients with
colorectal cancer, only one had a negative FOB test (114), although it was recognised that
multiple samples were required, and a positive test might occur due to any cause of haem
being present in the stool. This included the presence of animal related haem, which
stimulated meat-free diet restriction in a subsequent study. This study demonstrated that the
majority of cancers detected by FOB testing were confined to the bowel wall and hence
potentially curable by surgery fl 15).
The observation that patients with surgically curable colorectal cancer frequently had positive
FOB tests, coupled with its safety and low cost, stimulated interest in this as a screening
modality. An additional postulated benefit was that FOBT might detect a proportion of
benign polyps, a positive FOBT resulting in a colonoscopy and polypectomy. According to
the adenoma-carcinoma sequence, it might therefore be expected that in the long term there
would be less remaining polyps in the screened groups in which cancer might develop, and
hence FOBT might be expected to reduce the subsequent incidence of colorectal cancer.
There is now a wealth of published data, of varying grades, on the impact of FOBT on
colorectal cancer mortality and incidence. There are many series and case-control studies
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supporting benefits ofFOBT in selected populations (116; 117) ((JJ_8). However with regard
to its usefulness as a screening test the highest quality data is provided by population based
randomised, controlled trials ofwhich there are a number that have not only published their
complete initial results, but also with mature, long-term follow up data.
a) Types of FOB Test
Different studies have employed variations of FOBT that warrant consideration prior to
examining the evidence generated from those trials. The most reliable and high quality, long
term data have been generated using guaiac tests, generally not hydrated, with follow-up of a
positive test by colonic imaging. As such the results of smaller series with modifications of
the type of test employed must be interpreted with caution. A joint committee representing
the WHO and the World Organisation for Digestive Endoscopy (119) concluded that no
single type ofFOBT was applicable across all populations, and that the balance between
sensitivity and specificity should take into account the availability of colonoscopy services.
Guaiac tests are prone to false negative results for a variety of reasons, including the presence
of peroxidase containing food in the faeces, which can be reduced by dietary restriction
(120). Rehydrated FOBT results in a higher positivity rate, hence improving sensitivity but
decreasing specificity as demonstrated by the high positivity and hence colonoscopy rate in
the Minnesota study described below (121). and similar results have been demonstrated
elsewhere (122). Whilst increased sensitivity is desirable, in the context ofpopulation
screening the sacrificed specificity results in increased demand for colonoscopy that impact
both the safety of and ability to deliver a screening program. Practical difficulties in
interpreting the test can be lessened by alteration of the developing agent, such as with
HOSENSA (120). although the impact on sensitivity and specificity may be similar to that of
rehydrated Hemoccult (123).
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Immunochemical tests (ICTs) have the theoretical advantage of being unaffected by other
sources of faecal peroxidase, but are substantially more expensive. There is a lack of data
comparing ICTs to guaiac tests with respect to CRC mortality and ICTs have not to date
fonned the basis for implemented screening pilots or programs. There are data that ICTs may
have marginally better sensitivity than guaiac tests, that is not at the expense of
specificity,(122U24) but the levels are comparable and the additional expense and need for
laboratory development appear to have limited the use of these tests. However studies
employing guaiac and ICT tests have suggested that a combination of the two types of test
might improve accuracy (125). Additionally automated reading ICT tests are now available,
with comparable performance characteristics, which may improve usability (126). Blood
related markers other than haemoglobin have been examined in stool in including calprotectin
(127)and lysozyme (128). However these do not appear to result in improved cancer
detection rates when compared to FOB testing (129).
b) Large Randomised Controlled Trials
The results from the three largest RCTs of FOBT are summarised in the table below:




USA 48.000 2.4 (unrehvdrated)
9.8 (rehvdrated)




UK 150.000 2.1 (unrehvdrated) 52 vs 44 Biennial 15%
Denmark 62.000 1.0 (unrehvdrated) 56 vs 48 Biennial 18%
i) Minnesota
The first large randomised controlled trial ofFOBT was the Minnesota study, published
in 1993 (121). This was a study of over 46,000 volunteers, aged 50-80, who were
randomly assigned to receive either standard care (control group), annual FOB testing or
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biennial FOB testing, with 83% of tests rehydrated. 46,551 subjects aged 50-80 were
offered either 6 or 11 FOBTs over the course of the study period.
ii) Nottingham
A larger population based was the Nottingham trial with nearly 153,000 recruited
participants, aged 50-74, generated through general practitioner registers (23). There were
approximately 75,000 controls, who were not contacted or given information about the
study having been randomly allocated to be controls, although eligible members of the
same household were allocated to the same arm of the trial. 75,000 individuals in the
biennial screening group were sent haemoccult, and asked to test 2 samples from each of
either 3 or 6 consecutive stools. FOB tests were not rehydrated and dietary restriction was
employed prior to retesting only for participants with a borderline initial result. The
median follow-up was 7.8 years.
Hi) Denmark
A further population based from Denmark enrolled 140,000 45-75 year olds, allocating
30,967 to the screening ami of the trial to receive biennial FOB screening (130).
c) Outcomes
i) Mortality
The primary outcome measure of screening programmes is that of death rates both in terms of
disease specific and overall mortality. In the Minnesota study colorectal cancer mortality was
significantly improved, with the cumulative 13 year CRC mortality per 1000 improved from
8.83 (7.26-10.40)) in the control arm, compared to 5.88 (4.61-7.15) in the annual screening
group compared, with a non significant difference in the biennial screening group (8.33
(6.82-9.84)) (121). In the Nottingham study, the disease specific survival was significantly
better for individuals in the screening group compared to the control group (p<0.0001).
However all cause mortality was not different between groups, presumably reflecting that
death caused by colorectal cancer in the population is an infrequent event (2% of all deaths)
and hence for a study to have sufficient power to demonstrate an effect on overall mortality,
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the sample size would have to be very large (131). The size of the survival advantage in the
screening group depended on whether the cause of death was taken as that on the death
certificate, or that verified by the study group. Using verified deaths there was a 15%
reduction in disease specific mortality- odds ratio 0.85 (95% CI: 0.74-0.98) p=0.026. Using
certified cause of death the confidence interval just straddled 1.0. The greatest CRC mortality
reduction was seen in those in the screening group who accepted their first invitation for
FOBT, with a 39% reduction (odds ratio 0.61 (95% CI: 0.50-0.74), whereas those who
refused their first FOB test had a non significant increase in their CRC mortality. The
difference in colorectal cancer mortality started to become apparent at 3-4 years after
recruitment into the study.
In the Nottingham study the same number of cancers were detected by FOB screening (236)
as were diagnosed subsequently after a negative FOB test (false negatives), demonstrating the
limitations of the test. However the stage distribution was significantly improved in the
screened group. There was both a higher proportion of earliest stage disease 20% versus 11%
(p<0.001), and a lower proportion of late stage disease (Dukes C and D) 46% versus 52%
(p<0.01). The incidence of advanced CRC was also lowest in those who accepted their first
screening invitation, with a ratio of 0.76 (95% CI: 0.63-0.93).
Ahlquist (132) has argued that the deleterious effects of screening are responsible for the
absence of an overall mortality reduction in the screened groups, with the benefit being
restricted to disease specific survival. He suggested that false negative results are falsely
reassuring resulting in delayed presentation and poorer outcomes for those with cancers
missed by the poor sensitivity of FOBT. However analysis of interval cancers in the
screening group, i.e. those who declined testing or those with a falsely negative test,
demonstrates that these cancers have a similar stage distribution to controls, and that survival
following interval cancer is actually better than cancers in the control group (p<0.01)(131).
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However there is clearly a difference between individuals who were motivated to attend for
screening and had a falsely reassuring test, than those who did not take up the invitation to be
screened, yet these patients were included together in the analysis of the interval cancers.
Additionally Ahlquist postulated that screening detects a subset of 'innocuous' cancers that
were not destined to injure that patient in their remaining lifetime, and hence produced an
'overdiagnosis' bias of indolent cancers in the screened population. The authors of the
Nottingham study refuted this with data on screening participants who subsequently died
between 30 days and 2 years after surgery. This was a small group the majority ofwhom
(26/36) died of recurrent colorectal cancer. Analysing those initially found to have either
advanced adenomas or Dukes A cancers, there were 6 individuals, all of whom died of causes
unrelated to colorectal cancer. They postulated that there were only 6 patients in their very
large trial who would likely have died of other causes before presentation of their colorectal
neoplasia, and hence that 'overdiagnosis' was not a significant problem. Subsquently the
Nottingham group reported on all deaths within the trial groups, showing that significantly
more people died from verified colorectal cancer in the control group compared to the FOB
arm (133).
ii) Test Performance
The Nottingham study did not generate figures for sensitivity or specificity of FOB testing,
however the positive predictive value was 12% for colorectal cancer and 46% for all
neoplasia.
The overall sensitivity in the Minnesota study was around 85%, with improved performance
with multiple tests, rehydrating specimens and dietary restriction. However whilst this
sensitivity is impressive, the positive predictive value of FOB testing for CRC was only 2.2%
in this study, which is likely partially a reflection of the rehydration of the FOBT slides (121).
compromising specificity for improved sensitivity.
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Other studies that have specifically assessed the performance characteristics of FOBT have
generated sensitivity figures of around 50% (134), with generally high specificity at over
90% depending on the type of test used (125).
Hi) Colonoscopy Rates and Risk
Whilst FOBT in itself is an extremely safe test, the implication of a positive result is to
undergo bowel visualisation, predominantly by colonoscopy, which is not without risk.
Indeed any benefits of screening by FOBT are derived from interventional investigation and
treatment.
In the Minnesota study 38% of those screened annually, and 28% of those screened
biennially underwent colonoscopy at least once, a much higher colonoscopy rate than in other
randomised controlled trials where the colonoscopy rates were under 5%. Critics of the
Minnesota study suggest that observed benefits in the screening group occurred as a result of
nearly a third of that arm undergoing colonoscopy rather than as a result of the effectiveness
ofFOBT (121).
In the Nottingham study 4% of patients (1778 out of 44450) who underwent at least 1 FOBT
underwent colonoscopy on at least 1 occasion. Whilst this a greatly reduced proportion to that
seen in the Minnesota study, when extrapolated to the general population as a whole this
constitutes a dramatic increase in demand for colonoscopy.
In the Nottingham trial the complication rate of colonoscopy was 0.5%, the majority ofwhich
required surgery, but none ofwhich resulted in death. 5 patients died within 30 days of
surgery for screen detected colorectal cancer, and a further 2 died without any surgery (131).
However these figures included only colonoscopies that directly resulted from a positive
FOBT. Clearly positive findings at initial endoscopy might clinically warrant further
procedures, with a similar level of risk, but the figures from these follow-on procedures were
not included in this analysis.
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However one of the strengths of FOBT is its high specificity, hence resulting in relatively few
unnecessary colonoscopies compared to other modalities, albeit at the expense of sensitivity.
iv) Uptake
The acceptability of a screening modality is fundamental to its potential to have impact on the
disease in any population. This may be especially the case for colorectal cancer screening
using modalities reliant on faeces, which may have a level of stigma associated with it that
varies across societies.
Compliance was high in the first randomised controlled trial to report, with 75% of the annual
screening group and 78% in the biennial group accepting screening. There was a level of
drop-out from this with 83 and 84% of test positive subjects undergoing diagnostic follow-up
either by colonoscopy or flexible sigmoidoscopy and barium enema (121). However the
Minnesota trial studied a volunteer population, who by their nature constitute an interested
and motivated group hence limiting the applicability of these figures to population screening.
Indeed in the population based Nottingham trial only 38.2% of the screening group
completed all the FOBTs they were offered, with 21.4% completing at least one but not all
and 40.4% of invited subjects did not complete any FOBT.
As such, uptake by the general population was less than 60%, for any test at all, and just over
a third for complete compliance with testing. Therefore around half of the potential
population benefit of screening could not be realised. The reasons for the low uptake are
likely multifactorial, as reflected in the wide variation in compliance rates in participants
from different general practices (29%-74%). Partly it is likely that poor disease awareness,
and lack of understanding of the screening test and process may cause a degree of apathy in
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the asymptomatic population. These considerations are likely to be less of a factor now than
during the time frame of the study period due to increased publicity of colorectal cancer
screening, and health promotion with regard to colorectal cancer in general. This may partly
be reflected in the increased compliance between the pilot study (36.9%) and the study proper
(57.0%)
However it seems likely that there is a reluctance to perform faeces based testing in the
community. Clearly having to collect individual stools, and then smear portions of that stool
onto slides is not an attractive proposition, particularly for people who feel well and do not
perceive themselves to be at great risk of a given disease. Use of tests which are easy to use
and are self reported by the individual have not been shown to increase compliance rates
(135). Additionally a requirement to undergo dietary restriction has been shown, in some
studies to impact on acceptability, rising where not required from 53% to 66% (136),
although a meta-analysis suggested no difference in completion or positivity rates with mild
dietary restriction for non-rehydrated guaiac tests.
Initial compliance rates in the Danish study were higher than in the UK at 67%. The Danish
study did not re-offer screening to those who refused the first invitation. Unsurprisingly
therefore their screening group became a selected and motivated one, with 90% accepting
repeat screening.
d) Metaanalysis
There have been meta-analyses of data from controlled trials of FOB screening with
haemoccult (137; 138) including using intention to treat analysis, and analysis according to
whether screening was actually performed.
Identified were the 3 randomised trials described above, plus a further scandanavian study
(139). and 2 non-randomised trails (140:141). In all trials there was part of the protocol that
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included dietary restriction. The majority of trails had non-rehydrated tests giving a lower
positivity rate and higher positive predictive value for cancer (5.6-17.7%), compared to
rehydrated tests (positive predictive value 2.2-4.2%). The sensitivity of FOBT ranged from
46% unhydrated (130) to 92% rehydrated( 121), and was defined as screen detected cancers
over all cancers in screening group within 2 years. Cancer related mortality reductions in
each of the trials were comparable and formal testing confirmed a lack of heterogeneity.
Therefore mortality results were combined to give a reduction in disease related mortality of
16% (relative risk 0.84 95% CI: 0.77-0.93) rising to 23% for those who actually underwent
screening (relative risk 0.77, 95% CI: 0.57-0.89). The number needed to screen in order to
prevent 1 death from colorectal cancer over 10 years was 1173 (741-2807), and would relate
to between 20 to 800 colonoscopies per life prolonged. At the time of the meta-analysis only
medium term data was available (8-13 years) and at that time there was no apparent effect of
screening on CRC incidence. Since then longer term results have been published and are
described below.
e) Long Term Follow Up
The long-term data for the Minnesota study was published in 2000 (45), totalling 18 years of
follow-up. Whilst at 12 years follow-up there was no significant reduction in colorectal
cancer incidence, by 18 years there was a statistically significant reduction in cancer
incidence in those subjects undergoing either annual (cumulative incidence ratio 0.80 (95%
CI: 0.70-0.90) or biennial (0.83 (95% CI: 0.73-0.94)) FOBT. Completeness of 18 year
follow-up data was excellent, being over 90% in each of the three groups, and cause of death
was accurately ascertained for essentially all participants who died. It is important to
highlight that although the study completed in 1992, those patients who had positive findings
upto that point, continued to have surveillance as deemed clinically appropriate. Therefore
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the 'protective' effect of screening was not derived only from the period of study, but also
from continued follow-up and endoscopic intervention. These benefits occurred despite a
period during the study of around 4 years, where screening did not occur, and which
presumably would likely attenuate the effects of screening on colorectal cancer incidence.
The longer term mortality results from the Nottingham study (142) demonstrated that the
reduced CRC mortality in the screened group (on an intention to treat basis) was maintained
at a median follow-up of 11 years, being a 13% reduction in the screening group as a whole,
rising to 27% for those who actually accepted screening.
0 Psychological Aspects of Screening
Screening tests may have psychological impact on individuals offered testing, and
particularly those with positive tests(143). With relation to FOB screening, individuals'
psychiatric morbidity has been evaluated by questionnaire, and found not to differ before the
offer of screening compared to 3 months afterwards (144). The anxiety of a positive test
result may be unavoidable for true-positives, but is a particular disadvantage for poorly
specific tests by creating unwarranted anxiety in false-positives. However this anxiety was
shown to be short lived in a small sample of individuals, falling the day after the index
investigation that demonstrated them to be false-positive (Parker MA).
g) Implementation and Cost Effectiveness
A Dutch group concluded that screening with FOBT met criteria for disease screening and
should be implemented on a national basis (145). In addition to the large population based
trials of FOB screening described above, there is now data derived from screening pilot
schemes in areas of the UK (2), such thatthere is nationwide implementation of population
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based FOB screening for CRC in the UK. Many international health agencies have issued
guidelines for colorectal cancer screening including the WHO 019).
Clearly widespread implementation of screening programmes requires the screening test to be
cost effective. Evaluation of data from the Nottingham trial suggested that FOB screening has
comparable cost-effectiveness to breast cancer screening, which is widely established in
developed countries. Combination of the impact and costs of FOB screening in a
mathematical model to generate quality adjusted life-year gained, estimated cost-
effectiveness to be similar in the short term and superior in the long term compared to breast
cancer screening (146). Later analysis of the complete data from the same trial, calculated the
cost of screening to be £5290 per cancer detected and £1584 per life year gained (147). This
compares favourably with costs of breast cancer screening elsewhere in Europe, which had
costs of £10365 per cancer detected and £8561 per life year saved (148). Clearly the
accuracy and particularly the specificity of the means of testing impact cost-effectiveness,
and the costings given above where generated from non-rehydrated tests with high
specificity.
Data from an earlier American study (149) again suggested that annual FOB screening was
affordable, with a cost of $20 per person screened per year, including follow-up testing of all
positive findings. Addition of 5 yearly sigmoidoscopy to screening increased the cost 2.5
times taking into account only direct costs. Estimated cost of each life day gained was $57,
equivalent to $20805 per life year (~ £12238 at 1.7 dollars to the pound). Clearly the health
economics differ between the UK, where services are free at point of access, and the USA.
The cost of screening tests in the USA does not however appear to be the main determining
factor in uptake ofCRC screening (150).
49
Despite the cost effectiveness ofCRC screening compared to other screening programmes,
implementation of national screening programmes certainly alters the need for CRC services.
Some of the effects of FOBT screening studies have been beneficial in this regard, including
decreasing the amount of emergency admissions with the disease (151). However demand on
diagnostic and follow-up services is substantially increased by individuals returning a
positive FOBT. A study ofUK pilot study areas demonstrated a 20-30% increase in
colonoscopy activity, with associated increases in pathology and outpatient demand (152).
There is a further 28% increase due to follow up colonoscopy after positive findings at index
investigation. Whilst there is a suggestion that this demand improves the quality of
colonoscopy services, and may reduce cancer incidence in the long term, this dramatic
increase in workload necessitates planning and provision of resource in areas implementing
population screening, which may be predicted by modelling(153).
Modelling of implementation in Canada (154) using an actuarial model in the age group 50-
74, postulating screening from 2000-2010 using unrehydrated tests on either an annual of
biennial basis. Over 10 years they estimated that 4,444 and 2,827 CRC cancer deaths would
be prevented for annual and biennial screening respectively, needing 3,400 and 2,700 FOB
tests respectively to prevent each death.
FOBT screening has now been rolled out in the UK. Prior to this,large scale pilot schemes
had been undertaken in a population of around 1 million, with close to half that offered
screening (2). 56.8% of participants offered screening accepted, and the test positive rate was
1.9% (and hence over 5000 colonoscopies). Encouragingly 48% of the 552 screen detected
cancers were Dukes A (with 92 of these being polyp cancers) and only 1% had distant
metastasis at diagnosis.
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Therefore population based FOBT screening is a reality, and despite the limitations of the
test, and the attendant health delivery and cost implications, there are clear clinical and public
health benefits as demonstrated from several randomised controlled trials.
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1.3.2 Endoscopy
One approach to colorectal cancer screening is by direct visualisation of the colorectal
mucosa at endoscopy. Colonoscopy remains the gold standard for detection of colorectal
neoplasms in clinical practice, with utility for foreshortened examinations by way of rigid and
flexible sigmoidoscopy. Extrapolation of these techniques to screening asymptomatic
populations is not however straightforward on account of the degree of risk associated with
these tests as well as the costs and ability to deliver these investigations, which require skilled
operators to perform, on a large scale.
a} Sigmoidoscopy
The extent of sigmoidoscopy is limited to essentially the left colon for flexible
sigmoidoscopy and the rectum for rigid sigmoidoscopy. These approaches can therefore only
expect to detect a proportion of all colorectal cancers, although left sided cancers are
preponderant, and particularly so within certain epidemiological groups.
i) Detection rates
The MRC/ICRF prospective randomised controlled trial of screening asymptomatic
populations using once only flexible sigmoidoscopy trial has recently reported(J_55).Initial
results of the yields of testing were published previously, both for the whole study (156) as
well as a subset (157). Adenomas were detected in 10% and 12.1% of screened individuals in
the subset and whole study respectively. Cancer detection rate was 0.7% and 0.3%
respectively with a referral rate for colonoscopy for the subset of 6% (similar to that of
FOBT). 55% and 62% respectively of screen detected cancers were Duke's stage A.
Projections of the impact of flexible sigmoidoscopy screening in the UK suggested that it
would prevent 5500 cases and 3500 deaths annually, thus saving 40,000 years of life (158).
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Proposed examination interval has been 5 years, with little postulated benefit from more
frequent examinations, from data generated from a cohort study that generated annual CRC
incidence for the first 5 years after a negative sigmoidoscopy (159). However flexible
sigmoidoscopy is unable to detect neoplasms that are not left sided (160), and also distal
colonic findings are not a good predictor ofmore proximal neoplasms, resulting in a
sensitivity of 44% in one study (161).
ii) Protective effect
Previously case controlled studiesof sigmoidoscopy suggested a reduction in the risk of
developing fatal cancer of around 60%, limited to cancers within the reach of the endoscope
(162)..Another studv(164) investigated whether flexible lower GI endoscopy protected
against the development
of cancer, showing a risk reduction with an odds ratio of developing cancer of 0.51 (95% CI;
0.44-0.58) for colon cancer and 0.55 (95% CI; 0.47-0.64) for rectal cancer.
There s now however level 1 evidence of the protective effect of once only screening flexible
sigmoidoscopy from the MRC trial (155), with a 23% overall reduction in colorectal cancer
incidence at median 11 years follow up, and with numbers needed to be screened to prevent
cancer diagnosis or death of 191 and 489 respectively.This benefit was greater still when
analysed for those who underwent screening, and for distal tumours.
Hi) Other considerations
Compliance for flexible sigmoidoscopy based screening programmes is likely to be poorer
than that of non-invasive screening tests on account of the potential for discomfort and the
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need for bowel preparation. A study of over 6000 asymptomatic patients compared screening
by FOBT with screening by a combination of FOBT and flexible sigmoidoscopy (165).
Whilst they concluded that the yield for neoplasia was 4 times greater with the combination
of tests, compliance was 48% for the FOB portion of the combined arm, but only 20% agreed
to flexible sigmoidoscopy. A study comparing FOBT and flexible sigmoidoscopy in 55-56
year olds, had an attendance rate of 59% for the FOBT arm compared to 49% in the flexible
sigmoidoscopy arm (166). The initial compliance results of the ICRF/MRC randomised trial
demonstrated that 23246 offered screening flexible sigmoidoscopy , around 60% expressed
interest, but only 75% of these attended, giving an uptake of only 45% (157). although for the
whole study attendance was stated as 71% (156). Recently an assessment of the barriers to
screening flexible sigmoidoscopy identified a lack of awareness of bowel cancer, and fear of
test invasiveness and of cancer diagnosis as relevant factors across ethnic
groups( 167).FIowever of 4422 individuals attending flexible sigmoidoscopy screening in the
context of a multicentred randomised controlled trial, 99% reported that they were glad they
had the test, and 91% that they had only mild or no pain (168).
Flexible sigmoidoscopy is variable in aspects of the examination including the amount of
colon visualised, the degree of discomfort caused to patients and the interpretation of results.
Whilst guidelines have been generated to minimise heterogeneity of examination quality
(169). considerable variation exists. Within a large randomised controlled trial there was wide
variation in the adenoma detection rates between centres, thought to relate to endoscopist
performance and related to screening experience (170). In relation to patient factors, a study
in asymptomatic volunteers demonstrated that the procedure was classed as difficult in 33%
of cases (171). and that length of insertion related to being female and having previous
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surgery, as well as poor bowel preparation. Indeed women who have undergone hysterectomy
may have technically more difficult procedure (172), resulting in significantly more pain and
shorter distance of insertion, also resulting in a significant trend toward lower relative
detection rates.
Factors resulting in sub-optimal flexible sigmoidoscopy will impact on the efficacy of
flexible sigmoidoscopy as a screening test, and these considerations should be included in
projections of performance and cost-effectiveness.
Flexible sigmoidoscopy is relatively expensive in comparison to FOBT. The direct costs of
performing once-off flexible sigmoidoscopy have been published and were estimated at £56
rising to £91 when considering the cost of subsequent management, with additional cost also
incurred to the patient (173). A mathematical model of the costs of flexible sigmoidoscopy
screening suggested the cost would be around £80 per person invited, or £117 for those
undergoing screening given an optimisitic compliance rate of 70%, and estimated the cost per
life year saved to be £2889 (1741. This compares to estimated cost, within a different time¬
frame in a different health care system, of $20 per person screened per year, including
follow-up testing of all positive findings (149). Within the UK there is evidence that flexible
sigmoidoscopy with or without FOB testing is a potentially cost effective strategy for the
early detection of colorectal cancer (175).
b) Colonoscopy
There are no randomised controlled trials of population screening using colonoscopy,
however it has been adopted as the modality for screening in some countries including the
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USA and Germany (176)according to guidelines from several leading gastroenterology
societies (177).
There are theoretical advantages of screening using colonoscopy, including its high cancer
detection rate along with its evident sensitivity and specificity. That said, there
is a definite failure rate, with one study of back to back colonoscopies for 183 patients
showing an overall miss rate for adenomas of 24%, albeit predominantly for adenomas less
than 5mm in size (178). That said, whilst there is a potential for FOBT to detect left sided
tumours more sensitively than right sided ones(T79), complete colonoscopy visualises the
entire colorectal mucosal surface. Colonoscopy with polypectomy has the advantage of being
therapeutic, with removal of adenomatous polyps implicated in a reduction in CRC incidence.
Evidence to support this includes a cohort study of patients who had undergone polypectomy,
compared to patients who did not undergo polypectmy and a population based reference
group, resulting in an up to 90% reduction in incidence (34) as well as reduction in incidence
in high risk groups such as HNPCC (180). Clearly these groups are at higher CRC risk than
the asymptomatic population, but in the absence of data from a randomised asymptomatic
population trial aimed at detecting an incidence reduction rather than initial cancer detection,
the inference remains that polypectomy reduces colorectal cancer incidence.
There have been a number of case-controlled studies of screening colonoscopy.
A retrospective study of 40-49 year olds determined the prevalence of colorectal lesions
found at screening colonoscopy, for 906 asymptomatic individuals, in which 3.5% had
advanced neoplasms and none had cancer. They extrapolated that between 250 and 1000
examinations would be required to detect one cancer in this age group, and concluded that the
low yield supported screening not being offered to individuals under 50. (181).
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A further study ofwomen aged 50-79, consecutively referred for CRC screening, and also
40-49 year olds where a first degree relative had CRC, assessed colonoscopic screening of
'average risk' women for colorectal neoplasia 082). This study excluded patients with a
positive FOB within 6 months, symptoms that might be attributable to CRC, or colonic
visualisation within 10 years. The study used distal colorectal findings as a surrogate for
flexible sigmoidoscopy. Of 1593 eligible patients, 1483 (93.1%) participated, although all
those approached had been referred for screening, therefore these acceptance rates are not
suitable for extrapolation to the general population. The colonoscopy completion rate was
98.7% with no complications of colonoscopy. 4.9% of patients had either large / advanced
polyps or CRC. The yield increased with age and with a family history of CRC.
Distal colorectal findings would have had a yield of only 1.7% (missing 3.2%), and this
'flexible sigmoidoscopy' yield did not vary with age or family history.
Ifpositive distal findings had gone on to trigger colonoscopy, then 94% of cases of advanced
proximal neoplasia would have been missed (47/50), therefore they concluded that distal
findings at flexible sigmoidoscopy are not a good predictor of those needing a colonoscopy.
The study authors concluded that colonoscopy was the preferred method of screening
women.
The parallel study to the one in females described above was in men aged 50-75 (183). Men
have a higher prevalence of colorectal neoplasia (160). and hence benefits might be expected
to be greater.Taking the results from Lieberman's and Schoenfeld's studies and comparing
men and women without a family history and with a negative FOBT, the diagnostic yield in
men was significantly higher (66.3%) than in women (35.2%) (p<0.001). The study ofmales
was of a fairly highly selected group ofmen (3196 enrolled from 17,732 patients screened for
enrolment) had a yield of 10.5% for advanced adenomas and 1% for cancer. Of those which
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advanced proximal colorectal neoplasia, 48.4% had some sort of adenoma in the distal colon,
falling to 37.9% if the distal colon was quantified as the sigmoid and rectum only.
However whilst colonoscopy remains the gold standard for diagnosis of colorectal cancer,
including as a follow up test for other positive screening modalities, there are a number of
considerations when applying it to screening asymptomatic populations.
Clearly colonoscopy is invasive, requires bowel preperation, and can be uncomfortable for
patients, all of which are likely to impact on acceptability and hence compliance. There are
studies suggesting colonoscopy is a safe form of screening with major morbidity related to
colonoscopy in 0.3% (9 of 3196) procedures and 0.1% in only diagnostic procedures (184),
none ofwhich were perforations. However perforation rate at colonoscopy is generally
accepted to be in the region of 0.1% along with a small but undeniable risk of mortality
(185). Therefore higher morbidity and mortality would be expected to occur as a result of
colonoscopic population screening compared to non-invasive methods.
There are also delivery and cost implications for colonoscopic screening, although whilst
colonoscopy is expensive when compared with sigmoidoscopy in absolute terms, there is
evidence for better for cost per neoplasm detected (186).
Given the safety, cost and logistical implications of population based colonoscopic
screeningthe UK screening programme, and others, advocate the use of therapeutic
colonoscopy for other screening test positive individuals.
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1.3.3 CT Colonography
Over recent years adaptations of conventional CT have been developed that allow more
detailed visualisation of the colon, including detecting intraluminal pathology. This technique
has variously been termed virtual colonoscopy (VC) and CT colonography (CTC), and has
been evaluated in its ability to detect colorectal neoplasms. The accuracy of the test for
detecting pathology is fundamental to its potential utility as a screening modality, but there
are a number of other theoretical advantages and disadvantages of this method of colonic
imaging. These are discussed in more detail below, during discussion of the data from CTC
trials. Briefly the potential advantages include that CTC is considered less invasive, does not
require sedation and has a lower risk of complication when compared to conventional
colonoscopy. The disadvantages compared to colonoscopy include the inability to derive
histological material or be therapeutic at the same examination, radiation dosage, and a
relative poor availability in current colorectal practices. However as colonoscopy has not
been evaluated as a screening modality by way of a randomised controlled trial, comparisons
with conventional colonoscopy should perhaps be limited.
A brief consideration of the technical requirements of CT colonography is helpful
when considering the applicability of this test to the asymptomatic general population.Whilst
there are many modifications of examination protocols, the general principles include the
performance of a high resolution CT scan following some form of bowel preparation. The
images are reconstructed using software and interpreted by a radiologist with training and /or
experience in the technique.
The characteristics of the hardware appear to have great relevance to the performance
ofCT colonography as discussed when considering the accuracy data below. As such multi
slice scanners appear to have better performance, as do more advanced software analysis
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packages that allow 3 dimensional, virtual fly-through reconstruction. The difference in
scanners and analysis software is the main rationale in the literature to try to explain the
disparate accuracy results in clinical trials of CT colonography.
Each of the larger trials ofCT colonography have utilised standard bowel preparation
as part of their protocol. Bowel cleansing improves data quality, as for example residual stool
can be mistaken for neoplastic masses. The main disadvantage of requiring bowel preparation
is reduced acceptability to patients, and may require inpatient preparation in elderly or infirm
patients. The advantage however of having a fully prepared bowel is that confirmatory or
therapeutic colonoscopy can be undertaken either the same day or without the need for
further bowel preparation, which is not the case after barium enema or indeed if rectal
contrast has been used as an adjunct to CT colonography. Various techniques have been
investigated in order to try to decrease the amount of colonic preparation needed before CT
colonography. Orally ingested agents, such as barium, have been used to bind retained faeces,
and have been termed tagging agents. Whilst in some studies tagging agents have been
administered in addition to bowel preparation, in others bowel preparation has been
substituted with tagging agents 087). Digital subtraction software processing allows
subtraction of labelled stool from imaging. The proposition of obviating the need for bowel
preparation would make CT colonography more attractive both as a diagnostic test and a
potential screening modality, however it seems likely that convenience would be at the
expense of image quality to some degree, and it appears that image quality is fundamental to
test accuracy and hence applicability as described in analysis of clinical trials below.
Also standard practice to date is colonic distension using rectal insufflation of gas,
such as carbon dioxide. Colonic distension improves image quality, but is unpleasant for the
patient. Discomfort is not considered sufficient to require routine sedation, which is heralded
as an advantage over conventional colonoscopy. Certainly this is the case in terms of
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recovery time and patient convenience in being able to be alone the night of the examination,
and in view of negating the cost of recovery facilities and staff. However unmodulated
discomfort may be a factor in suboptimal patient acceptability. A number of drugs have been
administered in an attempt to improve colonic distension and reduce colonic spasm, but are
yet to be of proven benefit. Use of intravenous contrast can help differentiate benign and
malignant strictures but has the attendant risks of the administration of contrast media.
Initial reports in small numbers of symptomatic patients suggested sensitivity for large polyps
and cancers of around 90% (188:189). although the sensitivity for smaller polyps was around
50% or lower. Additionally these studies suggested a false positive rate of 19% (188). and a
large proportion had technical difficulties resulting in a suboptimal examination, with 28%
unable to hold their breath sufficiently and a further 8% were deemed to have insufficient
bowel preparation.
Since these initial reports larger scale studies have been performed and generated
conflicting results, with the results summarised in the table below
Study Protocol Sensitivity Specificity
Cotton 2D >10mm = 55% 90%
Johnson 3D, prep >10mm = 63% 90%




The results from these studies demonstrate that performance characteristics for CT
colonography have been varaible. Sensitivity and specificity appear to depend fundamentally
on polyp size. If it is assumed that a cut off of >10mm is clinically useful then CTC is likely
to be a good screening test. Certainly conventional colonoscopy has a four and a half times
greater yield at detecting and recovering subcentimeter polyps (193). There is some debate as
to whether this arbitrarydistinction is valid. Some studies have grouped lesions sized 5-9mm
together, but Pickhardt suggests that the threshold for referral to colonoscopy (and
polypectomy) may lie within this range e.g. at 8mm. The threshold level for referring for
colonoscopy would obviously have major implications for the resultant colonoscopy work¬
load (e.g. 6mm: 29.7%, 8mm: 13.5%, 10mm: 7.5%, would get colonoscopy (192)).Clearly
technical considerations effect test performance. There is a learning curve with data
interpretation, and also technical difficulties including insufficiently distended bowel (194),
as well as aspects of continually evolving data interpretation and image analysis software that
may partially explain the suboptimal results of early studies.
An additional feature of CT colonography is the detection of extracolonic pathology or
'incidentalomas'. One study demonstrated thatt 11% of 264 CT colonographies had
'important' extracolonic findings, 7% had further investigations, and just over 2% had
surgery on the basis of the findings (195). Further work-up cost an average of $28 per
examination. Therefore these findings are relatively common, causing further costs to be
considered. However 3 extracolonic malignancies were overlooked at CT colonography,
presumably since this is not the ideal modality for detecting extracolonic pathology. The
frequency is high in this study and lower in asymptomatic populations, where important
extracolonic findings were detected in 4.5% of patients (56), including cancer in 5 patients
(0.4%) and 2 abdominal aortic aneurysms that were subsequently repaired (192). This is
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presumably as extracolonic disease may have accounted for symptoms felt to warrant
colonoscopy and hence inclusion in trials of symptomatic patients. In asymptomatic female
populations there is an appreciable (4.1%) rate of detecting adnexal masses, although this is
not a good predictor of ovarian cancer, and normal adnexal findings at CT colonography was
not protective against the development of ovarian cancer in the short term! 196).
Additionally it has been suggested that 81% of colorectal cancers can be accurately staged by
the initial CT colonography (197).
CTC is non-invasive and hence considered to be low risk, excluding the fact that positive
findings require follow up conventional colonoscopy with attendant risks. However CT
exposes patients to a significant radiation dose estimated at a median dose of 8.8mSv 1198).
that may predispose to secondary cancers (199). Studies have propsed a reduction in CTC
radiation dose, for example 50 CT colonographies at 100 mAs, and then added noise to the
data to correspond to scans performed at 50 and 30 mAs. Whilst they suggested that image
quality decreased appreciably with reducing dose, the sensitivity for polyp detection
remained unchanged with lower radiation doses. Whilst it is a very attractive proposition to
reduce the radiation dose, particularly when considering exposing the asymptomatic, and
generally disease free population to these levels, caution must be used when interpreting this
data. Firstly and most importantly the quality of the CT colongraphy images appear,
unsurprisingly, to be fundamental to the quality of the test in the context of screening.
Technological and image quality arguments are held to be the difference between CT
colonography being a poor screening test (190) and a good screening test (192). Sacrificing
radiation dose for test accuracy would be counter-intuitive. Secondly the above-mentioned
study was small, and did not actually perform scans at lower dosage levels, but only
simulated them. A slightly larger study of 158 patients with indication for colonoscopy
63
underwent low-dose multi-detector row helical CT colonography, with radiation doses of 1.8
mSv for men and 2.4mSv for women. These lower dose scans had a sensitivity profile similar
to the larger studies already discussed, which was again polyp size dependant. Performance
was a sensitivity of 96.0%, specificity of 96.6% and a positive predictive value of
94.1%.(200).
Although perforation has been described (201), it is generally not considered as a risk of CT
colonography.
Despite these caveats, if test accuracy was shown to not be compromised by reduced
radiation dose, in a large series within the asymptomatic population, then the argument for
CT colonography as a screening modality would be enhanced further. That said, despite the
technique being available for some time now, there remains debate about the applicability of
the technique to thegeneral population (202). although there is a trial underway from the
Netherlands directly comparing CT versus conventional colonoscopy as a means of
population screening(203).(201)
There has been a metaanalysis ofCT colonography (204). which included 33 studies of 6393
patients. They included several protocols and importantly a number of different technological
variables in a variety of symptomatic and asymptomatic study populations. As discussed
above it is not surprising therefore that the sensitivity results for different size categories of
polyps were heterogeneous. Reassuringly however specificity was homogenously high at
over 90 % for all 3 categories of polyp size and increasing with increasing size category. The
authors recognise the heterogeneity of their included studies, however they conclude that CT
colonography cannot be advocated for screening until a number of the heterogeneity issues
are resolved. It would seem more progressive however to suggest that independent
corroboration of the results from studies using the most advanced techniques and hardware,
might allow advocation of CT colonography as a screening tool.
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A further consideration for CT colonography as a screening tool is patient acceptability.
54.3% of patients recalled greater discomfort with virtual colonoscopy, compared to 38.1%
for optical colonoscopy (p<0.001), although only 8.2% rated the virtual colonscopy as severe.
In terms of overall acceptance, under 10% rated their experience of virtual colonoscopy as
less than good.A total of 68.3% rated virtual colonoscopy as more acceptable than actual
colonoscopy. It is hard to attribute this increase in acceptability compared to the proportion
that found the test more uncomfortable. Certainly bowel preparation was the same for the
tests. There may be an effect of avoidance of sedation and the recovery time from this,
however this is a selected study group, who are highly motivated towards disease screening,
and it is conceivable that the potential extracolonic information might sway opinion to some
degree. That said there is evidence that CT colongraphy is the preferred method of colonic
visulaisation for screening by patients with one study suggesting that 36% of study
participants would have forgone screening if CT colonography had not been available(205).
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1.3.4 Summary
There is clearly a rationale for colorectal cancer screening. Several modalities have been
adopted based on differing quality of evidence, but as yet all approaches are suboptimal in
some respects.
Overall uptake of current colorectal cancer screening methods are poor, as highlighted by an
American study, the rates of colorectal cancer screening compliance were markedly lower
than that for other cancers, with compliance of 77.2% - 91.7% for cervical smear tests versus
9.9% - 35.2% for FOB testing. This study also noted a wide range of uptake levels within the
study population, with a 3.6-fold difference in the range of estimates for FOB testing (9.9%
to 35.2%). This study was unable to demonstrate significant associations with educational
status or race with FOB testing(206). There is a lack of data to elucidate why CRC screening
uptake is sub-optimal, although is likely to be multifactorial. It seems likely that part of the
reason for poor uptake is stigma surrounding tests involving analysis of the lower
gastrointestinal tract or faeces directly.
There is clearly a need for improved screening tests for colorectal cancer. There remains
considerable effort in both improving the effectiveness of current modalities, but also in
molecular biology translational research. Particular interest has centred on the detection of
tumour derived DNA in body fluids, discussed in the following section.These approachesmay
have greater overall impact if they can also improve compliance rates , for example by the
generation of a blood test.
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Since this work was undertaken there has been considerable interest in the development of
biomarkers, including the categorisation of differentbiomarkers according to their proposed
clinical application. Briefly biomarkers might be intended to supplement currently available
tests (add-on), be intended to identify individuals whop might benefit from further tests
(triage) and those intended to replace currently available modalities (substitute). Alternatively
biomarkers can be classified according to the potential clinical information they provide
including prognostic, early detection/screening, prediction and pharmacodynamic.
Increasingly it is appreciated that these different classes of biomarkers are best served by
different performance characteristics.
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1.4 Molecular Detection in Stool
Analysis ofDNA extracted from stool has been investigated as a method for translating the
knowledge of the molecular genetics of colorectal cancer into a clinically useful test,
ultimately with a view to screening for disease. The ability to detect specific mutations in
collected stool samples may reflect exfoliated neoplastic cells from a primary tumour, and
hence constitute a marker of cancer and adenomas.
The theoretical advantages of this approach are great in that testing is non invasive, does not
require bowel preparation, may reflect changes throughout the colon and has the potential to
have superior sensitivity and specificity compared with FOB testing.
Certainly there are limitations ofFOB as a test that limit its effectiveness to impact on disease
outcomes. Despite this there is a significant and appreciable impact of FOB testing on disease
related mortality in asymptomatic population screening groups, discussed above. It seems
likely that a more accurate test, particularly in terms of sensitivity would increase these
benefits even further. Detailed below is the evidence from clinical studies aimed at
determining the sensitivity and specificity of stool based molecular tests. It is important to
note that one of the main limitations of FOB testing is acceptability to those offered testing,
with uptake of around 50-60%. Whilst advocates of stool based molecular tests argue that this
is likely to be largely in part due to the unreliability ofFOBT (207). it seems more likely that
an appreciable factor is the fact that the test is stool based, with the attached social stigmata in
certain societies. As such molecular stool testing can only possibly circumvent some of the
difficulties with FOB testing, although a sensitive and specific clinical test would be a
significant step forward.
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1.4.1 Pathophysiology of Faecal Molecular Markers
Looking in stool for DNA that is derived from neoplastic cells has further theoretical
advantage over FOB in that it constitutes a direct marker of the neoplasm rather than of blood
hence likely improving specificity, and it is expected that cell exfoliation is a more constant
process than occult bleeding (207). Gastrointestinal mucosa has a high turnover rate,
occurring completely every few days, although not all old coloncytes are removed by
exfoliation (208). Neoplastic coloncytes have been shown to have a higher rate of exfoliation,
and neoplastic cells and neoplastic DNA are relatively enriched in effluent to account for 14-
24% of human DNA recovered from stool(209;210). Additionally cell density in the mucous
layer overlying a colorectal cancer has been shown to be appreciably higher than that over
normal epithelium (211). This enrichment of target material has been suggested to be the
result of several pathophysiological processes including impaired apoptosis (212). cell
adhesion (213). phagocytic removal and increased cellular proliferation (214). Additionally
shed neoplastic colonocytes may have an ongoing survival advantage by being relatively
spared the programmed cell death that normal cells undergo when separated from the
basement membrane (211).
Whilst this apparent enrichment of neoplasia related targets would appear to make stool an
ideal target for molecular approaches, there are a number of inherent difficulties in analysing
faecal DNA:
1.4.2 Difficulties of Faecal Molecular Markers
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Colonocytes may be trapped in the mucous layer, predominantly on the stool surface (215).
and hence not evenly distributed. Therefore adequate sized stool samples are required and
should include a portion of stool surface. Also processing may require agents to release
neoplastic material from the mucous layer to optimise target recovery (207).
Several assays have analysed intact colonocytes recovered from stool, with high sensitivity
and specificity in selected cases of colorectal cancer (216:217). However there is evidence
that colonocytes undergo intraluminal lysis, and hence whole colonocyte assays are less
sensitive at detecting proximal cancers than distal ones. Additionally storage of faeces for
more than 1 day prior to analysis also results in lysis and decreased test accuracy (216).
These same technical difficulties also apply to approaches aimed at exploiting abnormal gene
expression in colorectal neoplasia by detecting altered levels ofmRNA, since mRNA is not
stable in faeces and therefore the collection and processing of intact coloncytes is required
(216).
DNA is relatively stable in stool, in comparison to mRNA. However the proportion ofDNA
derived from the host is estimated to be 0.01%, with the remainder being derived from
dietary sources (218). Added to this is the presence of inhibitors of PCR within stool,
resulting in difficulties across studies at isolating amplifiable quantities of host target DNA.
Leading authors in the field advocate the use of a sequence specific hybrid capture technique,
and report sufficient quantities to allow consistent analysis ofDNA from faeces (210:219).
1.4.3 Faecal DNA
Given the technical considerations discussed above there has been a relative focus on the
detection ofDNA in stool. Investigators have assessed both absolute levels of human DNA in
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stool and specific mutations related to colorectal cancer as discussed in the section on the
molecular genetics of the disease.
a) Total DNA and Long DNA
Quantitative assessment of total human DNA has been shown to be of some discriminatory
value in determining patients with colorectal cancer from those without, in an attempt to
exploit the relative enrichment of neoplastic DNA in stool. When applying the necessarily
stringent specificity for a test proposed as a population screening test, sensitivity is around
50% (218:219). Combined quantitative and qualitative assessment has also been performed
by analysing the quantity of different length DNA extracted from stool. Apoptosis results in
DNA being degraded by endonucleases resulting in small fragments. If exfoliated neoplastic
coloncytes undergo relatively little apoptosis as a reflection of their neoplastic characteristics,
then it might be expected that the DNA recovered from stool of a patient with cancer might
be less degraded, or occur in longer fragments, 'long DNA'. Using over 200 base pairs as the
criterion of long DNA, the sensitivity of this assay was 64% for cancer and 55% for
adenomas in a small selected cohort of patients (210). It may be that this methodology is also
less sensitive for proximal tumours as it seems likely that some degradation occurs during
faecal transit, and has technical implications for collection and storage of samples.
Additonally faecal long DNA may be detectable in patients with inflammatory conditions
(220) or with altered colonocyte proliferation post adenoma (221). and may be persistently
elevated following resection of tumour, hence reducing specificity for cancer and clinical
utility. This said in subset analysis of multitarget assays, long DNA was the single most




Mutations of K-ras were amongst the first genetic aberrations sought in stool (222). on
account of the proportion of colorectal tumours exhibiting these changes and the well
characterised mutational hot spot at codons 12 and 13. Many institutions have examined stool
for the presence ofmatched ras mutations to those seen in the primary tumour, using a variety
of PCR related techniques (222-233). These matched changes can be rcproducibly detected in
between 50 and 100% of cases examined, but the sensitivity of K-ras assays in isolation is
under 50% on account of the mutational frequency at these loci in sporadic colorectal cancer.
As such the work on K-ras mutation detection in stool was important in demonstrating that
tumour derived mutations were indeed detectable in stool, however in isolation would not be
sufficiently sensitive to provide a clinically useful test. Furthermore, work has suggested that
K-ras mutations are not specific for cancer, and can be detected in both normal and benign
gastrointestinal conditions (234:235). A landmark study using multiple stool markers
demonstrated a sensitivity and specificity ofmutation detection for cancer of 91% and 93%
when K-ras was included in the panel of markers, but improved specificity that was not at the
expense of sensitivity when K-ras was omitted from the panel (210). As such K-ras mutation
in stool cannot be considered either sufficiently sensitive or specific.
ii) APC
Whilst mutational events involving the APC gene are considered fundamental in
tumourigenesis, the frequency of detectable mutations in sporadic colorectal cancer is similar
to that of the K-ras gene. This is likely to partly result from the large number of inactivating
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mutations described and the diffuse locations of the mutations with the gene, such that
detecting a mutation involves analysis of large numbers of base pairs. Therefore detection of
APC mutations in stool is a less attractive technical proposition than alternative approaches.
However methodologies have been developed which do not require analysis of large portions
of the gene, but which have the ability to detect a proportion ofAPC mutational events.
Vogelstein's group applied one such novel methodology called digital protein truncation to
stool DNA. This is based on the principle that many APC mutations result in generation of a
stop codon and hence protein truncation upon translation, and that PCR of stool DNA that has
a high level of integrity (i.e. long DNA) can then be subjected to in vitro translation and then
analysis of transcribed products. Using this technique they were able to detect APC mutations
in stool with a sensitivity of 57% (in both polyps and cancers) and specificity of 100% (28
controls) (209). Again, analysis ofAPC alone will result in suboptimal sensitivity, but many
multi-panel assays include some form of assessment ofAPC mutations, discussed further
below.
iii) p53
A study of 25 patients determined detectable mutant p53 in stool samples using a PCR single
strand conformation polymorphism assay, claiming a sensitivity of 64%. However this was
64% of the 11 patients with a comparable mutation in the primary tumour, and hence the
sensitivity for the whole study population was only 28% (236). Further analysis of p53
mutation in stool has occurred as part of a multi-assay panel.
iv) Microsatellite Analysis
Microsatellite analysis of stool DNA is most commonly employed as part of a multi-target
panel in an attempt to detect microsatellite unstable tumours (210;225;231 ;233;237-239T
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Microsatellite analysis alone has been suggested to be suboptimal. Utilisation of the
polymorphic BAT-26 to detect microsatellite unstable cancers, predominating in the proximal
colon was suggested as an adjunctive screening modality to flexible sigmoidoscopy to detect
distal tumours. A strategic limitation of this approach is that whilst MSI is more common in
proximal tumours than distal ones, the majority of proximal cancers are microsatellite stable
and hence cannot be addressed by this approach. However a small study demonstrated
detectable BAT-26 changes in stool in 17 of 18 (out of 46 cases in total) patients with BAT-
26 alterations in their primary tumour (240).
There has been little investigation of LOH in stool either at microsatellite or other markers.
This is despite apparently good results in a report from Japan, looking at several markers
including APC, p53 and hMLHl. This study compared stool DNA to neoplastic tissue and
normal blood DNA in sporadic and HNPCC cases, and determined a sensitivity of 96.7% and
a specificity of 100% using only p53 and APC markers (239).
v) Methylation
The importance of epigenetic changes in tumourigenesis is increasingly recognised. The
phenomenon of promoter hypermethylation provides a strategic opportunity to detect the
totality of colorectal cancer with similar technical methods. Application of methylation
sensitive PCR to stool DNA has been shown to be feasible (207). although reports to date,





In view of the limitations of each individual marker in stool, there has been a relative focus in
applying a panel of markers to stool DNA, in an attempt to improve sensitivity and overall
test accuracy. To this end there is a commercial kit, Pre-GenePlus (Lab Corp, Burlington,
NC) constituting analysis of K-ras, APC, p53, microsatellite analysis and DNA integrity
(long DNA). Results from different institutions vary, however test specificity is generally
reported as over 95%. Unsurprisingly test sensitivity varies for cancer compared to adenoma
detection, with cancer detection rates between 62-91%. Adenoma detection has greater
variation and is quoted at a sensitivity between 26 and 82%,
These results give encouragement to this approach to colorectal cancer screening, and are
theoretically superior to FOBT performance characteristics, although are yet to be tested in
such a large scale setting (242). Clearly stool DNA testing is far more involved than FOBT,
and hence more expensive, although modelling suggests that the multitarget panel might
compare favourably with the cost of screening by colonoscopy (243). Stool DNA analysis
does not address some of the practical deficiencies of stool testing as alluded to above. There
is limited data on uptake and acceptability, although high compliance and preference rates
were achieved against colonoscopy and FOBT in a highly selected and motivated population
of patients who had already attended for screening (244).
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1.5 Circulating DNA
Plasma DNA was first described in 1947(245;246)but the field of free circulating DNA was
pioneered by two plant biologists, Anker and Stroun, initially through their work on a plant
tumour, crown gall. This tumour is caused by bacterial DNA translocating into plant cells.
Affected plants develop secondary distant tumours which, since plant cells are unable to
circulate on account of their cell walls (247), stimulated the hypothesis of circulating, free,
non cell associated DNA. This observation led to experiments on frog hearts (2481 and
human lymphocytes (249) suggesting release of free DNA in higher organisms.
Detectable levels of free circulating DNA were subsequently demonstrated in both healthy
humans and those with diseases. High levels were seen in the presence of benign diseases,
but the highest levels were found in cancer patients (2501. Furthermore the concentration of
DNA was highest in patients with metastatic cancer and serum DNA concentration was
shown to be affected by anti-cancer therapy (2511. Nearly a decade later the first evidence
was generated that the detectable serum DNA of cancer patients was neoplastic in origin,
using strand stability assays (2521. These findings led to studies aimed at demonstrating the
same genetic aberrations in plasma and serum that were present in primary tumours. Initial
studies focused on mutation of the ras oncogene in a number of gastrointestinal tract cancers
with some success, discussed further below.
The ability to detect small quantities of tumour derived DNA in the blood stream provides a
target for translating knowledge of the molecular genetics of cancer into clinically useful
tests. Should low copy number mutant DNA be detectable in plasma or serum, it might infer
the presence of a primary tumour harbouring the same mutation. As such the presence of
mutant DNA in the circulation might be a surrogate for the presence of neoplasia elsewhere.
Blood is in contact with all other bodily systems and is easily accessible for sampling.
Therefore analysis of free circulating DNA potentially provides an essentially non-invasive
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way of detecting a broad range of both primary and recurrent tumours and in principle might
have a role in tumour detection and therefore screening. Additionally alterations in
circulating DNA might predict tumour behaviourand hence be of usefor monitoring of
recurrence, response to therapy and informing prognosis.
Accordingly over recent years there has been intensive investigation ofmultiple genetic
parameters in a broad range of tumour types. The approaches to utility of plasma and serum
DNA are presented below, with demonstration of the wide variety of genetic changes that
have been identified.
1.5.1 Quantification / detectabilty
The discovery that different diseases are associated with altered levels of plasma DNA, has
led to the hypothesis that the absolute quantity of detectable DNA might be a marker of those
diseases, specifically cancer. The early studies of plasma DNA concentration employed
various techniques for quantification. Landmark studies from the USA (250:251:253), used a
radioimmune assay, with the antibody derived from the serum of a patient with SLE. They
determined the sensitivity of the assay as 25 ng ofDNA per millilitre of plasma, with the
tested serum not requiring extraction or purification. In their initial study the concentration
range 0-50ng / ml was designated as normal, with a specificity of 93% from 55 controls
(251). Sensitivity was 50%, with half of 173 patients with various cancers having free DNA
levels within the normal range. Whilst there was no observed correlation between site or size
of primary tumour and free DNA concentration, although there was a significantly higher
mean concentration in patients with metastatic disease. Additionally the free DNA
concentration was altered by therapy, to degrees varying with the type of primary, and was
associated with clinical response to therapy. The authors suggested that the high proportion of
77
cancer patients with normal free DNA concentrations indicated low diagnostic value, but that
utility might be found in monitoring response to treatment. Addition of an assay for the DNA
binding protein C3DP did not improve accuracy, and levels of DNA and C3DP did not
correlate with each other (253). This paper did however document the presence of an
inhibitor ofDNAse activity in the sera of cancer patients, but this inhibition was not due to
the presence of C3DP. A follow up study of 386 patients with a variety of benign and
malignant gastrointestinal diseases demonstrated a significantly higher serum DNA level in
cancer patients (412 ng/ml (+/- 63ng)) compared to benign diseases (118 ng/ml (+/- 14ng)).
The sensitivity of a high serum DNA indicating malignant disease varied according to site of
primary tumour, but was highest for pancreatic cancer, where 90% of patients had levels
elevated above lOOng /ml (leon 1981 Eur J Cancer).
Another early study of 37 patients with advanced malignancy showed detectable levels of
plasma DNA in 10 of 37 patients, compared to none in 50 normal controls. Plasma DNA
required extraction and processing, during which an estimated 65% was lost. Values in
cancer patients ranged from 0.15-12 micrograms / ml plasma, and was of size 0.5 kb to 21 kb
(254).
The inaccuracy of serum DNA concentration to reliably detect patients harbouring tumours
from those with benign disease or no disease, gave insight into the lack of knowledge of the
biological processes involved in the release of free DNA into the circulation. Additionally
these studies began to highlight the technical difficulties of applying molecular techniques to
low copy number DNA in the presence of the milieu of substances present within plasma and
serum.
More recently attempts to utilise free DNA concentrations have continued using advanced
molecular techniques. For example plasma [DNA] assessed by quantitative real time PCR for
hTERT has been performed for 100 non small cell lung cancers and age/sex/smoking
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matched controls. Mean values were 8 times higher in cancer cases (24.3 vs 3.1 ng / ml), with
the area under the receiver operating characteristic curve being 0.94, suggesting that plasma
[DNA] may have utility in itself (255). However, as part of the multicentre European
Prospective Investigation into Cancer and Nutrition (EPIC) trial, plasma DNA levels were
analysed from 776 controls, 359 cancers (including lung cancer) and 49 individuals who
subsequently died ofCOPD. A high plasma [DNA] was associated with an increased odds
ratio of death from COPD (2.53, 95% CI: 1.06-6.02), but with no significant increase risk of
cancers (256). This would suggest that an absolute increase in plasma [DNA] is not specific
to cancer. Additionally they demonstrated high plasma [DNA] from certain centres involved
in the study, likely to reflect sample handling and processing, and highlighting the variability
in assessment of absolute plasma [DNA].
Further evidence for the role of sample processing in determining absolute plasma [DNA]
was provided by a study of thoracic malignancies, both oesophageal and lung cancers 1257).
Plasma samples from cases of oesophageal cancers, that had been previously collected and
stored, had higher plasma [DNA] than controls. However this was not the case for
comparable cancer cases whose samples had been collected prospectively and treated
uniformly. They concluded that quantitative analysis of plasma [DNA] is of limited
diagnostic value, and that utility required qualitative analysis ofmutant plasma DNA. A more
recent study in non-small cell lung cancer demonstrated that a circulating DNA cut off of
above 104.5 ng/ml resulted in a 52% sensitivity and 95% specificity for the detection of
cancer(258)
A further study of prostate disease demonstrated that whilst patients with prostate cancer had
higher mean levels than controls, those with benign prostate disease had significantly higher
plasma [DNA] than those proven to have cancer. They concluded that absolute plasma
[DNA] was not of value in the management of prostate cancer (259), although these findings
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were not supported in another study (260). Another prostatic study demonstrated elevated
plasma DNA levels in patients with benign prostatic disease, but those with localised cancer
had levels within the normal range, suggesting absolute levels have no utility in prostatic
disease (261). A small study in breast cancer demonstrated no significant difference in
plasma [DNA] between patients with and without distant metastasis (262). In terms of
prognosis a study of ovarian cancers, using quantification by RT-PCR, demonstrated an
increased risk of death with increased levels of circulating DNA (263).
A large study quantified plasma [DNA] using picogreen technology, which binds to double
stranded DNA and releases fluorescence proportional to the quantity ofDNA present within
the sample. The plasma [DNA] from 122 patients with neoplasms was compared to that from
164 patients with non-neoplastic disease and 44 controls. There was a significant difference
in the mean plasma [DNA] between groups. The area under the receiver operator curve was
0.90 for healthy controls and 0.74 for those with benign diseases. With specificity set at
100%, the maximum sensitivity achieved was 57%, with the sensitivity being lower when
comparing cancer cases to benign diseases as opposed to healthy controls (52). Picogreen was
also used to determine plasma DNA concentrations in lung cancer patients compared to
patients with benign lung diseases and controls (264). There was a significantly different
mean [plasma DNA] between each group and sensitivity of 96% for cancer patients
compared to controls and 73% for cancer cases compared to benign diseases, utilising a
receiver-operator curve.
It appears from the above evidence that there is a clear trend for the presence of higher
circulating DNA levels in patients with malignancy when compared to those without.
However the relationship does not appear to be straightforward since not all cancer patients
have raised levels and there is discrepancy in results according to tumour site and
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investigating groups. Additionally it appears that a number of benign diseases may also result
in altered circulating DNA levels(265) hence impacting on test specificity and overall
accuracy. It is apparent that sample collection standardisation. Additionally studies
employing more recent quantification techniques have generated more discriminatory results.
This approach seems inherently worth further investigation since analysis is straightforward,
inexpensive and utilises readily accessible bodily fluids and hence of great potential
applicability to large numbers of individuals.
1.5.2 Tumour Specific Mutations
With the discovery of tumour derived DNA in the circulation there has been a large body of
work investigating the presence of tumour derived DNA in plasma examining a wide range of
types of genetic aberration found in primary tumours, and detailed below.
a) EBV
An adaptation of pure quantification of circulating DNA has been extensively investigated in
relation to nasopharyngeal cancer. This malignancy is associated with Epstein Barr virus
(EBV) infection, the virion for which is incorporated into host human DNA, and replicated
during tumour clonal expansion. As such EBV DNA quantification equates to detecting
genetic aberrations associated with the tumour, rather than measuring plasma [DNA] per se.
Several studies have demonstrated the ability to detect EBV DNA in plasma. One study from
Thailand, using nested PGR, demonstrated detectable EBV DNA in plasma or serum in 98 of
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167 nasopharyngeal cancer cases prior to treatment, compared to 10 of 77 normal controls
1266). A group from Hong Kong have employed quantitative real time PCR to not only show
detectability, but also demonstrate temporal and quantitative relationships. In a small cross-
sectional study they demonstrated that 10 patients with tumour recurrence had a significantly
higher plasma EBV [DNA] than 15 patients remaining in clinical remission, whose plasma
EBV [DNA] remained negligible. In a parallel study 17 patients were followed up, all of
whom had detectable plasma EBV [DNA] prior to radiotherapy. 16 patients showed an initial
reduction in plasma EBV [DNA]. In those who developed recurrence, the plasma EBV
[DNA] rose gradually to levels deemed high prior to the development of clinically manifest
recurrence. Those cases who remained in remission maintained persistently low plasma EBV
[DNA] (267). Furthermore plasma EBV [DNA] was shown to be an independent prognostic
indicator for early clinical events (RR 3.8 (95% CI: 1.6-9.2) for each ten fold increase in
plasma EBV [DNA] ), and also in a further cohort to be a significant variable associated with
death from the disease (2681. These results demonstrated the possibility ofusing plasma
DNA as a marker of prognosis, response to therapy and recurrence. Similar results have been
replicated in a study of 99 patients with stage III and IV disease, but without distant
metastasis. Plasma EBV DNA was detectable in 94 of 99 patients and in none of 40 controls
or 20 patients cured of disease. Higher plasma EBV [DNA] was associated with increasing
disease stage, and poorer survival. Additionally genotyping of paired tumour and plasma
DNA samples suggested that the free circulating EBV DNA originated from the primary
tumour (269). In a temporal analysis of prospective cohorts, 65% and 96% of cases with
locoregional and distant recurrence respectively had elevated plasma EBV [DNA], on
average 100 days prior to the development of clinically detectable abnormalities (270)
The Hong Kong group have recently addressed the issue of using plasma EBV [DNA] to
determine the risk of treatment failure, with a view to utilising plasma EBV [DNA] as a
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factor in determining clinical treatment. They assessed the pre-treatment plasma EBV [DNA]
in 90 patients with early stage nasopharyngeal carcinoma, who went on to receive single
modality therapy on account of their early stage disease on standard clinical assessment. Over
a mean follow-up of nearly 4 years, 7 patients developed distant metastasis, and 12 developed
locoregional recurrence. The pre-treatment plasma EBV [DNA] was significantly higher in
those who went on to develop distant disease, and the probability of distant failure was
significantly higher in patients with a relatively low plasma EBV [DNA] of 4000 copies / ml
plasma. They concluded that patients with early clinical stage disease but with raised plasma
EBV [DNA] pre-treatment might warrant therapy that is classically reserved for more
advanced cases (271). Most recently there is evidence that plasma EBV DNA clearance rates
may be a prognostic marker for nasopharyngeal cancer, with cases with a short plasma DNA
half life having a significantly higher complete response rate and overall survival (2721
This approach which employs essentially both quantitative and qualitative (tumour specific)
assessment is as close to clinical application as the field of circulating DNA has come.
However this disease is in an essentially priviledged position of having a ubiquitous mutation
associated with viral infection, and hence is a unique but not reproducible scenario for other
malignancies. It is however likely to represent the fore-runner for clinical application of tests
in this field and likely to give helpful insights in terms of applicability, logistics and tumour
derived plasma DNA biology.
b) Ras gene
The ras oncogene family is commonly mutated in a range of human cancers. In Kirstcn ras
the point mutations responsible for gene dysregulation are most commonly found at
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mutational hot-spots in codons 12 and 13. The k-ras gene hence became an early target to
exploit the presence of tumour derived DNA in plasma. Many groups have intensively
investigated ras mutations in plasma in a broad range of tumours, particularly gastrointestinal
malignancies.
In pancreatic cancer, by way of example, 90% of cancers exhibit K-ras mutations (273), and
these appear to occur at an early stage of cancer development (274). Whilst there is evidence
that these mutations can be detected in pancreatic fluid (275), this is difficult to sample
clinically, and the ability to detect these changes in blood provides a less invasive and more
attractive proposition.
A study of 21 patients with irresectable pancreatic cancer demonstrated detectable K-ras
mutations in the plasma of 81% of them, with no changes being detected in a small number of
controls or with benign pancreatic disease. Additionally in 4 patients there were detectable
mutations in plasma DNA prior to a diagnosis being able to be established by conventional
means (276). A similar study found K-ras mutations in 71% of primary tumours and in the
matched plasma of 60% of these. The lower sensitivity may reflect that the patients in this
study had treatable disease, and indeed the persistence of detectable plasma ras mutations was
associated with poor prognosis (277) A subsequent larger study of 44 cases of pancreatic
cancer and 60 controls with either benign or no disease, demonstrated K-ras mutations in
only 27% ofmatched plasma DNA samples (278). Plasma positivity was significantly
associated with tumour stage and the presence ofmetastasis, and was an independent
prognostic factor. 5% of patients with chronic pancreatitis also had detectable mutant DNA in
plasma, suggesting poor specificity.
A more recent study employed a sensitive mutation specific mismatch ligation assay to
analyse 28 pancreatic cancer cases. Whilst 93% of primary tumours exhibited K-ras
mutations, these changes were detectable in only 35 % of these patients plasma. Whilst
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mutant plasma DNA was detectable in 5 patients with stage II disease, the authors of this
study concluded that the poor sensitivity precludes its use as a test for detecting treatable
disease (279).
Plasma K-ras mutations have been investigated in various other tumours including
lung (280;281) and colorectal cancer (282). Results have varied according to tumour site,
investigating group and specific differences in methods employed, but in no cases has test
performance been sufficient to allow clinical application. This is likely to be in part due to
lack of sensitivity inherent in methods, and the fact that neither K-ras mutations nor release of
mutant DNA into the blood stream is ubiquitous in any given tumour type.
The results of investigation of circulating K-ras mutations in colorectal cancer are discussed
further in section 1.5.3.
c) Methylation
Promoter hypermethylation has been recognosed to play an important role in carcinogenesis,
and is a common event in a range of cancers. Methylation of genes seen in neoplastic tissue is
rarely observed in normal tissue (283). Similarly to other plasma DNA based potential
biomarkers no single marker will be informative for the totality of a given cancer type.
However since methylation is a widespread phenomenon, and not specific to a given gene, a
panel ofmarkers based on the principle of aberrant methylation, may allow greater
informativity for a series of patients than any one genetic marker in isolation. Additionally
there is evidence that methylation of each gene appears to segregate independently (284).
Furthermore it is likely that analysis of the pattern ofmethylation across a panel of genes will
be informative as to the site of origin of the tumour, which clearly has impact on the
practicalities of assessing asymptomatic individuals' plasmas.
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Methylated DNA may also be preferentially present in plasma, since methylation alters
chromatin structure, with a more compacted nucleosome that may be less accessible to the
action of DNAse action in the circulation (284). Nucleosomes have been detected in serum of
cancer patients(285), and these studies are now at the forefront of the field. Additionally
methylated sequences have been reported at proportionally higher levels in the circulation
1286).Therefore the ability to detect methylated plasma DNA is an attractive proposition
across various medical disciplines and this is reflected by the variety of studies highlighted
below:
A study of 22 hepatocellular carcinomas detected pl6 methylation in 73% of tumour
specimens and in 81% of the matched pre-treatment plasma samples from those with
methylation positive tumours. Importantly those with detectable methylated plasma DNA
included 7 patients with stage T1 or T2 disease, and no methylation was found in 38 patients
with chronic liver disease or in 10 healthy controls. This suggests that this form of analysis is
both sensitive and specific with the ability to detect potentially curable hepaticellular cancer
(25).
Similarly in a study of non-small cell lung cancer, 15 of 22 tumours showed aberrant
methylation at one of a panel of 4 genes, and 11 of these had the corresponding changes
detectable in matched serum samples (287). This group also investigated promoter
hypermethylation using the same panel ofmarkers in 95 head and neck cancer patients. They
found that 55 % had aberrant methylation in the primary tumour and 40% of these had the
same changes detectable in serum DNA (288). A small study of breast cancer patients
showed pi 6 methylation in 23 % ofbreast cancer cases, with the same change detectable in
plasma of 63% of these (289) A study of h MLH1 methylation in plasma DNA of ovarian
cancer patients enrolled in a chemotherapy trial demonstrated that the rate ofmethylation was
increased at relapse, with 25% of 138 patients developing plasma DNA methylation that was
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not detectable in matched pre-therapy samples. This increase was mirrored by increased
microsatellite instability, and poorer prognosis (hazard ratio 1.99: 95% CI; 1.2-3.3), and was
postulated to be due to selection of tumour clones resistant to the effect of chemptherapy on
account of dysfunction of mismatch repair (74). A study of cervical cancer analysed
methylation status in plasma DNA of a panel of 5 genes where methylation was associated
with cervical cancer (290). Methylation of one of the panel was detectable in 87% of 93
cases, with the same methylation present in the limited number of matched tissue samples.
Methylation of the gene MYOD1 was detected more frequently in plasma in patients with
late stage disease, and therefore unsurprisingly was associated with poorer survival. A further
study of 93 cervical and 122 breast tumour patients used a high throughput methylation assay
and determined that plasma posivity was associated with poorer outcome in cervical cancer,
and that a marker of APC methylation was an independent marker of outcome in breast
cancer patients (291). A similar approach looked for hypermethylation at a panel of 6
markers in urine from renal cancer patients showing 88% sensitivity and 100% specificity in
a cohort of 50 cases (including early stage disease) althought there were no controls (292).
Whilst several of the results described above are impressive, less promising results have also
been reported, for example P16 promoter methylation has been reported as detectable in 82%
of 38 oesophageal squamous cell carcinomas, but with the same abnormality detectable in
only 23% of matched plasmas, and each of these were in late stage disease (293)
Overall methylation is an attractive target for the analysis of tumour derived DNA in plasma,
particularly since a panel of markers can be expanded using the same principle at different
loci in order to try to improve assay performance.
Recently there has been a relative increase in the field of papers assessing circulating DNA
methylation status, showing some promising results. Small panels ofmethylation markers
have been shown to be of use in discriminating benign from malignant abnormal chest CT
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findings (294). Additionally technological developments have increased the possibilities of
this approach including the ability to interrogate the status of the entire 'DNA methylome'
(295), and the ability to simplify to technical process of assessing multiple methylation
markers, such as a panel of 37 methylation specific assays within a single reaction (296).
Microarray mediated methylation analysis has also been performed on plasma DNA from
pancreatic cancer patients, showing sensitivity and specificity of 90% (297). The results of
recent studies ofmethylation in colorectal cancer are presented in section 1.5.3c.
d) Loss of Heterozygosity
Another attractive target for the analysis of plasma DNA is the near ubiquitous phenomenon
of LOH. LOH derives from genetic instabilty resulting in losses or gains of defined
chromosomal regions, has been termed a defining molecular signature ofmost human cancers
(51). and is characterised molecularly by allelic imbalance (AI) (52). As such a panel of
LOH markers may be able to give informativity for the great majority of cancers and
furthermore the pattern of LOH in plasma may have inference as to the site of primary
tumour. The rationale for detectability would be that a tumour with LOH/AI would contribute
relatively more of the allele that had not been lost into the circulation hence resulting in AI in
the plasma.
This rationale has been investigated in many different tumour types and body fluids as
described below. The predominant method used for analysis has been microsatellite markers
that have been variously quantified by autoradiography to fluorescent electrophoresis.




A study of clear cell renal cancer, where LOH of regions of chromosome 3 is a common
event (298), examined 4 microsatellite markers on chromosome 3p in 40 patients.
Microsatellite alterations were detectable in 65% of plasma DNA samples, with microsatellite
instability accounting for only one case. There were no alterations in healthy controls, and the
changes in plasma DNA of cancer patients were not significantly associated with disease
stage in this small sample (299). A later study of 60 patients, the majority of whom had early
stage disease, utilised 9 microsatelllite markers on 6 chromosomes. They detected changes in
serum DNA in 74% of cases, plasma analysis being called positive only if there was a
matching alteration in tumour DNA. The sensitivity was increased to 87% by increasing the
number ofmicrosatellites analysed to 20. Microsatellite alterations consistent with LOH were
observed in 15% of 20 normal controls, giving a specificity of this analysis of 85%. There
was a significant association of plasma positivity to advancing disease stage (300) .
An initial study in transitional cell carcinoma (TCC) of the renal tract using microsatellite
analysis suggested sensitivity of 84.5% and specificity of 100% in a small sample (301). In a
follow up study of 61 cancers and 20 controls, using a panel of 17 microsatellite markers,
80.3% of cancer cases had the same alterations in serum DNA to those found in the primary
tumour. However 20% of controls had microsatellite alterations detected in serum DNA,
giving a specificity of 80% (302). Whilst plasma positivity was not associated with tumour
stage, it was significantly associated with higher tumour grade.
These studies do not define what level of change was required to be seen to be called an
alteration. It seems likely that the high sensitivity is at the expense of specificity as small
changes in allelic ratio are being called that may simply represent PCR / analysis artefact.
Indeed recent study of 40 transitional cell cancer patients and 20 controls, using a panel of 16
microsatcllite markers, found plasma LOH frequency of 25% in the cancer cases and 14% of
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controls, a difference that was not statistically significant. This was despite demonstrating
LOH in tumour tissue in 78% of cases (103). The authors suggest that microsatellite analysis
of plasma DNA in transitional cell cancer should be interpreted cautiously, and that some of
the differences may reflect utilisation of plasma compared to serum DNA.
ii) Lung
A 1996 study performed microsatellite analysis on plasma DNA from 21 patients with small
cell lung cancer patients (304). 76% ofprimary tumours exhibited LOH using 3 markers,
with changes detected in plasma of 71%. In one case the alteration observed in plasma was
not observed in the tumour, which may reflect clonal heterogeneity or a lack of specificity of
this form of analysis. However the authors defined LOH as a change in band intensity of 50%
or greater suggesting fairly stringent calling ofmicrosatellite alterations. A similar study of
87 non-small cell lung cancer cases, using 2 markers showed alterations in 56% of tumours
and in 61% of these patients plasmas (305). Importantly there were detectable plasma DNA
abnormalities in 43% ofpatients with stage 1 or small tumours. However 5 patients had
changes in their plasma not seen in the primary tumour and there was no association with
tumour stage. A later study of both non-small cell (23 cases) and small cell (1 leases) lung
cancers, used 12 microsatellite markers and determined that 83% of primary tumours and
85% of matched plasma samples demonstrated LOH, although the pattern of the alteration
was seen to alter between tumour and plasma DNA (306). There was also a trend to plasma
positivity to advancing disease stage, but there were a proportion of patients with localised
disease that demonstrated plasma DNA alterations. A larger study of 86 cancers and 120
patients with benign disease demonstrated evidence of LOH in plasma in 60% of cancer
cases, but also in 40% of patients with benign disease although 7% of controls were
subsequently diagnosed with malignant disease (307).
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Hi) Breast
An early study of 17 breast carcinomas, showed few cases of LOH or shift (2 and 3
respectively) in the primary tumours, and only one case had concordant microsatellite
patterns in matched plasma. They noted that microsatellites over 200 bp were hard to
amplify, and suggested that this was due to plasma DNA being fragmented (308)- A
subsequent study of 62 breast cancer patients analysed 6 microsatellites, p53 mutations and
aberrant methylation ofpi 6, identifying a genetic abnormality in the primary tumour in 90%
of cases. They observed a similar mutation in 66% of the cases paired plasma DNAs, with
plasma positivity associated with clinical parameters indicative of poor prognosis (309).
Anker and Stroun's lab generated higher sensitivity, rising with the use of tetranucleotide
repeats to detecting changes in 81% of 23 primary tumours and 48% of matched plasma
samples including some small tumours (310) .
A larger study of 71 cases and 9 controls, using only 2 microsatellite markers found plasma
DNA LOH in 31.3% and microsatellite instability in 11.6% that corresponded to those found
in the primary tumour. They were able to detect tumour cells in blood by
immunocytochemistry in only one patient, but of 10 patients with plasma DNA alterations 5
had tumour cells by immuno-cytochemistry, and 6 had elevated rnRNA for tumour markers
within bone marrow samples. This may suggest that plasma positivity is a reflection of
clinically indetectable tumour load (31 IT
A more recent study analysed a small study population with a large number ofmicrosatellite
markers. They were able to detect microsatellite abnormalities in 40% of serially taken
samples. 80% of these changes were concordant with those seen in the primary tumour, but
the volume of allelic loss was small (0.05 compared to 0.52 in tumour) and was inconsistent
91
in serially collected samples. This would suggest that in attempting to improve the sensitivity,
the reproducibility of this analysis made it uninformative 13121.
iv) Melanoma
LOH is a common phenomenon in malignant melanoma. A study of 10 microsatellite
markers in 76 melanoma patients, 19 ofwhom had early stage disease clinically, 52.6% of
cases had matched alterations in their plasma and tumour samples. However the positivity
rates were 29% and 25% for stages 1 and 2, and plasma positivity was associated with later
stage disease (313).
To investigate if plasma DNA LOH might have a role in predicting response to systemic
therapy for advanced malignant melanoma, the same group monitored LOH in plasma DNA
in 41 patients with metastatic melanoma (314). The overall response rate to targeted
treatment with standard chemotherapy agents plus interleukin and interferon, was 56%,
including 32% undergoing complete response. However those patients with LOH detectable
in plasma had a response rate of 17%, significantly worse than those without detectable
changes in plasma DNA (72% response rate). As such plasma positivity was the only
significant independent predictor of disease progression.
v) Head andNeck
An early study of 21 patients with head and neck squamous cell carcinoma examined 12
markers ofmicrosatellites in matched plasma and tumour specimens. One or more of the
microsatellites had a matching alteration in plasma to that in the tumour tissue in 29% of
cases. All of those with plasma positivity had advanced disease. However this demonstrated
the ability to detect tumour derived DNA in plasma by microsatellite analysis (315). A larger
study of 117 head and neck cancer patients found microsatellite alterations at a single marker
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in 55% of the primary tumours, but in only 1 case was there corresponding change in plasma
DNA. They concluded that <2% of total plasma DNA was derived from the tumour (316). A
further study that included 40 controls determined both sensitivity and specificity to low at
around 30% (317). whilst conversely a large study indicated a sensitivity of 100% for
informative cases, although was unable to generate specificity levels as did not include
controls (318)
Clearly from the results described above there is variation in assay performance between
tumour types as well as according to the precise methods and panel ofmarkers used for
analysis. The results of studies in colorectal cancer are discussed further below. There are a
number of technical considerations that are likely to have bearing on results and their validity
which are considered further below and in the discussion in chapter 6 that relates to this work
on microsatellite analysis of plasma DNA in colorectal cancer.
f) Digital SNP analysis:
Amore recent approach to determining allelic status has been described (319). that allows
counting of individual alleles in multiple replicates, and has been termed digital single
nucleotide polymorphism (SNP) analysis. This approach has some inherent advantages over
technical difficulties experienced with microsatellite analysis that are discussed further below
and in chapter 8 on allele counting experiments.
Digital SNP analysis has been investigated using ovarian cancer as a paradigm (52), initially
being applied to defining allelic ratio in malignant ascitic fluid, demonstrating the ability of
this technique to detect the same allelic distortion in ascites and tumour samples in 95% of
known malignant ascites (320)
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They analysed 122 cancers (54 ovarian, only 11 gastrointestinal), 44 healthy controls and 164
individuals with non-neoplastic diseases for plasma [DNA], then subset analysis of 54
ovarian cancer cases with 31 individuals with benign disease and plasma [DNA] higher than
50ng/ml. The highest sensitivity and specificity was at an allelic proportion of 0.6, where
specificity was 100% and sensitivity 93% (50 out of 54), using a panel of 4 informative
markers. Whilst the majority of ovarian cancer cases had late stage disease, digital SNP
analysis had sensitivity of 87% for stage I and II disease. In 15 of 17 available matched
tumour samples, the same AI was detectable. Additionally when estimating the contribution
of tumour DNA to the total plasma DNA using mathematical modelling, the majority of cases
contributed 0.48 (0.43-0.53) although the total range was 0.26-0.89.
Criticisms of this study include the fact that patient recruitment was retrospective and the
patients had already been diagnosed by conventional methods, and therefore does not
necessarily indicate improvement over methods already available. Additionally LOH has
been demonstrated in benign diseases such as endometriosis, therefore patients with these
conditions should be included in the control group to see if the methodology is able to
discriminate (321).
A further elegant adaptation of this approach, called BEAMing, has been more recently
described (322). that allows counting of multiple individual alleles in large numbers by
binding each one to magnetic beads and then counting them by flow cytometry. This
approach has been employed to quantifying APC gene copy numbers in plasma DNA from
colorectal cancer patients (323) and is described further below in the section on colorectal
cancer.
Another adaptation of this approach has been employed in the assessment of EGFR
mutations in lung cancer. A microfluidic digital PCR system was employed to assess a panel
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of 2 markers, with the ability to perform 9,180 PCRs at nanolitre quantities, and claimed to
be able to detect a single mutant DNA molecule. This study demonstrated a sensitivity of
92%, with specificity of 100%, for analysis of plasma from those patients with the
appropriate mutation in the primary tumour (324). An interesting outcome from another study
of EGFR status in lung cancer demonstrated that analysis of plasma DNA could be used as a
surrogate for analysis of primary lung tumours, where there was an insufficiently sized
clinical sample from the primary tumour, showing that assessment of circulating DNA could
infer the EGFR status of the tumour and the response to EGFR inhibitors (325).
g) P53
P53 mutations are difficult to identify efficiently due to the multiple sites in the gene at which
mutation has been shown to occur resulting in gene inactivation. Sequencing of large tracts of
the gene are feasible, if labour intensive, such as exons 5-8, as performed in tumour and
paired plasma DNAs from 25 patients with either breast or small cell lung cancer (326). This
study identified p53 mutations in 6 primary tumours and in the matched plasma of 50% of
these, giving a sensitivity of 12% in this small group.
An exception to the diffuse nature of p53 mutation is of codon 249 of exon 7 in
hepatocellular cancer patients caused by aflatoxin metabolites. Several studies have examined
the detectability of this mutation in plasma DNA. An early study using RFLP assay, with
results confirmed by direct sequencing, demonstrated the mutation in 36% of the cancer cases
plasma from West African patients, but not in European patients. Flowever the same mutation
was detected in plasma DNA in 15% of patients with cirrhosis and 6% of normal controls,
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indicating little likelihood for clinical utility (327). Subsequent studies have demonstrated
higher rates ofmutation in plasma DNA of affected cases, e.g. 46.7% of cases from China.
Whilst there were no changes in control plasmas in this study their controls were healthy and
taken from a Western population, so of less relevance to the utility of the test (328). A larger
study
of 158 cases from South Africa found a plasma mutation rate of 18%, indicating a suboptimal
sensitivity (329). The most promising results came from a further study population in the
Gambia where 35% of 29 primary tumours showed the mutation, with the same mutation
detectable in 88.5% of matched plasma samples (330).
One approach to more diffuse p53 mutation detection is to screen exons 5-8 by temperature
gradient gel electrophoresis. These methods have been employed in the analysis of
gastrointestinal malignancies both generically (331) and in colorectal cancer in isolation
(332). Promising results have been obtained for GI malignancy in general, with a sensitivity
of 78.6% prior to treatment, and also as part of a panel of markers in colorectal cancer as
described in the following section. However methods are somewhat involved with multiple
steps required in analysis that require repetition for subdivisions of the examined gene,
perhaps resulting in limited practical applicability.
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1.5.3 Colorectal Cancer
Colorectal cancer is an ideal paradigm disease for plasma DNA as a biomarker for reasons
already discussed in this chapter. These include the high incidence and mortality of the
disease as well as the extensively investigated mutational events in tumour initiation and
progression. Additionally current non-invasive detection and screening methods are
suboptimal, although there is a priori evidence that early detection is worthwhile in terms of
mortality and disease incidence.To this end there is a body ofwork assessing plasma DNA
utility as a biomarker, predominantly assessing K-ras status but also with analysis at other
genetic loci.
al K-Ras
K-ras mutation has been extensively studied in colorectal cancer and hence was an early
target for assessment ofmutant plasma DNA. An early study of K-ras mutations in 14
patients with colorectal cancer used sequence specific primers (PASA-PCR), with
confirmation ofmutations by cloning and sequencing, and additional mutational analysis
using RFLP PCR. The sensitivity of the PASA-PCR was down to detection of 1 mutant gene
copy in 10,000 wild-type copies, with DNA from SW-480 cancer cell lines used as a positive
control. Extraction of plasma DNA was with phenol-chloroform and quantification with
spectrophotometry. Normal and tumour DNA underwent 35 cycles of PCR with 45 cycles for
plasma DNA. Using PASA-PCR K-ras mutations were detected in 7 (50%) of primary
tumours, 6 of these being at the second base of codon 12. Six of the 7 cases (86%) with a ras
mutation in the primary tumour had identical mutations detected in paired plasma samples.
Whilst 3 cases had metastatic disease, 1 patient with each of Duke's stages A,B and C also
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had K-ras mutations detectable in plasma. There were no mutations detected in plasma of 6
healthy controls, suggesting that the results were not false positives. This preliminary study
showed feasibility of K-ras mutation detection in colorectal cancer patients' plasma DNA,
with apparent high sensitivity and specificity.
A larger study examined K-ras mutations in plasma of 240 patients undergoing colonoscopy
for colorectal symptoms (333)- They employed a RFLP assay for codon 12 mutations, with
visualisation by gel electrophoresis, a method found to have sensitivity of 1 mutant copy in
105 in their hands, although not specifically in the context of plasma DNA (but rather mutant
copies added to placental normal DNA). Mutations in tumour were confirmed by dot-blot
hybridisation. Of 240 patients 8 had colorectal cancer and 62 had adenomatous polyps alone,
with half of these having only one polyp. There were therefore 170 controls without
neoplasia at colonoscopy. K-ras mutations were present in 43% of primary neoplasms. K-ras
mutations were also present in colonic biopsies in 5 of 65 controls. All 5 patients with ras
mutations within colorectal cancer had changes detectable in plasma. Of 25 patients with ras
mutations in their polyp, 20 had changes detectable in plasma (80%). A total of 28 of 105
controls had mutant ras in plasma DNA, including those with mutant ras in non-neoplastic
biopsies. This study showed a high sensitivity for mutant ras analysis of plasma DNA,
including in patients with pre-malignant lesions, but a poor specificity suggestive of some
false positive results. However ras mutations can be observed in non-malignant tissue, and
also in a common phenomenon in non-colorectal cancer that may present with symptoms
mimicking those of colorectal cancer.
The utility of detecting mutant K-ras in plasma DNA of colorectal cancer cases in relation to
follow-up and prognosis has also been assessed. A study of 58 patients with a full range of
disease stage underwent plasma DNA analysis for K-ras mutations and aberrant p 16 promoter
methylation (68). They used mutation specific primers for K-ras mutations and methylation
98
specific PCR for p 16 methylation. 38% and 53% had ras mutations and aberrant methylation
respectively in their primary tumours. Sensitivity of detecting changes in plasma DNA was
45% for K-ras and 68% for aberrant p 16 methylation. Plasma positivity was significantly
associated with poorer prognosis, p<0.03 by log rank test when stratified for tumour stage,
and was an independent prognostic factor.
Similarly a prospective study of 94 cases of colorectal neoplasia examined K-ras mutation
plasma positivity and its relation to prognosis (282). They followed a total of 94 patients for
three years, with blood samples at 1 week and 1 month post-operatively and then at three
monthly intervals. The control group was 20 patients who underwent normal colonoscopy.
Analysis was of serum DNA for K-ras mutations using a semi-nested mutant enrichment
PCR technique and enzymatic digestion. K-ras mutation was detected in 53% of tumour
samples and 41% of plasma samples of a cohort undergoing pre-operative testing only,
including in 4 of 7 cases with adenomas with K-ras mutations in the polyp., and indeed there
was no significant association between plasma positivity and disease stage. Of the cohort
undergoing longitudinal follow up, 64% had K-ras mutations in their primary tumour, and
there was no association between the primary tumour K-ras status and prognosis. 16/60
(27%) of patients with mutant K-ras in their tumour became persistently positive for serum
K-ras mutation during follow-up and 10 (63%) of these developed recurrent disease,
compared to 1/44 (2%) that developed recurrence but remained serum K-ras negative.
Therefore the odds ratio of recurrence given a positive serum K-ras was 71.6 (7.7-663.9,
p<0.001). Plasma positivity was an independent predictor of recurrence by cox regression
analysis with a relative hazard of 6.37 (2.3-18.0, p<0.001), higher than that of Dukes stage.
Overall detection of post-operative serum mutant K-ras was 52.6% sensitive and 92%
specific for disease recurrence, rising to 91% sensitive and 88% specific when analysing
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those with mutant K-ras in their primary tumour. These results would suggest that K-ras
mutation status in plasma DNA may be of prognostic significance, but also demonstrates that
mutant plasma DNA is detectable in patients with early stage and pre-malignant disease,
when amenable to surgical cure.
A significant deficiency with plasma DNA K-ras analysis in colorectal cancer is that
strategically it can only possibly detect the minority of tumours. Given the relatively low
prevalence of K-ras mutations in colorectal cancers (40-50%), even an assay with sensitivity
of over 80% could only detect upto 40% of the totality of colorectal cancer (334)- However
this approach remains the most extensively studied with respect to colorectal cancer and is
likely to form part of a panel of markers should plasma DNA in CRC reach the point of
clinical utility.
b) Microsatellite Analysis
In contrast to K-ras assessment, microsatellite analysis provides potential for strategic
informativity for the great majority of colorectal cancer, however remains little investigated.
An initial study ofmicrosatellite alterations in serum DNA of colorectal cancer patients was
performed in 44 cases. They also performed p53 mutational analysis and mismatch ligation
assay for K-ras mutations (335).The microsatellite markers used were: Chromosome 18q:
DS18S55, DS18S58, DS18S61 and DS18S69; Chromosome 17p: CHRNB1 and D17S786;
Chromosome 8p: D8S133 and D8S254.
The primers were radioactively labelled, and the PCR products analysed by autoradiography.
LOH was scored if there was >30% decrease in allelic frequency.
Either LOH or microsatellite instability was detected in 80% of primary tumours, but was
observed in none of the matched serum DNA samples. The authors suggested that this
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negative result might be the result of filtering ofmutant DNA by the liver, or a lack of
sensitivity of the type of analysis. Additionally serum DNA was used as opposed to plasma,
and there is evidence of increased release of normal DNA from blood cells during clotting,
that might mask the relatively small allelic ratio differences in DNA derived from the tumour.
Autoradiography is an older technique for microsatellite analysis, whereas fluorescently
labelled primers using commercially available platforms allow more accurate quantification
of allele frequency. These findings had led observers to suggest that 'Microsatellite
alterations seem of no interest since their frequency is low or absent in colorectal cancer
patients' plasma and their detection in plasma could be subject to artefacts' ("681
However a subsequent study employed fluorescent microsatelite analysis to paired tumour
and plasma samples from 27 colorectal cancer cases and 10 healthy controls. They employed
9 microsatellites across 7 chromosomal regions (336). They demonstrated at least one
microsatellite alteration in 96% of microdissected primary tumours, with alteration frequency
at individual markers ranging from 19 to 59%.
Serum DNA was extracted using QIAgen commercial kits. PCR cycling was for only 30
cycles. LOH was scored when there was an alteration in peak intensity of >50%.
Microsatellite alterations were detected in 59% ofplasma DNAs from the cancer cases, with
robust ability to generate products at all markers studied. LOH was detectable in 26% of
serum samples and microsatellite shifts in 48% of samples. There was no association between
plasma positivity and advanced disease stage. When these figures were compared to the
changes observed in the primary tumour, LOH was detectable in plasma of 35% of the
patients with the change in their primary tumour, compared to 93% for microsatellite
instability, with this difference being statistically significant. However microsatellite shifts
were detected only in the plasma DNA and not the primary tumour for 3 patients. Providing
evidence against these observations being due to artefact, no changes were seen in the plasma
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DNA from healthy controls. The authors' rationale for the increased sensitivity of
microsatellite shifts compared to LOH is that the methodology favours the identification of
new alleles as a new peak over the discrimination of subtle variations in peak intensity which
might be associated with LOH.
An additional reason for the relative inability to detect LOH in plasma of colorectal cancer
cases is the presence of genetic heterogeneity. The increased amount of one allele released
into circulation by tumour clones might be 'cancelled out' by DNA from a different clone
that exhibits LOH of the other allele (alternate AI). Therefore despite AI in particular
portions of the tumour, plasma DNA might remain in allelic balance. The multi-step theory of
colorectal carcinogenesis would expect low tumour heterogeneity as each mutation results in
a proliferative advantage for that clone. This would be expected to be the case particularly for
early mutational events, such as inactivation of the APC gene. There is evidence however that
tumoral heterogeneity exists in colorectal cancer albeit in advanced stage disease.
A study to investigate genetic heterogeneity was performed with relation to plasma DNA
(337). This study investigated 24 lung cancer cases and 26 colrectal cancer cases with
documented liver metastases, using 33 dinucleotide repeat microsatellite markers across the
majority of chromosomes for the colorectal cases. An alteration in peak intensity was classed
as LOH. Whilst this study demonstrated the presence of alternate AI in the plasma of 25% of
lung carcinomas, the colorectal cohort had analysis of primary tumour to liver metastasis only
(not of plasma DNA). However alternate AI was observed in 54% of liver metastasis
compared to primary tumour, suggesting a substantial degree of heterogeneity in advanced
colorectal cancer. Notably alternate AI was not observed in relation to chromosome 5q in
colorectal cancer, possibly a reflection of this being an early mutational event. As such
alternate AI in metastasis may be the result of polyclonal extension of cells that are already
malignant hence the predominant clone in the primary tumour may not be the clone
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responsible for metastasis. Alternatively incongruous results may be a reflection of artefact
with methods employed a possibility discussed further in the discussion in chapter 6.
c) Methvlation
A 2001 study of hMLHl promoter methylation in serum DNA analysed 19 CRC cases 1338)
using methylation specific PCR. Their assay was tested on cell lines with methylated and
unmethylated hMLHl promoters, and derived a sensitivity of 1 methlayted copy in 100
unmethylated promoter copies . 10 of the CRC cases had microsatellite instability, and 9 of
these exhibited promoter methylation in the primary tumour, compared to none of those that
were microsatellite stable. 3 of the MSI cases, all with late stage disease, had detectable
methylated serum DNA, giving a sensitivity of 33% (given knowledge of those that were
MSI), and a specificity of 100%.
A further study of 52 cancers, 34 adenomas and 10 controls demonstrated pl6
hypermethylation in 38% of cancer cases and 70% of these had matching changes in plasma,
with no changes found in the tumour negative, adenoma or control plasmas (339).
Subsequentlymethylation status in serum DNA from 104 colorectal cancer cases was
demonstrated to associated with tumour size and stage and significantly poorer prognosis,
using a panel of 3 methylation markers (340). A larger study using 3 different methylation
markers gave sensitivity of50-70% and specificity of 65-85% for inference of the primary
tumour by analysis of plasma DNA (341).
More recently methylation analysis of SEPT-9 in plasma yielded sensitivity of around 70%
and specificity of approximately 85% in 2 separate populations (342). Simulataneously there
have been technological advances which have allowed simple analysis ofmany more
methylation markers, and with higher technical sensitivity. Vogelstein's group described a
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variation of their beaming technique for methylation analysis, able to detect 1 methylated
copy in 5000 unmethylated copies, detecting 59% of colorectal cancer cases, hence being
four times more sensitive than CEA (343). In a large study of early colorectal cancer cases,
polyps and controls, 10 genes were assessed for methylation in tumour and plasma, and a 4
marker panel generated which performed with positive and negative predictive values of
around 90% (344).
The application ofmethylation based approaches in colorectal cancer have progressed
significantly in recent years, and are now generating performance figures that rival those
which are close to clinical utility. In combination with the strategic informativity of this
approach and the technological advances in methylation detection, it seems likely that
methylation analysis will have a role, in colorectal cancer particularly, should circulating
DNA translate to implementation in clinical settings.
d) Panels of markers
Little work has been done with panels of markers in colorectal cancer with the exception of
multiple microsatellite markers, and now methylation panels. A few studies have examined
more than one genetic locus, such as a study of P53 (exons 5-8 were amplified and directly
sequenced) and K-ras mutations (mismatch ligation assay) (3351. One small study of 20
colorectal cancers analysed multiple genetic alterations (332). Analysis was performed of the
APC gene mutation cluster region (MCR) between codons 1286 and 1513 of exon 15 and p53
mutation analysis of exons 5-8 was performed by dHPLC scanning analysis. K-ras and BRAF
mutations were investigated using mutant allele specific amplification (MASA). This study
was able to detect alterations at one or more of the above regions in all 20 CRC cases
(including 2 Dukes A cancers). Clearly a sensitivity of 100% is impressive however no
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controls were included for analysis to allow assessment of specificity. Additionally the
analysis as described for each of the loci for each case would be extremely labour intensive
and costly and hence of limited practical applicability. A further study examined the use of a
5 marker panel using quantitative real time PCR, generating an area under the curve in ROC
analysis of 0.88. That said specificity remained suboptimal at 65-75%(345). It seems likely
however that application of plasma DNA biomarkers to CRC will constitute a panel of
markers, as has been suggested at previous international meetings in the field (Stroun,
personal communication). By this approach it is likely that each of the different genetic
pathways thought responsible for colorectal cancer could be represented by specific markers
and hence improve the strategic informativity and sensitivity of these approaches.
e) Quantification
Until recently there has been little data in the literature regarding quantification of plasma
DNA in colorectal cancer. Diehl's paper regarding APC mutations in plasma of colorectal
cancer patients gives some information on plasma DNA quantity, although this was not the
primary aim of the study and draws no conclusions as to plasma [DNA] per se (323).
Two similarly sized studies demonstrated a significant difference in quantity of circulating
DNA between cancer cases and controls (346;347). The slightly larger study (75 cases and 75
controls) quantified serum DNA, again using real-time PCR (347). and correlated the results
with carcinoembryonic antigen (CEA) levels. Median serum DNA concentration was 5 times
greater in cancer cases compared to controls (p<0.001), and whilst there was a higher mean
concentration in patients with metastasis at time of treatment, there was not an association of
higher levels with increasing disease stage in patients without metastasis. Analysis of test
accuracy using ROC curves demonstrated that serum DNA concentration performed
marginally better than CEA concentration, with a quoted sensitivity of 81.3% at a specificity
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of 73.3%. Combining both serum DNA and CEA concentration improved sensitivity to 88%
without a reduction in specificity. These findings led the authors to conclude that this
approach represents a potentially useful tool for the diagnosis of early stage colorectal cancer.
A subsequent studyagain described a significant difference in plasma DNA quantity between
cases (n=70) and controls (n=20), but surprisingly reported no overlap in plasma DNA
concentrations between groups and hence 'perfect discrimination' in inferring the presence of
colorectal cancer from quantification of plasma DNA(348).
One further study assessed the utility of plasma DNA concentration in determining prognosis
in and monitoring the response to chemotherapy treatment of patients with stage IV
colorectal cancer (349). They reported a significantly poorer survival for those patients with
markedly elevated levels plasma DNA concentrations, but observed fluctuating levels at
differing points of treatment in the small subset of their patients with follow up data.
1.5.4 Biology and Technical Considerations
Much remains to be elucidated regarding the biology of circulating DNA. The source of
circulating DNA remains unclear, despite investigators searching for 30 years (350). The
majority of commentators suggest thatrelease from apoptotic or necrotic cells is the
fundamental process(351), alongside impaired enzymatic and cellular DNA clearance
(336).Evidence to support this hypothesis includes the ability to detect cancer derived
mutations and the classical ladder pattern of degradation ofDNA from the circulation as seen
from apoptotic cells. It also appears that macrophages are central to the process since mice
lacking in macrophages have an impaired response to stimuli that would otherwise result in
increased plasma DNA levels (352).
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However living cells can spontaneously secrete DNA (350;350;350;350;353). and benign and
malignant disease processes may effect the balance of synthesis and clearance.Alterations in
plasma DNA are detectable in patients with benign diseases and premalignant lesions.
Examples of this include raised levels in myocardial infarction and diabetes (354). as well as
in benign naevi influencing the diagnostic accuracy for melanoma (265) suggesting that the
process of altering plasma DNA may not be due to the presence of cancer per se. There is
evidence of increased endogenous DNA from a mouse model, whereby mice bearing human
tumours, had increased plasma DNA resulting from both exogenous and endogenous sources
(355).
Furthermore it has been suggested that cell free DNA may have biological activity(356), with
some evidence for the ability to transform cultured cells (357).
Whatever the origin, it is clear from the evidence described earlier in this chapter that not all
tumours result in mutant DNA being detectable in the bloodstream. The inability to detect
mutant DNA in circulating body fluids may be due to not all tumours releasing DNA, limited
stability ofDNA in the circulation, or normal DNA may interfere with assay sensitivity
(246). Non-neoplastic tissue DNA released from normal cells can mask tumour derived DNA
since potentially small quantities from tumour cells may be overwhelmed by the larger
quantities of normal DNA. There are wide ranging estimates of the relative contribution of
tumour derived DNA to the totality of plasma DNA. Estimates have been reported from 5-
48% of total DNA (52;358) to a more recent study using BEAMing technique estimated the
contribution of tumour DNA to between 0.001-1.75% for early stage CRC, upto 27.4% for
metastatic disease (323).
107
This fundamental issue remains to be conclusively resolved and is likely to prove difficult to
do so as it seems likely to vary according to the tumour type studied as well as the precise
details of collection, extraction and quantification which remain non standardised.
The exact nature of plasma / serum DNA remains debated. Plasma DNA is degraded to a
variable extent, potentially artificially enriching for smaller alleles (359)
Analysis of plasma EBV DNA from nasopharyngeal cancer and lymphoma patients,
suggested that the fragments are short, with 87% of them being shorter than 181 bp, and also
that they are indeed free, rather than associated with virions (360). Further evidence of the
fragmentary nature of circulating DNA has been obtained from cloning, with the majority of
cloned sequences being of around 200bp. However sequencing of the cloned DNA
demonstrated heterogeneous sequences including large repeats (361)
The integrity of free DNA within plasma is subject to decrease by the action of DNAse,
resulting in smaller fragments in which the sequence that confers neoplastic characteristics is
no longer recognisable. The presence of an inhibitor ofDNAse activity has been documented
in the sera of cancer patients (253). however degradation is certainly a problem, with DNAse
resulting in decreased DNA vields(362). That said, DNA based markers have advantage
because of the inherent stability ofDNA when compared to RNA and some proteins, and
there is some evidence to suggest that plasma DNA in cancer patients has higher integrity
(363).
Mutant DNA clearance from the circulation has been most extensively studied in head and
neck cancer, following both radiation therapy and surgery, showing first order kinetics and a
faster clearance following surgery (2.3 hours vs 3.8 days) (246:364). Evidence from
investigation of foetal DNA in maternal plasma also indicates rapid clearance (365-367).
With respect to colorectal neoplasia it has been suggested that the half life ofmutant DNA is
less than 1 week (282). The mechanism ofDNA clearance also remains to be conclusively
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determined, although from studies of renal dialysis patients it does not appear to be cleared
by the kidneys (368).
Fastidious collection and processing within specific time frames appears to be the best
solution to counter the problem ofDNA breakdown or clearance, and the storage of
processed samples should be uniform and repeated freeze thawing avoided. Since plasma
DNA may be low molecular weight short amplicon markers and specific extraction kits may
be better, with a study showing higher proportion ofmutant to wild-type ras sequences in
urine from CRC patients with the low molecular weight extraction protocol; but this is in
urine and hence may have been filtered to some degree (358). However doing the same
comparison of extraction on plasma gave detectability in 1/6 for high molecular weight
extraction compared to 5/6 for low molecular weight. They suggest improving mutation
detection by selectively amplifying the mutant by various means. Similarly it has been shown
that >80% of circulating EBV sequences are shorter than 181 bp (360). Additionally it has
been demonstrated that circulating DNA from control subjects is no more degraded than that
from cancer patients (369). with a further study of lung cancer patients demonstrating no
difference in circulating DNA integrity between cancer patients and controls (370).
Not only is the quantity and quality of template an issue for work on plasma DNA, but what
template there is may be replicated less efficiently than standard preparations ofDNA. Each
fraction of blood has been shown to be highly inhibitory to standardised PCR (371). and size
exclusion chromatography suggested the inhibitor within plasma was IgG. Further
experiments suggested that IgG was a potent inhibitor of a range of polymerases. Whilst pre-
treatment of IgG at 95 degrees obviated the inhibitory effect, heating of the IgG and target
DNA together to 95 degrees blocked amplification, suggesting hot-start PCR is not the
solution.
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Early studies in the field highlighted the quandry of using DNA extracted from plasma or
serum. Suggestions that free DNA in serum is a result of release from leucocytes during
clotting, were supported by a study using 4 assay methods on plasma and serum from normal
subjects (372). They were unable to detect DNA from plasma where serum DNA was
detectable from the same individuals, and advocated the use of plasma where free DNA
detected would be the result of pathological processes. A study of patients with colorectal
cancer metastasis, matched with healthy controls, demonstrated a differing relationship
between concentrations of plasma compared to serum DNA (373), and concluded that plasma
DNA levels better represent in vivo levels of circulating DNA. A further paper demonstrated
increasing levels of detectable DNA in serum over plasma, with higher levels still in serum
samples left for a period of time before processing. However there remains no consensus
regarding the use of plasma versus serum and no standardised method for processing and
extraction (374)despite increasing calls in the field for standardisation.
A potential biological difficulty with the assessment of plasma DNA in gastrointestinal
tumours is that it has been suggested that first pass metabolism by the liver may result in
clearance of tumour derived DNA. This has been suggested as a particular issue for colorectal
cancer. One study examined detectability in portal venous blood at time of operation
compared to that in peripheral blood, and reported higher detectability in portal blood overall
(375). However there are a number of explanations for these results, including tumour
manipulation during surgery, and the detection of LOH was not significantly different
between the two sources of blood. Additionally tumour derived DNA has been repeatedly
demonstrated in the blood ofCRC patients and it is counterintuitative that the liver would
clear some types ofmutant DNA but not others (e.g. K-ras).
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Given the uncertainties regarding the biology of plasma DNA, and the implications for
performance when applied as clinically useful tests, there is need for considerable further
work in this regard. Encouragingly there are increasing reports of biological models to try to
delineate these issues, including mouse models with xenograft tumours (376)
A considerable further hurdle for the field of plasma DNA as a biomarker is that studies to
date are of patients already diagnosed with tumours. The ultimate aim of these biomarkers is
to provide non-invasive diagnostic or screening tests and hence extrapolation of described
assay performances to asymptomatic populations as indication of performance as a screening
test must be interpreted with caution.
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1.6 Other Approaches To Circulating Molecular Markers
1.6.1 Mitochondrial DNA:
An alternative approach to the analysis of genomic DNA in the circulation is the assessment
ofmitochondrial DNA (mDNA), mutation of which has been implicated in neoplasia
(377:3781. Potential advantages of this approach is that mutational rates in mDNA are high
on account of a high level of reactive oxygen species generation, and an apparent mutational
hot spot within the D-loop ofmDNA. An attractive paradigm disease for the study of the
presence ofmutant mDNA in plasma is melanoma on account of the association with UV
exposure in carcinogenesis. A study of 12 melanoma patients demonstrated m DNA
alterations in 42% of tumour samples from metastases, and in 40% of the paired plasmas
from the positive tumour cases, giving an overall sensitivity of 17% (3791. Whilst these
preliminary results are suboptimal this approach warrants further investigation.
1.6.2 RNA
An alternative approach to analysis of circulating DNA is the more recent development of
detection of plasma RNA. An inherent disadvantage of this approach is the instability of
RNA (3801. although it has been shown to be robustly detectable in plasma of cancer patients
by several investigators, particularly when comparing endogenous to exogenous RNA (3811.
and may be protected from degradation to some degree in plasma (3821. Plasma RNA
detection has developed predominantly since the advent of real time reverse transcriptase
PCR which allows quantitation of specific RNA sequences. The presence of human
telomerase reverse transcriptase (hTERT) as a marker of telomerase expression has been
reported in a small number of colorectal cancer patients using a quantitative real time PCR
assay (3831
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Thyroglobulin mRNA has also been reported at significantly higher levels in thyroid cancer
patients than controls (384). Similarly prostate specific membrane antigen mRNA has been
detected in prostate cancer patients although with suboptimal sensitivity and specificity in
comparison with benign prostate disease.
1.6.3 Proteomics
Investigation of abnormal proteins in the circulation of cancer patients is another potential
biomarker that holds considerable promise. The field of proteomics has undergone rapid
expansion in recent years since the more widespread availability of advanced detection
hardware such as surface enhanced laser desorption ionisation (SELDI) and matrix assisted
laser desorption ionisation (MALDI) time of flight (TOF) mass spectrophotometers. An
advantage of this approach is that the proteins that are abnormally expressed do not
necessarily need to be identified. The protein expression patterns are however extremely
complex and require sophisticated analysis hardware and attendant software. Impressive
initial results have been reported in ovarian cancer (including stage 1 ovarian cancer which is
amenable to surgical cure) with 100% sensitivity and 95% specificity (385). Many groups
and institutions are employing similar approaches in many diseases with a view to
determining disease specific protein profiles.
For these and other approaches, continuing technological advances hold promise for
improving the utility and accuracy ofmutation detection with particular reference to
circulating biomarkers such as the single base primer extension method termed shifted
termination assay (STA) that allows primer extension only in the presence of a given
mutation. A large panel ofmarkers or potential mutations may be analysed in high
throughput methods utilising a 96 well microplate (386). Additionaly the BEAMing
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technique holds promise for the detection for high volumes of individual alleles in a relatively
inexpensive way.
Whilst there is much that remains to be clarified in the field of circulating nucleic acids, there
is much that makes the field attractive for further investigation. Work in this field not only
has the potential to delineate biological processes but also to be truly translational research
with the generation of clinically useful tests. The added benefit that these tests would be
essentially non-invasive, and hence likely to be embraced by at risk populations, make their
potential application to disease screening a tantalising target.
1.7 Biomarker Classification
Given the proliferation of translational studies in disease detection and response monitoring,
there has been an increasing focusin recent years on robust means of biomarker classification
and development. Several leading clinical research bodies have issued guidelines in this
regard including Cancer Research UK and the National Cancer institute in the US. In the last
few years it has become accepted that biomarkers may classified on a number of levels
(http://clincancerres.aacrjournals.Org/content/16/6/1745.)
Firstly biomarkers may be classified according to their intended purpose into
a) Pharmacodynamic; aimed to provide evidence that there is a direct pharmacological effect
of a drug
b) Prognostic: providing evidence about the patient's overall disease outcome independent of
any specific intervention.
c) Predictive: determining the probability of benefit or toxicity from a specific intervention
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d) Surrogate: reflecting subsets of biomarkers that are intended to serve as a substitute for a
clinically meaningful end point.
Secondly clinical biomarkers may be classified according to their envisaged clinical role i.e.
early detection, diagnostic or prognostic and how that new biomarker might integrate with
currently available diagnostic methods, which are often held as the 'gold standard' prior to
introduction of a further test. As such new tests might be considered as substitute (replacing
current modalities), triage (to be used as an initial test to identify those who might benefit
from further more invasive investigation) or add-on (able to provide some additional
information for a subset of patients in their management)(387). A particular biomarkers
performance characteristics reflect its potential application, with the ideal characteristics
varying by class, e.g. a triage test can have a low specificity but should be cheap and easy to
perform.
Thirdly within biomarker development there is a general distinction between biomarker
validation and qualification. Biomarker validation refers to the extent of the process by which
biomarker assay characteristics are tested, including test sensitivity, specificity and accuracy,
whereas qualification is the extent of the process by which a biomarker is linked to a clinical
significance. Therefore the majority of the work described in this thesis refers to biomarker
validation, with the clinical correlation and assessment of prognosis described in chapter 3
having relevance to biomarker qualification.
Finally biomarkers can be classified according to their delineated applicability into known,
probable or exploratory. Most biomarkers in early development constitute exploratory
biomarkers, as is the case with the work described herein.
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1.8 Hypothesis
The hypothesis of the work presented in this thesis was that it is possible to detect DNA
extracted from plasma, and to differentiate between samples with induced alterations in that
DNA, and subsequently to differentiate between colorectal cancer cases and controls based
on analysis of plasma DNA.
Specific Aims
1) Optimise DNA extraction methods applicable to small volumes of plasma
2) Quantify extracted plasma DNA and investigate a relationship between plasma
DNA concentration in disease states and survival
3) Develop novel assays to detect tumour related DNA alterations with respect to
mutations in TGFBR2 and K-ras genes.
4) Assess the ability to detect relative proportions of alleles in plasma DNA with a
view to detecting tumour derived LOH in clinical samples (i.e. fluid tissue biopsy)
5) Assess whether the performance characteristics of tests developed might have





In order to test hypotheses on clinical samples a prospective cohort of control subjects and
cases with colorectal neoplasia was ascertained.Local research and ethics committee (LREC)
and appropriate managerial approvals were obtained; reference number LREC/2002/5/6.
Copies of LREC patient information sheet and consent forms are provided in appendix 1.
2.1.1 Controls
The control group were derived from two sources
PHealthy volunteers.
8apparently healthy volunteers consented to blood sampling, with their samples processed,
quantified, assessed for plasma LOH and genotyped for a chromosome 5 SNP as described
below.
2) Patients undergoing a normal colonoscopy.
These supercontrols were identified from elective colonoscopy lists.Patients undergoing
investigation for rectal bleeding or a positive family history of colorectal neoplasia were
approached, with blood collected prior to colonoscopy. Patients were included as controls




Colorectal cancer cases were identified from planned elective lists at a single institution
(Western General Hospital (WGH), Edinburgh), under the care of 7 consultants. Patients
were approached more than 24 hours prior to surgery to allow due consideration by trial
participants. Inclusion criteria were patients aged 18-89, with histologically proven colorectal
adenocarcinoma (n=87) or undergoing resection of benign colorectal neoplasia (n=7).
Exclusion criteria were: previous diagnosis of extra-colonic malignancy or metachronous
colorectal cancer, pre-operative chemotherapy or radiotherapy, learning or memory
difficulties or psychiatric illness.
Patient demographics, including site of disease, are provided in appendix 2. Summary
demographics are presented in table 2.1 below.
Table 2.1
Right colon Transverse Left colon Rectum
Number of
cases
28 5 24 38
Table 2.1 legend: summary table o:^locations of neoplasms.
The mean age was 63 with a range of 22-88
There were 62 males and 65 females.
b) Stage
Disease stage was ascertained directly from pathology records.
Classification was performed according to AJCC staging, details of which are provided in
appendix 2.. with summary data in table 2.2.
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Table 2.2
Controls Adenomas Staae I Stage II Stage III Stage IV Unknown
Number 24 8 14 29 26 15 I
of cases
Table 2.2 legend: summary table of disease stage in prospective series of patients.
c) Treatment
Treatment modality intent for cases is given in table 2.3
Curative Palliative Local resection Endoscopic
resection resection resection onlv
Number of 11 12 i 9
cases
Patients who had preoperative adjuvant treatment were specifically excluded, as from the
literature it was unclear what effects these treatments might have on plasma DNA in pre¬
operative blood samples,
d) Survival
Survival was determined directly from clinical records. Date of death was also ascertained
from Scottish central records. Survival data were not available for 5 patients and these were
excluded from analysis. Patients were censored at the date last known to be alive. Censoring
is a form ofmissing data problem which is common in survival analysis. 'Right censoring'
occurs when death occurs at some point after a prescribed time, and applies when patients arc
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alive when lost to follow up or at the end of the study period, and applies in this analysis.
Start time refers to the date of entry into the study- for these investigations at the point of
surgical cancer treatment.
All cause mortality was subjected to survival analysis, performed with Kaplan-Meier curves,
with significance of differences between groups assessed by Wilcoxon test using Statsdirect
software. This approach is commonly employed in aanalyse the survival ofpatients in a
clinical trial, and to isolate the effects of treatment from the
effects of other variables. It is also known as proportional hazards regression analysis.
Briefly, the procedure models or regressesthe survival times (or more specifically, the so-
called hazard function) on the explanatory variables
("http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/cox model.pdf).
Calibration refers to how close the predicted risks are to the actual observed risks using this
model.
The CONSORT flow diagram of study subjects is given on the following page
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Blood samples were taken from subjects' arm with use of a tourniquet. Equal volumes of
blood (10 mis) were taken in both EDTA tubes and Lithium-heparin tubes for the majority of
the cohort (n=103). For the remaining 24 patients a larger volume of blood (40mls) was
collected in EDTA tubes only, for the purpose of allele counting experiments described in
chapter 7.
Following sampling, collection tubes were placed directly on ice, and remained on ice until
further plasma processing, which was performed within 2 hours of collection.
Separation of blood fractions was performed using centrifugation on ficoll hypaque gradient.
Blood was added onto an equal volume of ficoll hypaque. Centrifugation was then performed
at 2500 rpm for 10 minutes. Following this the plasma (top layer) was carefully pipetted off,
placed in sealable eppindorphs and stored at -80 oC until DNA extraction. The white blood
cells in buffy coat were also pipetted off and stored separately and used as the source of
patient's normal DNA.
2.2.2 Extraction
a) Normal DNA extraction
Normal DNA was derived from buffy coat, which was defrosted on ice. The sample was
centrifuged at 2,000 rpm for 10 minutes, then excess plasma carefully removed with a pipette
(leaving approximately 50ul of plasma on top of pellet). The sample was washed with 1ml of
phosphate buffered saline (PBS), then centrifuged at 2,000 rpm for 10 minutes, and the PBS
removed. A further wash was performed with 1ml of PBS and centrifuged at 2,000 rpm for
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10 minutes. The cell pellet was resuspended in 200ul of PBS. Resuspended buffy coat DNA
was extracted using Qiagen blood mini kit protocol, as described for plasma DNA extraction.
b) Tumour DNA extraction
Matched tumour samples were identified for all cases where available.
i) Blocks
The majority (n=85) of tumour samples were obtained as fixed blocks directly from the
histopathology department with a corresponding H&E slide to allow idenification of tumour
tissue. Tumour blocks were not microdissected. Approximately 25mg of tumour tissue was
dissected from the block and submitted to processing.
Tumour DNA was extracted as per the protocol for the Qiagen tissue protocol as follows:
25mg of tissue was cut up into small pieces, placed into a 1.5 ml centrifugation tube and
180ul buffer ATL added. 20ul of proteinase K was added, mixed by vortexing and incubated
at 56 °C overnight in a shaking waterbath. The sample was then briefly centrifuged to remove
drops from the inside of the lid. 200ul of buffer AL was added, mixed by pulse vortexing for
15 seconds and incubated at 70 °C for 10 minutes. 200ul ethanol was added and mixed by
pulse vortexing for 15 seconds. This mixture was then applied to a QIAamp spin column and
centrifuged at 6000g for 1 minute and the filtrate discarded. 500ul of buffer AW1 then added
to column and centrifuged at 6000g for one minute, with the filtrate collected in a clean
collection tube. 500ul of buffer AW2 was then added and column centrifuged at 20,000 g for
3 minutes, following which the filtrate was discarded. 200ul of buffer AE was added to the
spin column and incubated at room temperature for 10 minutes, then the column was
centrifuged at 6000g for 1 minute. This final step was repeated with further 200 ul ofbuffer
AE giving total elution volume of 400ul.
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ii) Slides
Six patients did not have tumour blocks available on account of disease recurrence (n=3), no
resection (n=l, asystole on induction), or block not received from histopathology as routine
(n=2). For these patients slides were obtained from the pathology department with
corresponding H&E slides. For those patients with disease recurrence, slides from the
original resection were used in 2 cases, with tumour tissue from liver biopsy used for the
remaining case. The patient not undergoing surgery had tumour tissue sampled from slides
from the diagnostic endoscopic biopsies. The remaining 2 cases had slides from the resection
blocks processed. Tumour tissue was identified from the corresponding FI&E slides and
slides scraped to collect tumour sample. Tumour samples were then processed using the
Qiagen tissue protocol as described above.
Hi) Fresh Tumour
In a small subset of cases (n=3) the tumour tissue was collected unfixed directly from the
operating theatre. Thesecases were also enrolled in a separate study within the research group
necessitating collection ofRNA and hence unfixed samples. Specimens were opened and a
portion of tumour tissue sampled. Tumour samples were placed in universal containers and
put directly onto dry ice. Samples were taken directly to the laboratory for processing.
Samples were collected fresh to allow tumour RNA and protein analysis by other members of
the group and were therefore processed to allow extraction ofDNA, RNA and protein using a
trireagent protocol as follows:
25 mg of tissue was added to 500ul of TRI REAGENT solution and homogenised, then left to
stand at room temperature for 5 minutes. lOOul of chloroform was added, mixed by shaking
for 15 seconds and then allowed to stand at room temperature for 15 minutes. The resulting
mixture was centrifuged at 12 000 g for 15 minutes at 4 °C, resulting in 3 phases, with DNA
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contained in the interphase. The aqueous phase overlying the interphase was carefully
removed and stored for later RNA extraction. 150ul of 100% ethanol was added to the
interphase and organic phases, mixed by inversion and allowed to stand for 2-3 minutes at
room temperature. Sample then centrifuged at 2 000 g for 5 minutes at 4 °C. The resulting
supernatant was removed and stored for later protein extraction. The DNA pellet was washed
twice in 500ul of 0.1M sodium citrate, 10% ethanol solution. During each wash the DNA
pellet was allowed to stand for 30 minutes, then centrifuged at 2 000 g for 5 minutes at 4 °C.
DNA pellet then dried at room temperature for 1 hour, then dissolved in 400 ul of 8mM
NaOH.
c) Plasma DNA extraction
Plasma DNA extraction was submitted to experiments to identify optimal methods for
extraction and processing and are described in Chapter 3.
2.3 Real time PCR
Real-time PCR utilises specific hardware platforms that allow cycle-by-cycle visualisation of
PCR product through detection of fluorescent signal in real time. For these purposes training
was undertaken for the ABI 7900 HT platform (Applied Biosystems) (appendix 2).
Applied biosystems support different specific reaction chemistries, this project used SYBR
Green and Taqman probes (probes being either TAMRA labelled or minor groove binding
(MGB) probes).
SYBR Green technology is based on the generation of a fluorescent signal on binding of the
dye to double-stranded DNA. As such a signal is generated related to the quantity of PCR
product present at the end of each cycle of the reaction. Signal production occurs with
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binding to any double stranded DNA and hence is not sequence specific. The discriminatory
value of these assays is therefore dependant on the specificity of the primers employed.
Taqman probes employ fluorescently labelled sequence specific probes, with varying
fluorescence (reporter) for different sequences analysed by the assay. Fluorescent labels are
bound to quenchers that prevent signal generation whilst the probe is intact. The action of
Taq polymerase cleaves the reporter from the quencher resulting in signal production.
Detection of different fluorescent wavelength amplitudes allows analysis of proportions of
different sequences within a reaction. (388).Quenchers produced by Applied Biosystems
include minor groove binding non-fluorescent quenchers (MGB-NFQ). The advantage of
MGB-NFQ is that probes are stabilised and hence may be shorter in length, hence a single
base mismatch has greater impact and allows greater specificity(389). Therefore MGB-NFQ
probes were used for the majority of this project (Figure 2.1).
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Figure 2.1:
TAOMAN" PROBE BASED ASSAY CHEMISTRY
i. Polycation A fluorescent reporter IB) dye and a Quencher
IQ) are attached to the 5' and 3' ends of a TaqMan* probe,
respectively.
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) Reaction setup The SYBR* Green I Dye fluoresces when bound
to double-stranded DNA.
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2.4 Plasma DNA Quantification
2.4.1 Spectrophotometry
Extracted plasma DNA samples were diluted in dH20 by a factor of 20 (5ul added to 95ul of
d H20). Spectrophotometer GeneQuant pro (Biochrom, Cambridge, UK), allowed to calibrate
for 5 minutes, and used according to manufacturer's instructions including calibration
performed with d H20 alone to give zero reading. Readings were performed on each sample
in triplicate.
Plasma DNA concentration calculated according to the formula:
Absorption 260 x 50 (conversion factor) x 20 (dilution factor) in ng /ul.
Each plasma DNA extracted from 200ul eluted in lOOul of elution buffer.
Therefore total DNA per sample =absorption x50x20xl00 ng.
Therefore [plasma DNA]= absorption x50x20xl00 x5 ng per ml of plasma.
2.4.2 Real time PCR
Plasma DNA concentration was determined using real-time PCR employing an assay
individually designed assay for detection of differing alleles at a SNP within exon 15 of the
APC gene as described in section 2.7. Reagent concentrations and reaction conditions were
identical to those described in that section. In order to perform absolute quantification of
DNA samples a standard DNA concentration curve was generated using serial dilutions of
commercially available DNA standard at stock concentration of lOng / ul.
Dilutions were made to:
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1 in 20 0.5ng/ul
1 in 100 O.lng/ul
1 in 200 0.005 ng/ul
1 in 250 0.004 ng/ul
1 in 400 0.0025 ng/ul
Calculation of [plasma DNA] was performed as follows:
Total extracted plasma DNA (in lOOul) = reading x20
Plasma DNA concentration (from 200ul) = total plasma DNA x 5 in ng/ml.
2.4.3 Picogreen ®
Picogreen ® ds DNA quantitation reagent is a fluorescent nucleic acid stain for quantiating
double stranded DNA (ds DNA). Quantification was performed according to manufacturer's
instructions 1390). TE buffer (lOmM Tris-HCl, ImM EDTA, pH 7.5) was used to dilute the
Picogreen ® ds DNA quantitation reagent, and the working solution used on the day of
preparation. A DNA standard curve was generated using dilutions of the lamda DNA
standard provided at lOOug/ml between 0 and lOng of total DNA. 10 ul of extracted plasma
DNA samples were incubated in Picogreen ® ds DNA quantitation reagent for 5 minutes at
room temperature. Sample fluorescence was measured using a Victor 2 spectrofluorometer
(Perkin Elmer).
Analysis of test performance was performed using receiver operator curves (ROC). ROC
curves are a commonly employed method of assessing test accuracy, with a perfect test have
and area under the curve of 1. A ROC curve is a plot of a test's false positive rate versus its
sensitivity (plotted on the y axis). However patient management is more complex than is
allowed with a decision threshold that classifies the test into positive or negative, particularly
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when a quantitative test gives a continuous output of variables, necessitating the
adminstration of an often arbitrary cut-off point. Additonally different classes of biomarkers
may be best served by different performance charactersitics in terms of sensitivity and
specificity as outlined in biomarkers section of the introduction.
2.4.4 Dilution / Allele counting
Allele counting and dilution was performed as described in and section 2.8 and chapter 7,
using the APC SNP assay. Plasma DNA concentration was estimated by calculation as
follows:
1 genome equivalent ~ 6.6.pg. Dilution to concentration whereby 1 ul gives an allele in every
other well approximates to 3.3pg / ul. For the allele counting cohort plasma DNA extracted
from 2 mis of plasma and eluted in 400 uls of elution buffer.
Therefore plasma DNA concentration equals dilution factor x 33 x 400 / 2000
2.5 Tumour specific mutation analysis
2.5.1 Positive controls from cell lines
a) Microsatellite Instability
The colon cancer cell line LoVo has been demonstrated to have biallelic alterations in the
poly A tract ofTGF-(3RII gene (3911. and confirmed by our group (392) and was hence used
as a positive control for these experiments. LoVo DNA previously extracted from cultured
cells, and suspended in TE, was quantified using spectophotometry.
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b) Kirsten ras mutation
DNA was extracted from 2 colorectal cancer cell lines Colo 320 and SW 480 which were
used as positive controls. Colo 320 has been characterised as having GGT -> GAT (glycine
to aspartate) mutation at codon 12, whilst SW 480 has GGT->GTT (glycine to valine)
mutation at codon 12(393).
2.5.2 Positive controls from patient samples
a) Microsatellite Instability
Matched tumour and plasma was analysed from archived material constituting 10 patients
with metastasis (Stage IV), enrolled in previous genetic studies within the group (MD
numbers 1092,1801,1808, 1816, 1854, 1964, 1996, 2009, 2164, 2221). Microsatellite status
was available for these patients from previous data using Bethseda marker set, and
categorising 9 cases to be microsatellite stable and one to have MSI-H (MD 1092). These
cases were selected since without curative resection, tumour derived DNA might be expected
to be present at timepoints after surgery and since the prevalenceofMSI increases with
advancing disease stage, and hence might be expected to be a selected sample whereby
tumour derived DNA might be most detectable.
a) Kirsten ras mutation
Additional positive controls were derived from archived samples of patient tumours within
the group from previous studies, whose K-ras status had previously been determined by
sequencing as having the mutation GGT to GAT at codon 12
(n=2: refAM 17& 35).
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2.5.3 Cell culture
Cells were raised from storage in liquid nitrogen. Cells were defrosted in RPMI medium with
50 mis of 10% foetal calf serum and 5mls of penicillin / streptomycin, then incubated for 48
hours (Gibco BRL, Paisley, UK). Cells were then inspected and seen to be adherent and
confluent, and then split. Cell splitting involved transfer of the medium into a centrifugation
tube. The adherent cells remaining in the flask were washed with 1 ml of phosphate buffered
saline (PBS) that was then discarded. 1 ml of trypsin/versene (1:1) was then added to the
adherent cells and left for 5 minutes. The flask was then tapped to release some adherent
cells. 0.5 mis of solution was then added to the centrifugation tube. The remaining 0.5 mis
had 10 mis of fresh medium added and then was reincubated. The sample in the
centrifugation tube that had been separated offwas centrifuged at 1200 rpm for 8 minutes, the
pellet washed in PBS and then re-centrifuged. The pellet was then resuspended in culture
medium, transferred into a small flask and incubated.
DNA was extracted from cultured cells using QIAgen DNA extraction kit as per protocol
with 400ul of proteases added to 2 mis of PBS suspended cells and final elution in a total of
600 ul elution buffer. DNA was quantified by spectrophotometry.
2.5.4 Sequencing
Sequencing using sequence specific primers designed to the appropiate gene as described
separately in the materials and methods section relating to each chapter.
The constituents for the initial PCR reactions were 2ul lOx buffer, lul 50mM MgCl2, 2ul 2
mM dNTP, I unit of Platinum Taq DNA polymerase and 0.4ul each of 20uM forward and
reverse primers (Invitrogen, UK) and lul ofDNA template. PCR conditions were an initial
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denaturing step of 95°C for 3minutes, followed by 35 cycles of 60 seconds at 95°C, 60
seconds at 57 °C, and 90 seconds at 72 °C, with final 5 minutes at 72 °C.
PCR products were cleaned using Exonuclease I (EXO I) and Shrimp Alkaline Phosphatase
(SAP) (Amersham Biosciences) with 3ul of stock EXO/SAP added to 5ul PCR product.
Cycling was performed as 37°C for 15 minutes followed by 80°C for 15 minutes. The
sequencing reaction was performed using 4ul of EXO/SAP treated PCR product with 2.5ul
Big Dye terminator, 1.3ul of forward and reverse primers and 5.8ul dFf>0. The sequencing
PCR program consisted of 25 cycles of 96°C for 30 seconds, 50°C for 15 seconds and 60°C
for 4 minutes.
DNA was then precipitated by adding 55ul of 95% ethanol/ 10% volume NaOAc (pH 5.2), to
each well, and leaving on bench for 30 minutes. Samples centrifuged at 2000 g for 30
minutes at 20°C and supernatant removed, including inversion of plates on paper towels and
pulse centrifugation. 150ul of 70% ethanol then added and pulse centrifugation repeated.
Pellets were stored at -20°C until sequenced. Sequencing was performed on ABI 3700
platform with accompanying sequencing analysis software.
2.5.5 TGFB RFLP assay
Analysis was performed on a poly A tract of the TGFBRII gene as a paradigm for the
analysis of microsatllite sequences in plasma from microsatellite unstable colorectal cancer
patients. A restriction digest based assay was adapted from Mironov (394) specifically for the
detection of lbp deletions in the poly(A)io tract of the TGFBRII gene(392).
The poly A tract (highlighted) of the TGF-|3RII gene is a 10 base pair adenosine repeat (Aio)
at codons 125-128 of its 565 codon open reading frame:
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gcaactgcag catcacctcc atctgtgaga agccacagga agtctgtgtg gctgtatgga
gaaagaatga cgagaacata acactagaga cagtttgcca tgaccccaag ctcccctacc
atgactttat tctggaagat gctgcttctc caaagtgcat tatgaaggaa aaaaaaaagc
ctggtgagac tttcttcatg tgttcctgta gctctgatga gtgcaatgac aacatcatct
tctcagaaga atataacacc agcaatcctg acttgttgct agtcatattt caagtgacag
The assay is based on the introduction of a Hinfl restriction enzyme cleavage site in the
presence of a 1 bp deletion within the polyA tract (Figure 2.1). Reaction conditions as
described below result in the generation of a 141 bp wild type product and / or a 118bp

































































































































Figure 2.3 legend: Demonstration ofwildtype and mutant product from cancer cell line. (392)
5ul of PCR product was digested at 37°c for 16 hours in a total volume of 15 ul with 5 units
Hinfl restriction enzyme and lx buffer H (Boehringer Mannheim). Digested and undigested
PCR products were analysed on an ABI 310 automated genetic analyser (Applied
Biosystems) and Genescan 2.1 software. 3ul Hinf digestion product was added to 0.5ul size
standard and 10.5 ul of formamide. Samples then denatured at 95° for 5 minutes, then placed
on ice for 5 minutes. Sample ABI 310 injection times were 5 seconds for PCR products and
10 seconds for digestion products.
a) Determination of Sensitivity
Serial dilutions of LoVo DNA were added to control plasma to yield spiked concentrations of
1 OOpg, 500pg, 1 ng, 1 Ong and 50ng per ml of plasma. Plasma DNA was then extracted using
QIAgen extraction kit as described in chapter 3.
b) Primers and Reaction Conditions
i) Primers
Assay primers were as follows. The forward primer was initially labelled with FAM and
subsequently with HEX.
Forward (fluorescent labelled): CAC TCT AGG AGA AAG AAT GAC GReverse:
GAA AGT CTC ACC AGG CTT TTT GAT T
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ii) Reaction Conditions
Reaction constituents were as follows:
5ul each ofPCR buffer II, MgCl and dNTPs, 0.25ul of taq polymerase, 0.5ul of forward and
reverse primers, 5ul template and 29.25 ul of df^O. Following initial difficulties the taq
polymerase was substituted with high fidelity Taq (Expand High Fidelity PCR System-
Roche), and was used in all subsequent reactions.
Initial PCR reagents and cycling were as follows:
95°C for 3 mins followed by 35 cycles of 95 0 for 1 minute, 500 for 1 minute and 72 0 for 1
minute, followed by 72° for 5 minutes then 320 for 15 minutes. These conditions were
utilised for assay validation on positive and negative control genomic DNA as well as in the
analysis of tumour DNA from cases.
For analysis of plasma DNA, including determination of assay sensitivity in spiked plasma
samples, PCR cycling conditions required optimisation. Annealing temperature was serially
altered at inceasing cycle numbers. Performance was optimised at 45 cycles of the above
cycling with an annealing temperature of 58 oC.
Hi) Nested PCR
Given the limited performance of the assay with plasma DNA, the assay was adapted using a
nested PCR approach.
Primary PCR was perfomed using primers for exon 3 of TGFBRII, and secondary PCR with
the assay primers described above.
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Exon 3 primers:
Forward CCT CGC TTC CAA TGA ATC TC
Reverse TTG GCA CAG ATC TCA GGT CC
Optimisation was performed by serial alteration of primer concentration, annealing
temperature and cycle number in both primary and secondary, to a maximum of 55 cycles in
total. The minimum cycling at which product was reproducibly detectable was as follows:
Primary PCR 15 cycles at 58 oC annealing.
Secondary PCR 35 cycles at 58 oC annealing
iv) Analysis
5ul of PCR product was digested at 37°c for 16 hours in a total volume of 15 ul with 5 units
Hinfl restriction enzyme and lx buffer H (Boehringer Mannheim). Digested and undigested
PCR products were analysed on an ABI 310 automated genetic analyser (Applied
Biosystems) and Genescan 2.1 software. 3ul Hinf digestion product was added to 0.5ul size
standard and 10.5 ul of formamide. Samples then denatured at 95° for 5 minutes, then placed
on ice for 5 minutes. Sample ABI 310 injection times were 5 seconds for PCR products and
10 seconds for digestion products.
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2.5.6 TGFB Real Time PCR analysis
Fluorescently labelled MGB oligonucleotide probes were designed to the poly A tract in
accordance with manufacturers guidelines (Applied Biosystems)
Wt CTC CAA AGT GCA TTA TGA AGG AAA AAA AAA AGC CT
35 bases. Tm 69.3. GC 34.3%. 6 G's, 6 C's.
lbp deletion TCT CCA AAG TGC ATT ATG AAG GAA AAA AAA AGC C
34 bases. Tm 69.5. GC 35.3. 6 G's, 6 C's.
Primers: Forward TAC CAT GAC TTT ATT CTG GAA GAT GCT
Length 27 bases, GC 37%, Tm 59.5, 3'GC 2/5
Reverse CTA CAG GAA CAC ATG AAG AAA GTC TCA
Length 27 bases, GC 40.7%, Tm 58.9, 3'GC 2/5
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2.5.7 K-ras assay:
Sequence derived from nucleotide accession number L00045.1 (locus map 12p 12.1) showing
codon 12 at base 129 coding GGT, being the normal sequence:
1 gtactggtgg agtatttgat agtgtattaa ccttatgtgt gacatgttct aatatagtca
61 cattttcatt atttttatta taaggcctgc tgaaaatgac tgaatataaa cttgtggtag
121 ttggagctg-i tggcgtaggc aagagtgcct tgacgataca gctaattcag aatcattttg
181 tggacgaata tgatccaaca atagaggtaa atcttgtttt aatatgcata ttactggtgc
241 aggaccattc tttgatacag ataaaggttt ctctgaccat tttcatgagt
The specific mutation investigated was alteration GGT -> GAT (glycine to aspartate), which
has been reported as the most frequent mutation of codon 12 in colorectal cancer (395).
a) Sequencing
Sequencing of k-ras was performed as described in section 2.5.4 using the following primers:
Forward TTT ATT ATA AGG CCT GCT GAA AAT GA (Length 26,Tm58)
Reverse CAA AGA ATG GTC CTG CAC CAG (Length 21 ,Tm59)
Amplicon length 181 bp
b) Real-time PCR
H SYBR Green
Sequence specific primers were designed to wild type (wt) and aspartate mutant sequences
for use in real time PCR, according to manufacturer's guidelines, using the manufacturer's
primer design software (Primer Express, Applied Biosystems).
Wt ras forward: ATA TAA ACT TGT GGT AGT TGG AGC TGG
Length 27, Tm 59
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Aspartate mutant: GAA TAT AAA CTT GTG GTA GTT GGA GCT GA
Length 29, Tm 59.4
Common reverse TGG ATC ATA TTC GTC CAC AAA ATG
Length 24, Tm 59.6
Each primer diluted with dH20 to 100 pmol/ul
These primers were subsequently modified, with an induced base mismatch adjacent to the
mutation site to reduce annealing stability to increase primer specificity for wild type and
mutant sequences. These modified primers were termed wobble primers and the sequences
are given below:
Wt ras wobble forward: ATA TAA ACT TGT GGT AGT TGG AGC AGG
Aspartate mutant wobble: GAA TAT AAA CTT GTG GTA GTT GGA GCA GA
Common reverse: TGG ATC ATA TTC GTC CAC AAA ATG
Diluted 100 pmol/ul
For each of the above primer pairs, the primer concentration was optimised using a
SYBR green primer optimisation grid, given below with concentrations in nM:
50 Forward 50 Forward 50 Forward
50 Reverse 300 Reverse 900 Reverse
300 Forward 300 Forward 300 Forward
50 Reverse 300 Reverse 900 Reverse
900 Forward 900 Forward 900 Forward
50 Reverse 300 Reverse 900 Reverse
This identified primer concentrations of 300 nM forward and 900 nM reverse primers as
giving the lowest cycle number to cross threshold (Ct) for the same templates whilst not
giving false positive readings with non-template controls.
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This resulted in the following reaction constituents for SYBR green reactions:
12.5 ul SYBR green mastermix, 0.75 ul forward primer, 2.25 ul reverse primer, 4.5 ul df^O, 5
ul template DNA.
Reaction Conditions were
Step 1; 95°C for 10:00 minutes
Step 2; 50 cycles of 95 °C for 0:15 then 60°C for 1:00
ii) Taqman MGB Probes
Specific Taqman MGB primer and probe pairs were designed according to manufacturer's
instructions, generating the following sequences:
Wild type probe (antisense strand)
CCT ACG CCA CCA GCT (15 bases, Tm 69.1)
Aspartate mutant probe (antisense strand )
CCT ACG CCA TCA GC (14 bases, Tm 68.8)
Forward primer (antisense)
TAG CTG TAT CGT CAA GGC ACT CTT (24 bases, Tm 58.3)
Reverse primer (sense)
AAA ATG ACT GAA TAT AAA CTT GTG GTA GTT G (31 bases, Tm 58.6)
These primers and probes were tested on positive and negative controls as detailed above.
The real time PCR mixture consisted of 12.5ul of TaqMan Universal PCR Mastermix, 0.75ul
of both forward and reverse primers, 0.625ul of both FAM and VIC labelled probes, lul of
template and dhiO to a final volume of 25ul.
Reaction conditions were:
Step 1; 95 °C for 10:00 minutes
Step 2; 50 cycles of 95 °C for 0:15 then 60 °C for 1:00
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RealTimePCRAnalysisofK-r scodon12us gSYBRGree
K-rasexon1(fromaccessionn .L00045.1) 1012 TGAATACTGGOCTGCA AWildtype GATAspartatemu nt 1.SpecificPrimerstoMutantandWild-type WildtypeForwardPrim r T^GATATACTGG GC GAATATCTGGCGTC GAT(aspartatemutant) GAATATACTGGC Asnartatemut ntForw rdPri er GCTAAT ATGC C CATTTGG AACC CommonReversePrimer=TGGATCAGA
2.PrimersDesignedwithBasMismatch(Wobble) WildtypeobbleForwardPr m r ATATACTGGAT GGC
5»■———GAATATACTGGAT GCGTGGACGTTTA GAT(aspartatemutant)GAATATACTGGAT GCGT Aspartatemut ntWobblForw rd GCTAAT ATTGTG ACATCCTGACT CATTTGG AATTCC CommonReversePri er=TGGATCAGTCACA AG
2.6 MicrosatelliteFluorescent PCR Analysis
Fluorescent microsatellite analysis was performed on matching normal, tumour and plasma
DNA from 85 cases and 24 controls at 3 microsatellite markers. The microsatellite markers
chosen were D5S346, D17S250 & D18S58 on the basis of their being highly polymorphic,
located in chromosomal regions important in colorectal cancer and frequently used in
determining microsatellite status in biological samples.
2.6.1 Microsatellite markers
a) D5S346
Located at 5q22.2, within the region of chromosome 5q, related to the APC gene, commonly
deleted in colorectal cancer (396). D5S346 is one of five Bethseda markers for determining
microsatellite status. Estimations of frequency ofmicrosatellite alterations in colorectal
cancer at D5S346 are around 50% (397). Primers were as follows:
Forward (HEX labelled): ACT CAC TCT AGT GAT AAA TCG GG
Reverse (unlabelled): AGC AGA TAA GAC AAG TAT TAC TAG TT










Located at 17ql2, related to the phosphatase and tensin homologue (PTEN) tumour
suppressor gene. D17S250 is one of five Bethsada markers for determining microsatellite
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status. Estimations of frequency of microsatellite alterations in colorectal cancer at D17S250
are around 50% (397). Primers were as follows:
Forward (TET labelled) GGAAGAATCAAATAGACAAT
Reverse (unlabeiled) GCTGGCCATATATATATTTAAACC
Amplicon length —151 bp













Located atl 8q22. Related to the Deleted in colon cancer (DCC) gene, with estimated














The constituents for the PCR reactions were 2ul lOx buffer , lul 50mM MgC^, 2ul 2 mM
dNTP, I unit of Platinum Taq DNA polymerase and 0.4ul each of 20uM forward and reverse
primers (Invitrogen, UK). For tumour and normal samples lul ofDNA template was added,
and for plasma samples 2.4ul of plasma DNA was added. Distilled water was added to give a
total reaction volume of 30ul. All reactions included a negative, no template control well.
b) PCR Cycling
PCR conditions were an initial denaturing step of 95° for 3minutes, followed by 35 cycles of
60 seconds at 95 °C, 60 seconds at 57 °C, and 90 seconds at 72 °C, with final 5 minutes at 72
°C. A 55 °C annealing temperature was used for amplification ofD17S250 marker in plasma
samples.
c) Analysis
PCR products were processed for analysis by adding 0.25-5.0ul (tumour and normal) or 5.0-
6.0 ul (plasma) to lul of GeneScan 400HD size standard (Applied Biosystems) and denatured
Hi-Di formamide to a total volume of 14ul.
Samples were denatured at 95 °C for 3 minutes, cooled on ice and then analysed using ABI
3730 platform and GeneMapper version 3.7 software (Applied biosystems).
Maximal peak heights were recorded, corresponding to differing alleles. Where a single allele
was observed this was taken to represent homozygosity at the given marker and hence non-
informativity. A ratio of peak heights from differing alleles was calculated from normal,
tumour and plasma DNA and compared to determine the presence of LOH in tumour and / or
plasma samples.
146
There is no consensus in the literature as to what level of change in allelic ratio may be
classified as LOH, with studies using values between 30-70% alteration. Analysis was
performed at 50% change in allelic ratio.
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2.7 APC gene 15n Real time PCR Assay
2.7.1 Assay Design
Previous work within this group had identified a polymorphism within exon 15 of the APC
gene that was frequently heterozygous in colorectal cancer patients. This ' 15n' polymorphism
constitutes a base change CCA to CCG between bases 5886 and 5940 on accession number
M74088. The assay was designed according to the guidelines given by the primer and probe
manufacturer (Applied Biosystems), and performed using primer express software provided
with the real-time PCR platform, AB17900HT (Applied Biosystems). The resultant primer
and probe sequences are given below.
The assay is presented diagrammatically in figure 2.5.
a) Primers and Probes
APC 15n sequence:
APC exon 15atcodon 1961. Base 5883 of accession number M74088.
Polymorphism is CCA - CCG
5701
accagccaca cagaactaac ctccaaccaa caatcagcta ataagacaca agctattgca
aagcagccaa taaatcgagg tcagcctaaa cccatacttc agaaacaatc cacttttccc
cagtcatcca aagacatacc aqacaqagqq qcag|^^^^^^^|^^^B^I^IHHHI
^tattgaaa atactco gt ttgcttttbt cataattcct ctctgagttc tctcagtfgac
attgaccaag aaaacaacaa taaagaaaat gaacctatca aagagactga gccccctgac
tcacagggag aaccaagtaa acctcaagca tcaggctatg ctcctaaatc atttcatgtt
gaagataccc cagtttgttt ctcaagaaac agttctctca gttctcttag tattgactct 6121
















The real time PCR mixture consisted of 12.5ul ofTaqMan Universal PCR Mastermix, 0.75ul
of both forward and reverse primers, 0.625ul of both FAM and VIC labelled probes, lul of
template and dlUO to a final volume of 25ul.
Real time PCR was performed on the ABI 7900 HT (Applied Biosystems) with cycle-by-
cycle fluorescent product visualisation. Cycling conditions were 95° for 10 minutes, followed
by 40 cycles of 95° for 15 seconds and 62° for 1 minute.
c) Assay Validation
Assay validation was performed on buffy coat DNA from 45 cases from the prospective
cohort. Confirmation ofDNA sequence at the 15n SNP was confirmed by sequencing of 10
of these cases' normal DNA using 15n primers, with sequencing performed as described in
section 2.5.4.Sequenced cases were numbers MD 2535, 2536, 2537, 2538, 2540, 2541, 2543,
2544, 2565 and 2566.
The primers used for the sequencing reaction were:
Forward: 5' AAA GAC ATA CCA GAC AGA GGG
Reverse: 5' CTT TTT TGG CAT TGC GGA GCT
2.7.2 Determining the Limit of Resolution Allelic Imbalance Detection in Plasma
Using Taqman Assay
AI was experimentally introduced into control plasma by adding serial dilutions of known
quantity DNA homozygous for the CCA (FAM) allele. Control plasma was from patient ID
72. Homozygous DNA for the CCA allele was extracted from buffy coat from case 2536
(2536 N) as previously described (section 5.2.2).
Quantification of 2536 N DNA was performed using spectrophotometry.
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Serial dilutions of 2536 N DNA were performed and added to 1ml of control plasma DNA.
Concentrations of added CCA homozygous DNA were 100 ng / ml of control plasma,
lOng/ml, 5ng /ml, 3 ng/ml.
Plasma DNA was extracted using the QIAgen protocol, as described in chapter 3, from 200ul
of plasma in a total of lOOul of elution buffer. Spiking, extraction and analysis were
performed in triplicate.
2.7.3 Analysis of Tumour Samples
Comparison was made between the 15n assay and conventional fluorescence electrophoresis
in determining LOH in tumour samples. An unselected subset of the prospective cohort was
studied (n= 45). This cohort was analysed since these constituted the recruited patients at the
point at which this portion of assay development was undertaken,
a) Microsatellite analysis
i) Primers
Fluorescence microsatellite analysis was performed for matched tumour and normal samples
using the markers D5S346 and D5S82. These markers were chosen on the basis of their
location within the frequently deleted region of chromosome 5p, and hence their relation to
the APC gene and its 15n SNP. Primers for D5S346 were as described in section 2.6.1 a).
D5S82
Forward primer (FAM labelled) ATCAGAGTATCAGAATTTCT
Reverse primer (unlabelled) CCCAATTGTATAGATTTAGAAGTC
Amplicon 169 bp
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Sequence from accession M76582:
1 CCCAATTGTA TAGATTTAGA AGTCATTTTA CACACACACA CACACACACA CACAATTAAT
61 ATGATATGTG TGTGCATGTA TAATTTTTAT CTCAATATTT TAGATGTGAA CAGGGAAAAG
121 TCATAATCCG TTGGCCCTCA CTTCATTTGA AAGAAATTCT GATACTCTGA T
ii) Reaction constituents
PCR reaction mixture consisted of 5ul of lOx PCR buffer, 5ul ofMgCl, 5ul of dNTPs 1 ul of
each primer (at lOOng/ul concentration), 0.25ul of Taq polymerase, 2ul of template and dPhO
upto a volume of 50ul. PCR thermal cycling was performed on PTC-225 thermal cycler (MJ
Research). An initial denaturing step of 95°c for 5 minutes, followed by 35 cycles of 95 °c for
60seconds, 55 °c for 60 seconds, 72 °c for 90 seconds, with a final step of 72 °c for 5 minutes.
Hi) Analysis
PCR products were processed for analysis by adding lul product to lul ofGeneScan 350
Tamra size standard (Applied Biosystems) and denatured Hi-Di formamide to a total volume
of 14ul. Samples were denatured at 95 0 for 3 minutes, cooled on ice and then analysed using
AB1 310 platform (Applied Biosystems) with analysis ofGenescan 2.1 software (Applied
Biosystems). Where a single allele was observed this was taken to represent homozygosity at
the given marker and hence non-informativity. A ratio of peak heights from differing alleles
was calculated as described in section 2.6.2 c).
Levels of allelic loss were classified into 3 groups
1) Clear-cut LOH: where allelic ratio was altered >50% in tumour compared to normal
2) Ambiguous LOH: alteration in allelic ratio between 20-50%
3) No LOH: alteration of allelic ratio <20%.
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b) 15n assay
Analysis of the same 45 cases tumour and normal samples, as well as buffy coat DNA from
12 controls was performed using the 15n assay. Reaction constituents and conditions were as
described for assay validation.
The FAM and VIC fluorescence readings for each sample were recorded numerically. An
allelic ratio was generated by dividing the FAM fluorescence by the VIC fluorescence
reading. Allelic ratios were compared between control, normal and tumour DNA with
reference to the results of fluorescence electrophoresis.
2.7.4 Analysis of Plasma DNA
Real time PCR analysis using the 15n assay was performed on matched pre-operative plasma
samples for the same cohort of cases (n=45) as those with tumour DNA analysis described
above. Additionally plasma DNA 8 controls were analysed.
The primers and probes were as described, with reactions being performed in a final volume
of 25ul. Reaction constituents were therefore 12.5ul of TaqMan Universal PCR Mastermix,
0.75ul of both forward and reverse primers and 0.625ul of both FAM and VIC labelled
probes. Initially 5ul of plasma DNA template was used then experiments repeated using lOul
ofDNA template, with the remainder of the reaction mixture made up with dtDO.
Real time PCR was performed on the ABI 7900 HT (Applied Biosystems) with cycle-by-
cycle fluorescent product visualisation. Cycling conditions were 95° for 10 minutes, followed
by 50 cycles of 95° for 15 seconds and 62° for 1 minute.
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2.8 Dilutional PCR
The 15n assay was adapted to count large numbers of individual alleles. Dilutional small pool
PCR was performed using serial dilutions, similar to previously described digital PCR.
2.8.1 Assay validation
Assay validation was performed by allele counting normal DNA from a heterozygous control
subject (case number69) in triplicate.
2.8.2 Study Subjects
A subset of the prospective cohort was analysed where a larger volume of plasma had been
taken to allow sufficient template for multiple reactions. This subset constituted 13 cases and
7 controls (all with negative colonoscopies), and are presented in table 2.3. Patient allelic
status was determined using the 15n assay applied to DNA from buffy coat, under conditions
as described above. 4 heterozygous (informative) controls were identified, and 4
heterozygous cases.
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Table 2.3 Allele counting study group characteristics
Case number Case / Control Stage 15n status
5004 Case II CCA
5005 Case III CCG
5006 Case III CCA
5007 Case IV CCA
5008 Case III CCG
5009 Case II CCA
5011 Case III HETERO
5012 Case Adenoma CCA
5504 Control n/a HETERO
5505 Control n/a HETERO
5506 Control n/a CCA
5507 Case III CCA
5508 Case III HETERO
5509 Case II HETERO
6335 Control n/a HETERO
6336 Control n/a HETERO
6337 Case I CCA
6338 Control n/a CCG
6339 Control n/a CCG
6341 Case I HETERO
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A further informative case was analysed (2530- Stage IV) where there were sufficient
quantities of plasma DNA for analysis. Prior results for this patient described in chapter 6 had
determined that this patient's tumour had clear cut LOH of a region of chromosome 5,
confirmed with 15n assay analysis.
2.8.3 Assay conditions
For plasma DNA analysis 15n assay primers and probes were as described in section 2.7.
PCR reaction mixture and cycling were also unchanged, except for only lul of (diluted)
template was added with a corresponding increase in water (total volume 12.5ul). 384 well
plates were constituted using a Biomek automated robot (Beckman Coulter). The majority of
PCR cycling of plates was performed on an ABI 7900 (Applied Biosystems), with a
proportion were performed using PTC-225 thermal cycler (MJ Research), with analysis
performed on ABI 7900 using plate reading configuration.
Plasma DNA dilutions were based on the results of quantification using picogreen (chapter
3). Test plates were made with dilutions around the level suggested by these results, using 48
wells of a 384 well plate per dilution. Confirmed dilutions were chosen when 24 out of 48
wells registered no product, and remaining wells contained generated only FAM or VIC
fluorescence without evidence of heterozygotes. Multiple plates for each plasma DNA
sample were performed at these dilutions. Plates were included for analysis when >192 wells
were recorded as empty, and <20 wells registered as heterozygotes. Individual CCA and
CCG alleles were counted and recorded manually. Replicates were performed until >1000
individual alleles were recorded. Allele counting of plasma DNA from cases was performed
blinded, i.e. without prior knowledge of the allelic status of those patients' tumours, with the
exception of case 2530 (the test case).
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2.8.4 Analysis
The numbers of observed plasma DNA alleles was compared to the number of expected
alleles for a heterozygote with allelic balance (i.e. 1:1, or 500:500). Statistical analysis was
performed using the X2 test.
Subsequent to analysis of plasma DNA, allele counting was performed on matched tumour
samples. Methods were as described for plasma DNA analysis, with the exception of fewer
alleles were counted (>100).
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CHAPTER 3
EXTRACTION AND QUANTIFICATION OF PLASMA DNA
3.1 Introduction
The published literature on circulating DNA describes a broad range of published methods
that have been used in identifying tumour derived DNA in the circulation. Studies have
commonly analysed either serum or plasma DNA that has been extracted using various
generic and commercially available extraction reagents and protocols. Whilst the positive
results from these different methods suggest a degree of flexibility in the approach employed,
it also raises difficulties of comparing results between studies using different methods
particularly where contradictory results have been reported. Although discussion occurred in
this respect at an early international meeting (CNAPSI-circulating nucleic acids in plasma
and serum I) with methods published f399T to date there is no consensus on standard
methods employed by researchers in the field, despite subsequent meetings and remains a
source of much debate within the field (400), although there is evidence that new
commercially extration kits may give higher yields (401).
Authors have suggested that the process of blood clotting results in the release of normal
DNA from cells involved in initiation and propagation of the clot, and hence may result in the
'dilution' of tumour derived DNA in a further pool of normal DNA. In this project it was
therefore elected to analyse plasma DNA and this was performed throughout. There are
however potential problems with the use of plasma DNA, since the chemicals employed to
prevent clotting have been suggested to have an effect on the PCR process. To this end
duplicate samples were collected from all patients (except those recruited for allele counting
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experiments, on account of the relatively large volume required for this process) in both
EDTA and Lithium Heparin tubes.
The absolute quantity of plasma DNA from patients and controls has been correlated with
clinical states both in benign and malignant conditions, as discussed in section 1.5.land 1.5.3
e. Furthermore quantity of template added to qualitative reactions is likely to have an impact
on assay performance.
This chapter describes an assessment ofmethods of plasma DNA extraction and the results of
a number of assays to quantify total plasma DNA. The best performing assay for
quantification of plasma DNA was then correlated with the presence of disease as well as
disease stage and survival.
3.1.1 Quantification of plasma DNA:
a) Methods for quantifying DNA
Spectrophotometry is a commonly used method for quantifying and assessing the purity of
DNA. The principle is absorption of different wavelengths of light by differing substances
including DNA and protein. As such the quantity and purity ofDNA can be estimated
according to the equation given below in materials and methods, based on absorbance of light
at 260nm (A26o)- This approach is however relatively insensitive, is unable to discriminate
RNA from DNA and is affected by nucleotides and single stranded DNA.
Real time PCR allows cycle-by-cycle visualisation of template amplification. Inclusion of
template standards of known concentration allows generation of a standard curve and hence a
direct measure of target DNA template quantity.
Picogreen® ds DNA quantitation reagent is an ultrasensitive fluorescent nucleic acid stain for
quantitating double stranded DNA (dsDNA). Level of detectability has been suggested to a
level of 25pg/ml of ds DNA (3901. Additionally the technique for determining concentration
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is simple and can be performed quickly on multiple samples with the use of fluorescence
plate readers. Picogreen has been previously used to determine plasma DNA concentration in
patients with a variety of cancers (52;402;403)
b) Rationale for quantifying plasma DNA
The rationale for wishing to quantify DNA included the technical implications of quantity in
assay development for detecting tumour derived DNA in plasma. Additionally there is some
evidence that quantity of plasma DNA may have utility in the detection and prognosis of
disease states, including in colorectal cancer as discussed in chapter 1 (1.5.1 & 1.5.3 e)),
although there was little data in the literature at the outset of this project.
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3.2 Materials and Methods
3.2.1 Plasma DNA Extraction
Several methods of extracting plasma DNA were investigated with protocols for each of the
extraction methods used detailed below.
a) Phenol chlororform Extraction / CNAPS I protocol
Variations from published protocol are indicated in brackets (404):
i) DNA Extraction
1.5mls (200ul) of plasma was added to 1.5mls (200 ul) of IX SDS proteinase K solution and
mixed well. The sample was digested overnight in water bath at 55 oC. The digested sample
was then added to equal volume, 3mls (400ul) ofwater saturated phenol/chlororform (not
performed in vacutainer brand SST tubes with gel barrier). The sample was vortexed for 30
seconds, followed by centrifugation for 10 minutes at 2500 rpm. The upper layer was taken
off and phenol / chloroform treatment repeated as above.
ii) DNA Precipitation
The upper layer from repeat phenol / chloroform treatment was taken and 3ul (20mg/ml) of
glycogen added (Boehringer Mannheim), in addition to 1ml of 7.5M ammonium acetate and
8ml of 100% ethanol. The sample was mixed by inverting several times (sample placed in -
80 freezer for 60 minutes). The sample was then centrifuged at 6000rpm (4500g) for 60
minutes (at 20 oC). The supernatant was then carefully poured off, keeping the pellet at the
bottom of the tube. 10 mis 70% ethanol was added and further centrifugation performed at
6000 rpm (4500g) for 10 minutes. The ethanol was then discarded, and the sample left open
for residual ethanol to evaporate. 200ul of LoTE buffer was added and left overnight at room
temperature to resuspend pellet. Samples were stored at -20 oC.
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b) Nucleon Protocol
Variations from published protocol are indicated in brackets:
5 mis ofwhole blood (200ul plasma) were added to 40 mis (1,6mls) of reagent A. the sample
was mixed for 4 minutes at room temperature, then centrifuged at 1300g for 4 minutes. The
supernatant was discarded without disturbing cell pellet. 2ml of reagent B was then added
and vortexed to resuspend the cell pellet. (RNAse step omitted). 500ul of Sodium Perchlorate
was added and rotary mixed/shaken at room temperature for 15 minutes. Tubes were then
incubated in shaking water bath at 65 oC for 25 minutes. 2 mis of choloroform, which has
been stored at -20 oC, was then added and the sample rotary mixed/shaken at room
temperature for 10 minutes and then centrifuged at 800g for 1 minute. 300ul of Nucleon
Silica Suspension (shaken vigorously before adding) was added and then centrifuged at
1400g for 3 minutes. Holding the tube vertically and without disturbing the Nucleon Silica
Suspension layer, only the DNA containing phase above the nucleon layer was transfered into
a fresh centrifuge tube. The sample was centrifuged briefly at 1300g to pellet any residual
Nucleon silica and supernatant carefully decanted to a fresh tube. Aqueous DNA containing
phase was added to two equal volumes of cold ethanol at 4 oC. The sample inverted gently to
precipitate DNA.
c) Qiagen Protocol
200ul of plasma was added to 20ul proteinase K and 200 ul buffer AL and mixed by pulse
vortexing for 15 seconds. The sample was incubated at 56 oC for >10 minutes, then briefly
centrifuged. 200ul pure ethanol was added and mixed by pulse vortexing. This mixture was
applied to QIAamp spin column and centrifuged at 8000rpm for 1 minute. 500ul of buffer
AW1 was then added to spin column and centrifuged at 8000 rpm for 1 minute. Next 500ul of
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buffer AW2 was added to spin column and centrifuged at 14000 rpm for 3 minutes. 50ul of
buffer AE was then added to spin column and left to stand at room temperature for 30
minutes. The column was centrifuged at 8000 rpm for 1 minute. A further 50ul of buffer AE
was added to spin column and left to stand at room temperature for 30 minutes. Column
centrifuged at 8000 rpm for 1 minute. This extraction was performed for all cases and
controls.
Additionally for cases and controls utilised in allele counting experiments a further large
volume extraction using the QIAamp maxi kit was performed extracting DNA from 8 mis of
plasma with elution in 300ul of elution buffer.
d) Analysed Samples
Negative controls were performed with an aliquot ofwater, of the same volume as plasma
subjected to extraction, undergoing each extraction protocol.
Positive controls were provided by LoVo DNA derived from cell culture as described in
chapter 2
Normal subjects plasma was derived from 3 healthy control subjects (MD 68, 69 and 74).
Extraction and analysis was performed on plasma alone, and of serial dilutions of added
LoVo DNA (Ong, 50ng, lOOng and 1microgram).
e) Assessment
Assessment of extracted DNA was performed by
i) PCR and visualisation by gel electrophoresis as described in chapter 2.
ii) PCR with microsatellite markers and fluorescent microsatellite analysis as
described in chapter 2.
iii) Quantification: described below
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3.2.2 Quantification of Plasma DNA from Cases and Controlsa) Real time PCR subset
Plasma DNA from a subset of the prospective cohort was quantified by real time PCR. This
subset comprisedcolorectal cancer cases (n=24) and controls (n=10) heterozygous for a APC
gene SNP, derived from the first 75 subjects recruited from the prospective cohort.
b) Picogreen
Plasma DNA was quantified for the whole prospective cohort of cases and controls.c) Small pool PCR
Allele counting was performed for a total of 5 cases and 4 controls, being those cases where
sufficient quantity of plasma DNA was availableto perform the high number of replicate
samples required.
Plasma DNA Quantification was performed by spectrophotometry, real time PCR, picogreen




Initial experiments aimed to compare 3 extraction methods for plasma DNA, for ease of use
and reproducibility both of the extraction process and analysis of extracted DNA.
a) Phenol Chloroform extraction
Phenol chloroform extraction was performed as per the protocol published following CNAPS
I international conference (405), and as described in materials and methods with variations
from the published protocol indicated. Briefly, plasma DNA was extracted from 200ul of
plasma by double treatment with an equal volume of phenol choloroform, and precipitation
with ethanol.
Performing this extraction procedure however resulted only in a cloudy solution, without an
obvious interface between layers. Repeating phenol cholorform treatment a third time
resulted in semi-solid white matter on which it was not possible to perform further
processing. Precipitation of the cloudy solution with ethanol did not result in the generation
of a visible pellet, however reconstitution was performed with LoTE. Spectrophotometry of
the resultant solution gave very low values, not consistent with the presence of appreciable
quantities ofDNA, and PCR using standard microsatellite markers using the resuspended
solution as template failed to yield any demonstrable PCR product, by gel elctrophoresis, or
by fluorescent PCR analysis. Replication of this process in triplicate from further control
samples and samples with added serial dilutions of exogenous (LoVo) DNA resulted in the
same results.
b) Nucleon Extraction Kit
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Plasma DNA extraction was attempted using a Nucleon extraction kit, as described in
materials and methods. Attempts at extraction of plasma DNA, gave a large amount of
crystalline precipitant that was not possible to dissolve in TE. Further analysis was attempted
with the solution above the crystalline precipitant in which resuspension was attempted,
including leaving the solution on the precipitant for >24 hours following repeated vortexing.
However the 'resuspension' solution failed to yield any appreciable signal on
spectrophotometry, and failed to generate PCR products when used as template for standard
microsatellite marker PCR.
c) Qiagen Extraction Kit
Plasma DNA from 200 ul control plasma was repeatedly extracted using the QIAgen
QIAAMP mini body fluid protocol as described in materials and methods. This commercially
available kit is designed for use with small volume samples, and allowed reproducible sample
processing. Precipitants remained contained within the extraction column, resulting in a
predictable volume of clear elutant at the end of the process. Quantification of the extracted
DNA is described further below. Extraction in triplicate on test samples allowed consistent
generation of PCR products
Given the difficulties with the other extraction methosds detailed above, it was elected to




Spectrophotometry quantification of plasma DNA was performed in triplicate on samples as
described in section 3.2.. Extraction was performed from 200ul of plasma using the QIAgen
protocol, eluted in 100 ul of elution buffer.
Plasma DNA concentration was calculated for all samples, in micro gram quantities. This
was the case for each control and illustrated by the results in table 3.1 for control 1 (case
number 68). Additionally inter-sample variation was wide indicating the inaccuracy of the
technique when applied to low copy number template DNA. Finally results were incongruous
by giving smaller concentrations for plasma samples where large quantities (microgram) of







Extraction 1 0.039 1.311 19.7
Extraction2 0.103 1.375 51.3
Extraction3 0.019 2.397 9.3
Total 26.8
95%CI =-9.1 to 62.7
Table 3.1 legend: Spectrophotometry results (average of 3 readings) from triplicate




(average of 3 readings)
Ratio Concentration
ug/ml
Controlplasma 0.018 2.172 9







Table 3.2 legend: Spectrophotometry results from control plasma spiked with exogenous
DNA.
b) Real-Time PCR
Quantification of plasma DNA was performed utilising a real-time PCR Taqman assay
designed to a SNP on chromosome 5, as described in chapter 2. Standard DNA from Applied
Biosystems was serially diluted to provide concentration standards. Amplification was
performed using standard reagent concentrations and 50 replication cycles.
i) Test set
Real time PCR quantification was initially tested on control plasma that had serial dilutions
of exogenous CCA allele artificially added as described in sections 2.7.2 & 6.3.3. Triplicate
quantification results are presented in table 3.3.
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Table 3.3 Real time PCR quantification results from spiking of control plasma with known
quantities of normal DNA homozygous for the CCA (FAM) allele.
Sample Ouantitv 1 Ouantitv 2 Ouantitv 3 Mean
Control (68s) 16.4 40.5 11 21.4
C+ 3 ne CCA 28.7 22.0 34.3 28.3
C+ 5ne CCA 19.3 11.8 29,5 20.2
C+ lOnsi CCA 28.6 24.8 27.3 26.9
C+ lOOne
CCA
41.8 102.6 75.1 73.2
Table 3.3 legend: Triplicate results and mean quantities from real time PCR quantification of
control plasma spiked with known quantities of normal DNA from a CCA allele
heterozygote.
ii) Plasma from cases and controls
The assay was then assessed on a subset of the total cohort of prospectively collected
colorectal cancer cases and controls, namely cases (n=24) and controls (n=10) heterozygous
for the 15n SNP. Results are presented in table 3.4 for cases and table 3.5 for controls.
Examples of standard curves are given in Figures 3.1 and 3.2.
Table 3.4:
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Case number Mean[FAM] [plasmaDNA] Case number Mean[FAM] [plasmaDNA]
2461 2.335ng 467ng/ml 2605 0.932 186.4ng/ml
2488 0.0845ng 16.9ng/ml 2609 0.195 39.0ng/ml
2490 1.655ng 331ng/ml 2645 3.685 737.0ng/ml
2494 0.912ng 182.4ng/ml 2661 0.730 146.0ng/ml
2530 9.043ng 1808.6ng/ml 2662 1.106 221.2ng/ml
2532 1.518ng 303.6ng/ml 2679 0.391 78.2ng/ml
2537 0.884ng 176.8ng/ml 2683 0.556 111,2ng/ml
2539 1.545ng 309.0ng/ml 2684 0.589 117.8ng/ml
2541 0.788ng 157.6ng/ml 2699 0.112 22.4ng/ml
2567 1.455 291.0ng/ml 2700 0.414 82.8ng/ml
2568 1.398 279.6ng/ml 2710 0.694 138.8ng/ml
2597 25.485 5097.0ng/ml 2714 0.215 43.0ng/ml
Table 3.4 legend: p
Table 3.5:
asma DNA quantities from 24 cases analysed by real time PCR
Control no. Mean FAM Plasma [DNA] Control no. Mean FAM Plasma [DNA]
2535 0.132 26.4ng/ml 2726 0.136 27.2ng/ml
2542 2.487 497.4ng/ml 69 0.089 17.8ng/ml
2543 1.089 217.8ng/ml 71 0.241 48.2ng/ml
2721 0.237 47.4ng/ml 72 0.385 77.0ng/ml
2725 0.499 99.8ng/ml 75 0.149 29.8ng/ml
Table 3.51egend: plasma DNA quantities from 10 controls Spectrophotometry results from 10
controls analysed by quantitative real time PCR.
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Mean [plasmaDNA] was 108.88 ng/ml for controls and 472.68 ng /ml for cases. There was a
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Figure 3.1 legend:
Real time PCR quantification of plasma DNA from cases and controls (light blue crosses).
Standard dilutions of known concentration are indicated by blue squares, generating a
satisfactory standard curve line.
Generation of accurate quantities from plasma DNA is dependent on a reliable standard
curve. The standard DNA used in these experiments was at stock concentration of 1 Ong/ul,
and hence was diluted by up to a factor of 400 times in order to generate a standard curve
down to the concentrations observed in plasma DNA. Dilution to this level is prone to
inaccuracy due to pipetting very small quantities into large volumes ofwater. Therefore a
suitable standard curve was not always generated, as illustrated in figure 3.2, and resulted in












Real time PCR results for quantifying control DNA spiked with DNA from cultured cell
lines. Blue squares indicate dilutions of standard concentration DNA, which are widely




Picogreen quantification was performed on control plasma spiked with known quantity of
DNA, including samples spiked with LoVo DNA (as used for spectrophotometry assessment)
and those samples spiked with normal DNA homozygous for the CCA allele at the 15n SNP
as for the assessment of real time PCR quantification. The results from these assay
assessment experiments are presented in table 3.6.
Table 3.6
Sample Mean of triplicate
readings (ng/ml)
Sample Mean of triplicate
readings (ng/ml)
Control 21.1 Control 22.5
C + 50 ng LoVo 59.7 C+3ns CCA 23.2
C+100 ns LoVo 115.3 C+5ns CCA 26.8
C+ lug LoVo 976.9 C+ 10ns CCA 30.7
C+ 100ns CCA 113.8
Table 3.6 legend: IV ean quantities by picogreen analysis of control plasma with added
exogenous DNA
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ii) Plasmafrom cases and controls
Quantification using this picogreen method was performed for all of the prospectively
collected cohort, namely 87 adenocarcinomas and 7 adenomas. A total of 30 control patients
were analysed. One of these control subjects was subsequently shown to have a low grade B
cell lyphoma and was excluded from further analysis.
Linear standard DNA curves were generated, with similar results generated for replicate
samples. An example of a linear standard curve is presented in figure 3.3.
Figure 3.3
0 10000 20000 30000
y= 0.000414x
RFU R2= 0.998602
Figure 3.3 legend: Standard curve for picogreen quantification. The x axis demonstrates units
of fluorescence, and the y axis quantity ofDNA in ng. The blue diamonds indicate serial
dilutions of known quantity standard DNA.
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Mean and range values for each pathological stage, polyps and controls are presented in table
3.7.
Table 3.7
Stage I Stage II Stage III Stage IV Polyps Controls Unknown
Number 15 30 26 15 7 29 1
Mean[plasma DNA] 498 576 170 511 113 103
ng/ml (3.2 — (0- (8- (59- (56- (0-318)
(and range) 4143) 6790) 530) 2455) 269)
Table 3.7 legend: Plasma DNA quantity and number of cases by disease stage, with quantity
range presented in brackets.




Figure 3.4 Legend: Graphic representation of raw triplicate data from cancer cases, adeomas
and controls. The horizontal black bar indicates the mean value for each group.
There was a significant difference in mean plasma [DNA] between cancer cases and controls
(p=0.002). There was no significant difference between adenoma cases and controls
(p=0.611). There was no association of higher plasma [DNA] with increasing disease stage,
with no significant difference between early cancers (Dukes A&B) and late stage cancer
(Dukes C&D) (p=0.078).
The receiver operator curve for cancer is presented in Figure 3.5.
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Figure 3.5:
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0,8 0.9 1
Figure 3.5 legend: ROC curve for cancer
The area under the ROC curve for cancer was 0.696. Therefore given specificity set at set at
100%, sensitivity for cancer was 26.1%. With specificity set at 90%, sensitivity was 31.8%.
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d) Dilution
Further data on plasma DNA quantity was generated in allele counting experiments described
in chapter 7. Whilst these experiments were designed to examine allelic ratios within plasma
DNA, the methods necessitated dilution ofplasma DNA to visualise a single copy within a
reaction well, hence alsoproviding direct evidence of plasma DNA concentration in the
analysed samples. The test samples of control plasma spiked with exogenous concentrations
of DNA was not performed by allele counting given the high degree of reagent costs.
Allele counting was performed for a total of 5 cases and 4 controls.
Extrapolation of the degree of dilution required to give a single DNA copy in every other
well was performed and the results demonstrated in table 3.8:
Table 3.8
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1 : 200 3300 2455
5011 1 : 9 59 56
5508 1 : 20 132 184
5509 1 : 55 363 482
6341 1 : 28 185 285
Controls
5504 1 : 10 66 82
5505 1 : 11 73 127
6335 1 : 10 66 78
6336 1 : 9 59 28
Table 3.8 legend: Dilution required to generate one copy per well for allele counting
experiments, with calculated plasma DNA concentration and quantity by picogreen analysis
given in the last column.
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3.2.3 Survival
Survival analysis of cancer cases was performed. Mean survival was 1417 days. The survival
curve for all cases is presented in figure 3.6.
Figure 3.6:
Survival Plot (PL estimates)
Survivor
Figure 3.6 legend: Kaplan- Meier survival curve for all cancer cases.
Survival analysis was then performed to compare the survival of cancer cases with a plasma
DNA concentration of below 250ng/ml to those with a higher concentration as determined by
picogreen quantification. The survival curves for these 2 groups is presented in figure 3.7.
The hazard ratio for death for those with plasma DNA concentration lower than 250ng/ml
was 0.72 (95% confidence interval 0.36-1.46), with a Chi-square for equivalence of death
rates of 0.91 (p=0.34).
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Figure 3.7:
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Figure 3.7 legend: Kaplan- Meier survival curves for those with plasma DNA concentration
of under 250ng/ml (shown in black), compared to those with plasma DNA concentration of
over 250ng/ml (shown in red).
Further survival analysis was performed of those cases with early stage cancer (Dukes A and
B) to assess for an impact of plasma DNA concentration on survival in cases where survival
is expected to be good. These analyses are shown in figure 3.8. The hazard ratio for death for
those cases with Dukes A or B, and with plasma DNA concentration lower than 250ng/ml
was 0.59 (95% confidence interval 0.17 - 2.05), with a Chi squared equivalence of death
rates of 0.81 (p=0.37).
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Figure 3.8:
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Figure 3.8 legend: Kaplan- Meier survival curves cancer cases with Dukes stage A or B,
showing those with plasma DNA concentration of under 250ng/ml (in black), compared to




Experiments to investigate extraction methods were performed on small volumes of control
plasma DNA. This approach provides a stringent assessment of the reproducibility of the
methods due to small volumes and likely low plasma DNA concentrations. It is however
necessary for the approach to be valid under these conditions to allow interpretation of data
from samples with very low copy number DNA and where small volumes of plasma are
available. It is likely that archived samples constitute a limited stored biological resource, and
additionally that tests on prospectively collected cohorts may be more acceptable when a
smaller volume blood sample is required.
Phenol chloroform extraction of plasma DNA was unsuccessful. It is likely that this was on
account of the changes made from the published protocol, namely reducing the quantity of
plasma extracted from 1.5ml to 200ul. With the reduced volumes the precise collection of
different solution layers became technically difficult, and would also likely result in
significant inter-sample human error. The difficulties encountered with the nucleon extraction
kit likely reflected a similar problem. Additionally the nucleon kit is a protocol for extraction
ofDNA from whole blood of larger volumes, and hence further testing of this extraction
method was not performed.
Extraction using the Qiagen QIAAmp commercial extraction kit proved easy to use with
several different kits designed for use with differing volumes of plasma, mini (upto 200 ul),
midi(upto 2 mis) and maxi(upto lOmls ). There remained difficulties in the early part of this
study with both quantitative and qualitative assessment of extracted plasma DNA, as
described above, when the decision was being taken as to which extraction method to employ
through the remainder of the study. However the protocol proved easy to use, with samples
giving predictable volume of elutant and consistently amplifiable and detectable template by
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PCR using microsatellite markers. In view of this and the large number of published studies
employing this method of plasma DNA extraction, it was elected to standardise extraction
using this method. Subsequent to the completion of the laboratory work for this project there
has been ongoing debate in the literature as to optimal extraction methods., with authors
suggesting that isolation of nucleic acids from body fluids remains deficient in robust
methods (406). There are now many available commercial kits including anion exchangers
and magnetic beads (407)(su YH). Board et al described the qiagen kit as the most efficient
of 4 commercial kits(408) however others have demonstrated deficiencies in both
efficiency(409) and selectivity of size fragments (410).
3.3.2 Quantification methods
Quantification of plasma DNA has inherent difficulties due to the small concentrations,
particularly from normal controls. As such methods for determining plasma DNA
concentration are required to be robust. In this work, several methods of determining plasma
DNA concentration were utilised. The classical method ofDNA quantification using
spectrophotometry proved unreliable, due to the inherent variability in results on repeated
testing of the same samples. This was likely partly a reflection of the small quantities ofDNA
and also a relative lack ofDNA purity, an unavoidable factor when dealing with the complex
milieu of human body fluids. As such further quantification of plasma DNA using
spectrophotometry was not performed.
Real-time PCR affords cycle by cycle visualisation of template amplification, and is able to
determine relative quantities ofDNA within a template. The inclusion of standards of known
concentration allows the generation of a standard curve and hence the calculation of absolute
DNA quantities. This approach has been used with respect to circulating DNA, both for DNA
and RNA templates (260).
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However there are inherent problems with absolute quantification using real-time PCR, in
that calculations are dependent on accurate standards or an efficient assay reaction to remain
valid. In the results presented in this chapter plasma DNA concentrations were generated
using real-time PCR absolute quantification, for cases and controls. There was notan
association between higher concentrations in cancer cases compared to controls. These results
however need to be interpreted with caution since the assay reaction was not of optimal
efficiency to allow reliable calculation of absolute quantities without inclusion of known
concentration standards with each reaction plate. Additionally results were seen to vary
considerably, using the same standard DNA dilutions to generate the standard curve, as
illustrated when quantifying plasma DNA in spiked samples. Finally a relatively small
number of cases and controls were assessed by this method hence reducing the potential to
detect a significant difference between cases and controls.
Fluorescence DNA detection, using a fluorescent dye that generates signal when bound to
DNA, is a simplified method for quantifying DNA. Estimates of sensitivity for picogreen
detection are as low as 25 pg/ml (41 IT and this approach has been used to quantify plasma
DNA in clinical samples(362;412T
3.3.3 Quantification of plasma DNA in Prospective Cohort of Cases and Conrols
This study evaluated a prospective cohort of colorectal cancer cases and controls as to
whether plasma DNA concentration was a marker ofmalignancy, from triplicate data derived
using picogreen. A significantly higher mean concentration was demonstrated in cancer
cases. Additionally using ROC analysis the area under the curve for cancer was 0.68.
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Therefore using a cut off of 250 ng/ml, [plasma DNA] alone gave specificity of 93% with a
sensitivity for cancer of 31.8 %. None of the patients with adenomas in this series had high
plasma [DNA], although the numbers were small.
The performance of plasma [DNA] as a test to detect colorectal cancer is suboptimal, which
is unsurprising since there is much that remains to be elucidated regarding the biology of
tumour associated free circulating DNA. The majority of studies, whilst identifying a clear
association of increased levels in cancer patients, have identified both cancer cases with low
plasma [DNA] (comprimising sensitivity) and controls with raised plasma [DNA]
(compromising specificity). Reduced specificity is a particular concern when assessing a test
with potential utility for screening in asymptomatic populations, since false positive results
require further expensive and potentially hazardous investigation. Therefore in proof of
principle studies, controls must be carefully selected to exclude occult neoplasms of other
organs that might also cause a raised plasma [DNA]. To this end controls were ascertained
from normal colonoscopies from patients with a history of rectal bleeding or a mild to
moderate genetic risk of colorectal cancer, as well as from healthy asymptomatic volunteers.
Despite the careful selection of controls one was subsequently shown to have lymphoma and
hence were excluded from the control cohort, although interestingly had a markedly raised
[plasma DNA] (1142 ng/ml). Even given this exclusion and rigorous, uniform collection and
processing of samples some control subjects had high levels of plasma [DNA] detected.
These findings are in keeping with results of other studies that suggest raised levels are not
specific to cancer. However in our study population very high (> 325 ng/ml) plasma [DNA]
was specific to cancer. Importantly these high levels were seen in cases including earliest
stage cancer (Dukes A).
The figures for test accuracy demonstrate that plasma [DNA] is unlikely to be of clinical
utility in isolation. However current non-invasive tests such as FOBT have a sensitivity of
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only around 50% (134). and constitute the basis for population screening. FOBT is based on
different biological principles than plasma [DNA] and therefore the tests might prove
complimentary. Setting specificity of plasma [DNA] at the same level reported for FOBT
(around 90-100% f 124; 125;4134. sensitivity from our data is 26.1-31.5%. Potentially
therefore addition of plasma [DNA] assessment to FOBT might detect a quarter of the
cancers missed due to the poor sensitivity of FOBT, although our results were not obtained
from asymptomatic individuals. This hypothesis warrants further investigation, particularly in
regard to the possible effect of the presence ofbenign colorectal and non colorectal
conditions on plasma [DNA] that are prevalent in screened populations.
The relationship of plasma DNA concentration to survival is an important consideration for
its utility as a clinical test. If there is potential to detect early stage disease that is curable by
surgery, then the survival of cases with raised plasma DNA concentration might be
equivalent to those with lower levels. In this cohort there was no significant difference in
survival between those with plasma DNA levels above and below 250ng/ml. However there
is a tendancy in many cancers for those with highest concentrations of circulating DNA to be
associated with metastatic disease, therefore a subset analysis of cases with early stage
disease was performed, again with no significant difference between those with plasma DNA
levels above and below 250ng/ml. This would suggest that plasma DNA concentration has
the ability to detect cases with truly early stage disease, and not simply those with more
advanced disease that is not detectable by current staging modalities.
Conversely an increased hazard ratio of death with increased plasma DNA levels might
suggest clinical understaging of disease. There was a non-significant trend to poorer survival
of cases with high plasma DNA concentration both in the cohort as a whole and in those with
earliest stage disease. The non-significance of this finding may be a reflection of insufficient
sample size, particularly in respect to those with earlier stage cancers. Investigation on this
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finding on larger cohorts of colorectal cancer patients would be worthwhile. Should this
prove to be a significant association there might be potential utility for this biomarker in
detecting patients who might benefit from further treatment. One potential application might
be the identification of Dukes B cancer cases with a poorer prognosis who might therefore be
considered for chemotherapy. Another potential application is highlighted by one case of
particular interest, of a patient with a polyp cancer who had a markedly elevated plasma DNA
prior to polypectomy. This patient went on to develop a late disseminated recurrence and died
from the disease after 1808 days. Polyp cancers cause difficulties in management when
deciding whether a patient should go onto colonic resection after complete endoscopic
removal. Current pathological guidance is based on Kichuchi (414) or Haggitt (415) levels,
but these methods have limitations. Radiological staging of colorectal cancer has suggested
high sensitivity for distant metastasis but only around 85 % for lymphadenopathy in relation
to rectal cancer (416). Therefore understaging of disease using these methods is a clinical
problem. This is an increasingly common dilemma since the onset of FOBT screening for
colorectal cancer over 15% of screen detected cancers are polyp cancers (417). A biomarker
with the ability to infer the presence of residual disease would be of great benefit.
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CHAPTER 4
DEVELOPMENT OF ASSAYS TO DETECT TUMOUR SPECIFIC MUTATIONS IN
PLASMA
4.1 Introduction
Having investigated total DNA quantity in plasma and its associations in chapter 3,1 next
looked to develop assays aimed at detecting tumour specific mutations in plasma, namely a
TGFB poly A tract length variation and a mutational hotspot in codon 12 of the k-ras gene.
4.1.1 TGFB
TGF-(3 is an important growth factor implicated in carcinogenesis as discussed in section
1.2.6 e. TheTGF-P receptor II is integral to signal transduction, and contains a polyA tract
(Aio), mutation which has been demonstrated to display tract instability in 90% ofMSI
colorectal cancer (110). The ability to detect tumour-derived mutations of the polyA tract in
plasma might act as a marker ofMSI colorectal cancer.
Methods have been described that allow detection of a one base pair deletion within the
polyA tract, employing a RFLPassay, demonstrated diagrammatically on page**(394)- This
assay, confirmed by work within this group, is sensitive with ability to detect one mutant
copy within a population of 103 normal copies (392;394). This assay was therefore assessed
for its ability to detect mutant sequences in plasma DNA. Additionally the use of highly
specific real-time PCR probes (Taqman) might allow for mutation detection without post-
amplification processing, hence simplifying analysis and reducing the opportunity for
contamination of products prior to analysis. High throughput systems are available for
realtime PCR analysis, which might allow mutation detection on a large scale as would be
required for population based applications of an assay, should polyA tract mutations in
plasma be proven to be a reliable biomarker.
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4.1.2 Kirsten ras gene
The Kirsten-ras gene has been repeatedly shown to be an important gene in carcinogenesis, as
discussed in chapter 1. The gene is one of the most extensively investigated of those that have
been shown to be mutated in colorectal cancer, with implications in colorectal cancer
progression and prognosis.
An attractive element to studying the K-ras gene is that mutations are common within a
mutational 'hotspot' at codons 12 and 13. Mutational frequency has been reported to be
highest at codon 12 with the commonest mutation being GGT->GAT (glycine to aspartate) in
37.5% and GGT->GTT (glycine to valine) in 31.3% of one series (395). Hence mutation
analysis can be performed by targeting assays to these sites. This has been repeatedly
performed using a small panel ofRFLP assays both in tumour tissue and a variety of body
fluids. As such K-ras is the most extensively studied tumour derived mutation in circulating
DNA. A number of small studies have demonstrated detectability of tumour derived K-ras
mutations in plasma/serum of colorectal cancer cases as discussed in chapter 1. A larger
study demonstrated a sensitivity of 76% (in those cases harbouring a k-ras mutation) along
with an association of persisting plasma positivity of the assay with disease recurrence (282).
A particular difficulty ofRFLP methods to assess K-ras status is the need for multiple steps
in performing the assay. This results in assessment being relatively laborious and time
consuming, and increases the possibility of error by contamination.
An alternative approach is to employ real-time PCR technology that enables single tube
reactions, along with the potential to automate the process on a large scale. This chapter
describes experiments designed to develop real-time PCR methods for the assessment ofK-
ras mutations for application to plasma DNA.
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4.2 Materials and methods
4.2.1 TGFB RFLP assay
Analysis was performed on a poly A tract of the TGFBRII gene as a paradigm for the
analysis ofmicrosatllite sequences in plasma from microsatellite unstable colorectal cancer
patients as described in chapter 2. Positive controls, determination of sensitivity, study
population, primers and reaction conditions.and analysis, as well as consideration ofTGFB
Real Time PCR analysis,were performed as described in chapter 2.
4.2.3 K-ras
Mutation detection was performed at the mutational hotspot at exon 1, codon 12 of k-ras
gene, using real time PCR as described in chapter 2. Positive controls, including cell culture
and sequencingand real-time PCR, with both SYBR Green and Taqman probes were





Initial reactions revealed a product peak at 141 base pairs in both negative and positive
control samples, but also a peak at approximately 118 base pairs, consistent with the position
of the mutant digestion product in all samples including the no template control (Fig 4.1).
Fig 4.1
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Figure 4.1 legend: electrophoretogram demonstrating the presence of a peak present in all
samples around 118-120 base pairs.
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These results suggested the possibility of contamination of samples with the mutant digest
product. Therefore all reaction reagents, except primers were sequentially changed, but gave
similar results with the peak at 118 remaining in all samples. Primers were reordered and
reaction conditions replicated, however results remained similar. The peak at 118 base pairs
was visible both prior to and after product digestion (Fig 4.2).
Fig 4.2:
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Figure 4.2 legend: electrophoretogram demonstrating the presence of a peak present in all
samples around 118-120 base pairs.
To further determine whether the abnormal peak was due to contamination with Hinf
digestion product or an artefact of the digestion process, all reagents except primers where
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utilised to amplify a different marker, D17S250, and the products subjected to Hinf digestion.
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figure 4.3 legend: electrophoretogram demonstrating results ofD17S250 PCR, with absence
of a product peak between 118-120 bp.
To address if the abnormal peak resulted from residual constituents of plasma, not removed
during the extraction process, each of three extraction methods (chapter 3) were performed
and compared. Qiagen extraction process was also repeated on previously extracted plasma
DNA in an attempt to improve purity. Additionally fresh plasma samples were obtained and
re-extracted in triplicate. Alternate stocks of LoVo DNA were used for spiking plasma, also
in triplicate. Two sequential reagent changes for each of 3 different primer sets and 3 changes
in stock of Hinf and related buffers were performed. Consultation with the primer
manufacturing company (MWG) was carried out to check for a constitutive part of the primer
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manufacture process that might result in the generation of the peak at 118 bp. Analysis by
them concluded that only the designed oligonucleotides were present. Primers were also
ordered from the company (Abgene) who had previously made primers when the assay had
previously been performed by our group. PCR product was also cleaned by treatment with
SAP/exonuclease. Each of the above steps resulted in similar results with a persistent peak at
118 base pairs in all samples.
In the absence of evidence of contamination given above the possibility of fluorescence
artefact related to the FAM labelled forward primer was considered. It was apparent from the
multiple repeated reactions and runs that the peak around 118 base pairs had different
morphology to that of the undigested product peak at 141 base pairs, being broad based and
not sharply defined at the apex. This possibility was addressed by changing the fluorescence
label to HEX.
Demonstrated in figure 4.4 are undigested (left) and digested (right) positive control (LoVo)
samples. There is no peak at 118 bp in the undigested samples, whereas all product has been
digested to generate the 118 bp peak in the digested samples (arrowed) indicating the
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b) Determining Assay Resolution
Flaving ascertained that the assay gave reproducible results on positive and normal control
DNA, the sensitivity of the assay for detecting mutant TGFBRI1 polyA tract in plasma was
determined by spiking normal control plasma with serial dilutions of positive control (LoVo)
DNA. LoVo DNA was added to control plasma at dilutions, described in materials and
methods, consistent with levels described in the literature with respect to tumour derived
DNA in plasma.
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Application of the same reaction conditions as used in earlier TGFB assay experiments failed
to yield PCR product demonstrable by either gel electrophoresis or fluorescence
electrophoresis. Reaction conditions were therefore optimised with sequential alteration of
annealing temperature (2 degree intervals) and cycle number. Discernable PCR product was
reliably generated using conditions detailed in materials and methods. Annealing temperature
was 58°c and cycle number 45.
The results of spiking experiments are shown in figure 4.5. A peak was visible at 141 bp in
all undigested samples (left column), except the no template control (not shown),
corresponding to the undigested PCR product. Digestion resulted in generation of a 118 bp
peak, corresponding to digested mutant PCR product in samples spiked with greater than lng
of LoVo DNA per ml of plasma. There was not an obviously discernable 118 bp peak in
normal control sample, or with spiking below lng/ml (e.g.500pg/ml). These experiments
suggest that this assay is able to detect down to lng ofmutant TGFBRII DNA in 1ml that has







□□ 3R : 1 5-0.5-ajc-D-2 /
□□ 4R : 1 5-0.5-500p-D-2 /
□□ 6R : 1 5-0.2 5-1 On-D /
c) Clinical samples
Having demonstrated that the TGFBRII assay was functioning, and was sensitive to a level
relevant to tumour derived DNA in plasma, the assay was applied to patient and control
plasma samples. Three healthy volunteers were used for controls. Patient population 1
constituted patients previously enrolled in genetic studies of the group, and whose tumour
microsatellite status had previously been determined using standard methods. Patients with
metastatic disease were selected, since stored plasma samples were taken post-operatively,
and only those with residual disease could be assumed to have tumour derived DNA within
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plasma post-operatively. Archived plasma samples were obtained for patient population 1,
and DNA extracted from 200ul of plasma as per the Qiagen protocol.
Application of optimised reaction conditions from spiking experiments, generated a mutant
peak following digestion in all plasma DNA samples except from the normal control subjects.
This was the case for both the MSI case (1092) and all the MSS cases (n=9), with examples

















Figure 4.6 legend: Electrophoretograms from digested PCR product from negative control
(top left), normal control (bottom left) and 2 stage 4 colon cancer cases plasma DNA (right).
Mutant digest product (118 bp) is shown in green and arrowed.
All MSS cases had been designated MSS by microsatellite analysis with Bethsada markers,
but TGFBRI1 polyA tract assessment was performed on these tumour samples, to exclude the
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presence of a lbp deletion in the primary tumour that might also be detectable in plasma.
Assessment was performed at annealing temperature of 58 oC, and 35 cycles. Each MSS
tumour sample did not demonstrate a peak consistent with digested mutant polyA tract,
suggesting that the mutant peak in plasma DNA was due to artifact. Further optimisation of
the plasma DNA amplification protocol was performed to try and improve the integrity of
PCR products. High fidelity taq was substituted for standard Taq polymerase, but each MSS
plasma DNA continued to generate a mutant peak at 118bp.
A semi-nested PCR method was therefore devised, as described in materials and methods.
The number of cycles in both primary and secondary PCR were sequentially altered, as were
the concentrations of the outside primers to optimise this process. However each combination
resulted in a mutant peak at 118 bp being present. Reducing the cycle number resulted in
neither wild-type nor mutant product being reliably detectable.
4.3.2 TGFB Real Time PCR
Taqman probes were designed according to manufacturer instructions (AppliedBiosysytems)
for each of wild type (A10) and mutant (A9) TGFBRII sequences, as described in materials
and methods. Submission of these sequences to Applied Biosystems led technical support to
conclude that the ABI 7900 sequence detection platform was unable to discriminate a single
base pair deletion with an A10 polyA tract, therefore these probes were not purchased.
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4.3.3 K-ras SYBR Green Assays
a) Controls
Colo 320 cells were raised from storage and DNA extracted. The presence of PCR ready
DNA for each positive and negative control template was confirmed by standard PCR cycling
and conditions using primers used in microsatellite analysis for the marker D5S346:
Figure 4.7:
Figure 4.7 legend: Gel electrophoresis confirming PCR product for templates used in
subsequent reactions. First and last columns of each row contain kilobase ladder. Column 2
of both rows contains no-template control. Thereafter triplicate results for templates : Colo
320, SW480, normal DNA from case 2530, tumour DNA from case AM 17, tumour DNA
from case AM 35, tumour DNA from case 1851, tumour DNA from case 2487.
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b) Primers and Probes
Sequence specific primers were designed according to manufacturer instructions for wild
type and aspartate mutant K-ras sequences, yielding the following results:
Wt ras forward: ATA TAA ACT TGT GGT AGT TGG AGC TGG
Aspartate mutant: GAA TAT AAA CTT GTG GTA GTT GGA GCT GA
Common reverse TGG ATC ATA TTC GTC CAC AAA ATG
c) Assay Validation
Real-time PCR was employed using cycling described using positive and negative controls.
This demonstrated no difference in Ct for the two primer sets on each of the positive and
negative control samples.
The approach was adapted in an attempt to improve primer specificity by introducing a base
mismatch adjacent to the mutation site for the primer pairs:
Wt ras wobble forward: ATA TAA ACT TGT GGT AGT TGG AGC AGG
Aspartate mutant wobble: GAA TAT AAA CTT GTG GTA GTT GGA GCA GA
Common reverse: TGG ATC ATA TTC GTC CAC AAA ATG
Standard PCR cycling using this primer set 011 postive and negative controls failed to result in





Real-time PCR amplification plot using SYBR green technology with K-ras aspartate mutant
and wild type specific 'wobble' primers. By 40 cycles none of the wells have generated
sufficient PCR product to cross the threshold, designated by the red line.
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In view of the non-discrimination of this assay, the positive and negative controls were
sequenced as described. Sequencing revealed that the colo 320 cell line DNA lacked the
published (393) aspartate mutation, shown in figure 4.9. However cases AM 17 and AM35
tumour DNA contained the aspartate mutation as previously established by work within the
group, therefore positive and negative controls were present in the experiments described
above.
Figure 4.9:
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Figure 4.9 legend: Results from sequencing DNA from colo 320 cell line. Sequencing
performed on the antisense strand. Demonstrated in the hand drawn box in row 2 the
sequence confers to (from right to left) translation on the sense strand as GCT GGT which is
wild type sequence.
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4.3.4 K ras Taqman Probes
In view of the failure of the SYBR green approach to discriminate between templates it was
elected to design a taqman probe assay to the mutation site. Primers and probes were
designed according to manufacturers instructions and generated the following sequences:
Wild type probe (antisense strand) CCT ACG CCA CCA GCT
Aspartate mutant probe (antisense strand ) CCT ACG CCA TCA GC
Forward primer (antisense) TAG CTG TAT CGT CAA GGC ACT CTT
Reverse primer (sense) AAA ATG ACT GAA TAT AAA CTT GTG GTA
GTTG
Standard cycling conditions were employed to assess the same positive and negative controls
as used for SYBR green experiments. These results are demonstrated in figure 4.10. There
was no discrimination by fluorescence between positive and negative controls.
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Figure 4.10
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Figure 4.10 legend:
Allelic discrimination plot for K-ras MGB probes for positive and negative controls for
aspartate mutant K-ras. FAM fluorescence, corresponding to the wild type probe, is presented
on the y axis. VIC fluorescence, corresponding to the mutant probe, is presented on the x
axis. Results from positive controls are depicted in red. Results from negative controls are




The experiments in this chapter assessed the detectability ofmutant TGFBRII DNA in
plasma with a view to use as a biomarker of microsatellite unstable colorectal cancer. To this
end a previously described RFLP assay was employed, but considerable difficulties were
encountered in ensuring the assay functioned reproducibly. Systematic alteration of assay
reagents were required to identify an inherent problem with the fluorescent labelling of the
assay primers, which when altered allowed reproducible assay results. These difficulties
highlight the importance of validating published methods in the context to which they are to
be applied before utilising the irreplaceable biological resource of patient samples.
Having validated the assay, its sensitivity at detecting mutant polyA tract within plasma was
assessed by artificially introducing mutant DNA into control plasma. These experiments
appeared to indicate that the assay was sensitive at a level of detectability of 1 ng ofmutant
DNA per ml of plasma. This level of sensitivity is of relevance to published data on the
quantity of tumour derived mutant DNA within the plasma of cancer patients. However the
method of fluorescence electrophoresis generates an uneven baseline, and close examination
revealed a very small peak at 118bp, not sufficiently discernable from baseline noise to call
as a positive result, that might represent a very small number of amplified mutant copies.
This is important when considering the results derived from patient plasma samples, where in
both microsatellite stable and unstable cases generated a positive result for mutant poly A
tract was generated. Analysis ofMSS tumour samples did not demonstrate a mutant digest
peak indicating a deletion in the tumour and therefore suggesting that the positive plasma
results might be an artefact of the amplification process. A likely explanation of these results
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is that the large number of amplification cycles resulted in an induced artefactual one bp
deletion in the wild type poly A tract as a result of polymerase stutter. This artefact would
result in all samples being positive to some degree. In plasma samples with larger amounts of
plasma DNA the quantities of PCR product might be such that both wild type and artefactual
mutant products are detectable. In samples with small amounts of plasma DNA, such as
normal controls and those with little mutant DNA (e.g.500pg), the quantities of PCR product
are not sufficiently large for the mutant peak to be reliably detectable above baseline.
Attempts to improve the integrity of the amplification process to negate the above
explanation included the use of high fidelity polymerase and the devlopment of a semi-nested
PCR approach. These alterations do not negate the production of artefactual A9 polyA tract.
Reduction of the number of PCR cycles resulted in insufficient PCR product for reliable
detection.
These results highlight difficulties of investigating plasma DNA. Quantities of extracted
DNA are small, and this in combination with the potential presence of factors affecting the
PCR process that are not removed in the plasma DNA extraction process, necessitate an
extended number of cycles to reliably detect PCR product. However increased number of
PCR cycles compromises the fidelity of template DNA amplification, and results in
generation of artefactual sequence errors. This can be expected to be a problem particularly
for repetitive microsatellite tracts.
In summary these results highlight the difficulties of investigating plasma DNA, and
demonstrate that the use of this RFLP assay is not sufficiently robust to detect mutant plasma
TGFBRII polyA tract with a view to its use as a biomarker.
Since this work was completed a group have described an alternative method for detecting
polyA tract alterations. They addressed the possibility of polymerase slippage resulting in
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artefactual mutant sequences in polyA tracts by developing a so called probe-clamping
primer extension PCR (PCPE-PCR), applicable to TGFBRII (418). This technique employs
specific probes that preferentially produce extension products ofmutant DNA, which are then
extracted and hence enriched before further amplification and then analysis. Their results
suggested high sensitivity with ability to detect 1 mutant copy amongst 500 normal alleles
and to detect down to 3 mutant copies. Additionally the technique had some success in
detecting BAT-26 mutations in stool of a small cohort of colorectal cancer cases (n=6).
Assessment of this technique in relation to plasma DNA might address some of the
difficulties described above.
4.4.2 K-ras
Assessment of K-ras mutation has been commonly performed in circulating DNA, and has
been shown to be reproducibly demonstrable using RFLP assays. The development of a
single tube assay with the potential to be performed on a large scale might facilitate the
translation of circulating DNA K-ras assessment into clinically useful tests. To this end the
experiments described in this chapter were aimed to develop a real-time PCR assay able to
detect K-ras mutations.
Initial negative results might have resulted from lack of a true positive control. Whilst it was
demonstrated by direct sequencing that DNA from the cancer cell line colo320 lacked the
suggested mutation, alternative true positive controls were used, those of tumour tissue from
cases archived from a previous study within the group, that had previously been demonstrated
to harbour the codon 12 mutation, and confirmed again by direct sequencing.
SYBR green assay technology is a simple and relatively inexpensive form of real-time PCR
assessment as described in materials and methods. Primers specific to both wild type and
mutant sequences were designed, but proved to have significant cross-reactivity, with similar
signal being generated on control and mutant template with cither primer set. In order to try
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to improve primer specificity a base mismatch was introduced one base from the mutation
site, so that without the primer matching the mutation site primer annealing would not occur.
This however resulted in no appreciable product occurring even in the presence of the
matching template, either control or mutant.
Real-time PCR with Taqman probes potentially provides an increased assay specificity. The
development of probes with a stabilising adjunct that binds in the minor groove ofDNA
(MGB probes) has allowed further probe specificity and reduction in probe length. Therefore
Taqman MGB probes specific to the aspartate codon 12 mutation were designed and tested
on mutant and control DNA. The results presented with respect to these probes indicate that it
was not possible to clearly discriminate mutant from wild type DNA. Whilst there was an
indication of differing fluorescence between templates, the inability to clearly discriminate
large quantities of intact mutant tumour DNA from control suggest that this approach will not
translate to low copy number mutant templates with admixed normal DNA. It therefore
appears that the successful discrimination reported using RFLP assays is at least partly
dependent on steps that result in enrichment and preferential amplification ofmutant DNA.
Additionally the translation of K-ras mutant assays for colorectal cancer detection is
strategically flawed, since only a proportion of colorectal cancers exhibit these mutations.
Given that approximately 40-50 % of colorectal cancers exhibit K-ras mutations (47), with
our own studies suggesting an even lower figure in the Scottish population (~ 30%), even an
assay with optimal performance would have potential to detect under half of colorectal
cancers. Inclusion of K-ras assays within a panel of markers might also have inherent
problems as has been found using a similar approach in stool (210), where inclusion of ras






Analysis of polymorphic microsatellites is a common technique in the genetic assessment of
tumours, both for assessment of LOH and microsatellite instability. LOH is a defining
molecular characteristic ofmany human cancers and hence is a common phenomenon at
multiple loci(47). Information on LOH derived from microsatellite analysis has been shown
to be relevant to the phenotypic characteristics ofmany cancers, including having prognostic
relevance(4J_9).
LOH is frequently observed at multiple sites in colorectal cancer, as discussed in section
1.2.2. Analysis of LOH at a panel ofmarkers can strategicallybe informative for all sporadic
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This graph shows the cumulative frequency of LOH at 3 commonly affected sites in
colorectal cancer. Approximately 60% of colorectal cancers exhibit LOH at markers on
chromosome 5q(85), demonstrated in the left hand column. A similar proportion exhibit LOH
at markers on chromosome 17p(99), therefore around 80% of cancers would be expected to
demonstrate evidence of LOH at either 5q or 17p, indicated in the middle column. Around
75% of colorectal cancers exhibit LOH at markers on chromosome 18q(J_02), therefore 95%
of cancers may exhibit LOH at one of the three markers, assuming independent segregation,
indicated in the right hand column. However since the completion of this thesis further
refinement of the molecular classes of colorectal cancer (as discussed in section 1.2.6), has
suggested a subclass of cases that would not potentially be detected by this approach, in
relation to BRAF mutated cancers , that may constitute upto 20% of all sporadic colorectal
cancers.
Assessment of LOH in plasma DNA using microsatellite analysis has been performed for
many cancers with varying results, as discussed in section 1.5.2 d. The advantage of this
approach in colorectal cancer is the potential informativity for the great majority of cases
using a small panel of markers based on the same principle, which are relatively easy to
analyse. With respect to microsatellite analysis of plasma DNA in colorectal cancer, 2 small
studies have generated conflicting results(335;336)- One of the suggested explanations of
suboptimal and conflicting results in the analysis of LOH in plasma is the low copy number
ofDNA within samples.
There are numerous techniques for examining microsatellites, however a commonly
employed method is the use of fluorescently labelled primers with capillary electrophoresis of
the resultant fluorescently labelled PCR products, generating visual representation of product
size and amplitude with the use of designated platforms with attendant analysis software.
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This study aimed to perform fluorescent microsatellite analysis at a panel of 3 microsatellite
markers on a larger cohort than previous studies ofmatched tumour, normal and plasma
DNA, as well as control subjects. Additonally results were correlated with total plasma DNA
concentration derived from experiments in chapter 3.
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5.2 Materials and Methods
5.2.1 Study Population
Cases and controls were ascertained from the series of prospectively recruited patients
described in section 2.2.
In total 85 cases and 24 controls were analysed.
Cases included all disease stages as indicated in table 5.1
Table 5.1
Controls Adenomas Stage I Stage II Stage III Stage IV Unknown
(Transanal excision)
24 8 13 28 26 15 1
Controls were those normal individuals as described in chapter 2.
5.2.2 Reaction Conditions
The reaction conditions at the three chosen markers, along with the primers,
constituents and methods of analysis are decribed in section 2.6.
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5.3 Results
A total of 6 cases and 1 control were not fully analysed due to insufficient clinical
specimens, giving full results for 77 cancer cases and 8 adenomas. Of the 23 controls,
one was subsequently shown to have a haematogical malignancy and was excluded
from further analysis, giving results for 22 controls.
5.3.1 Tumour DNA
Results for each marker are given in table 5.2 below with the number of cases with
allelic loss.
Table 5.2:
D5 D5 D17 D17 D18 D18
Tumour Adenoma Tumour Adenoma Tumour Adenoma
Non - 11 4 9 3 23 4
informative
MSI 2 0 1 0 5 0
LOH 40% 50% 33.8% 0.0% 44.0% 50.0%
n=26 n=2 n=23 n=22 n=2
36 cases (42.4%) of cases were either non-informative or showed no LOH at all three
markers in tumour DNA. Therefore 49 cases (57.6%- 46 cancers and 3 adenomas)
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were informative, with allelic alteration at one marker in 30.2%, at 2 markers in
16.3% and at all 3 markers in 10.5% of cases.
5.3.2 Plasma DNA
LOH was classified according to the allelic pattern change as follows:
1) Matching LOH in tumour and plasma DNA (Figs 5.1 and 5.2)
Fig 5.1:
Thu Jul 13,2006 10:09PM, BST Printed by: Administrator Page 1 of 13
Fig 5.1 legend: Results from D5S346 for case 2461. The top row indicates normal
DNA. Tumour DNA shows a relative loss of the larger allele, demonstrated in the




Fig 5.2 legend: Results from D5S346 for case 2567. The top row indicates normal
DNA. Tumour DNA shows a relative loss of the larger allele, demonstrated in the
middle row. Plasma DNA (bottom row) shows matching allelic loss to that seen in the
tumour.
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2) Non matching LOH: Disparate LOH with one allele having reduced signal
amplitude in tumour but the other allele having reduced signal amplitude in
plasma DNA (fig 5.3)
Fig 5.3:
nolo Name I Panel I SOI i OS I SO
I ■
140 145 150 155
Fig 5.3 Legend: Results from D18S58 for case 2530. The top row indicates normal
DNA. Tumour DNA shows a relative loss of the larger allele, demonstrated in the
middle row. Plasma DNA (bottom row) shows opposing allelic loss to that seen in the
tumour, with a relative loss of the smaller allele.
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3) No LOH: Allelic balance maintained in plasma DNA, irrespective of allelic





3mple File Sample Name 1 Panel SQI








06 2544P D18 024.fsa !2544P 016 J Nona,
Jul 19,2006 01:51PM, BST Printed by: Administrator
Fig 5.4 Legend: Results from D18S58 for control 2544. The top row indicates normal
DNA. Plasma DNA (bottom row) shows maintained allelic balance
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4) De novo LOH: AI observed in plasma for control subjects or where not
present in tumour DNA for cases. (Fig 5.5)
Fig 5.5:
Sample Name Panel SQI I OS
2725N DMx I
106.5 109.5 112.5 115.5 118.5 121.5
106.5 109.5 112.5 115.5 118.5 121.5
Fig 5.5 Legend: Results from D5S346 for control 2725. The top row indicates normal
DNA. Plasma DNA (bottom row) shows unexpected reduction in the signal amplitude
of the smaller allele.
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5) Complete LOH: Absence of one of the alleles in plasma DNA that was present




Figure 5.6 legend: Results for D5S346 for case 2596. The smaller allele at 104-105 bp
is absent from plasma DNA
221
Figure 5.7
Figure 5.7 legend: Results for D5S346 for case 2849. The larger allele at 117 bp is
absent from plasma DNA.
A summary of the types of LOH observed is provided in figure 5.8.
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Figure 5.8:
Primary data for all analysed samples is presented in appendix 4.




D5 D17 D18 Any of the 3
markers
Not informative 15 11 26 36
MSI (tumour) 2 1 5 5
Tumours with
LOH
27 23 22 49
LOH matching 8 7 8 18
LOH non
matching
7 2 7 15
No LOH 12 12 6 16
Tumours
without LOH
36 44 28 34
LOH de novo 17 13 11 20
No LOH 18 24 17 14
Sensitivity 55.6% 39.1% 68.1%
Table 5.3 legend: Summary data table of LOH in plasma at the 3 studied markers.
a) Sensitivity
Calculation of sensitivity from the above data is dependent on the criteria applied.
Taking maximal sensitivity as the percentage of tumours with evidence of LOH that
show LOH of any kind in the plasma gives sensitivity of 67.3% (33 out of 49,
including adenomas). Inclusion of non-informative cases in the denominator reduces
sensitivity to 38.8% (33 out of 85). However if a positive result is taken as a matching
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change in tumour and plasma DNA at any of the markers (matching LOH) sensitivity
is reduced to 36.7% (18 out of 49) for informative cases or 21.2% for the whole
cohort.
The effect ofDNA quantity on assay performance was investigated by analysis of
plasma DNA concentration within the different groups of results fromplasma DNA
analysis.
Average concentration of plasma DNA in samples with matching plasma DNA LOH
at any one or more markers was 448.5 ng/ml. Average concentration of plasma DNA
in samples with non-matching plasma DNA LOH at any one or more markers (but
without concordant loss at any other marker) was 631 ng/ml (p= >0.5, t test).
Of those tumours with no LOH in tumour tissue, and correspondingly no evidence of
LOH in plasma either had mean plasma [DNA] of 329.5 ng/ml, whereas those with de
novo LOH in plasma had a mean plasma [DNA] of 144.5 ng/ml (t-test p=0.077).
b) Specificity
Test specificity based on the results from control subjects demonstrated that of 24
controls, 1 was not informative and one was excluded. Of the remaining 22, 7 had no
de novo LOH giving specificity of 31.8%.
The mean concentration of plasma DNA for those with no LOH in plasma (true
negatives) was 225 ng/ml. The mean concentration of plasma DNA for those with de
novo LOH (false positives) was 83.5 ng/ml (p=0.298, t test)
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Further controls from a plasma LOH perspective can be derived from cases without
LOH in tumour tissue, since they would not be expected to result in LOH in plasma.
Therefore cases with no LOH in tumour or plasma DNA may be considered true
negatives, whilst those with no LOH in tumour but de novo LOH in plasma false
positives. Including these cases as further negative controls specificity rises to 37.5%.
Addition of these cases to controls gives a mean plasma DNA concentration of 289
ng/ml for true negatives, compared to 199.5 ng/ml for false positives, with a
significant difference between them (p=0.0284 t-test)
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5.4 Discussion
LOH analysis by the use of microsatellites is an attractive target for the development
of a blood based biomarker in colorectal and other cancers due to its inherent
informativity, with the potential for tumours demonstrating LOH also resulting in
LOH in plasma DNA at multiple loci and the additional pick up ofmicrosatellite
instabilty. The experiments in this chapter investigated LOH in tumour and plasma
DNA by fluorescent microsatellite analysis in the largest cohort than has been
described to date. Previous similar studies in colorectal cancer have generated
conflicting results, as has also been the case for studies in other cancer types.
The results presented in this chapter demonstrate that this approach is a suboptimal
detection method for inferring the presence of a tumour by analysing plasma DNA
LOH. Sensitivity as defined by broad criteria was acceptable at 67.3%. Sensitivity
with only a matching change in tumour and plasma DNA (matching LOH) was 36.7%
of informative cases. The rationale for including cases with non-matching LOH
changes in plasma compared to tumour would be that the tumour cells sampled in the
tumour DNA sample might not give a true reflection of the allelic status of the tumour
as a whole or the predominant tumour clone. Therefore the AI detected in plasma
DNA may result from tumour clones not sampled or not predominant in the portion of
tumour from which tumour DNA was derived for analysis. When considering
application of this technique as a clinical test, there would not be prior knowledge of
the allelic status of the tumour, therefore the primary outcome would be either
presence or absence of LOH in plasma DNA. A further consideration in this regard is
the concept of tumour heterozygosity as discussed in section 1.2.3. Evidence from
studies analysing multiple portions of microdissected tumours suggest that differing
genetic aberrations occur at different sites of the same tumour. Clearly this may result
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in difficulties with sampling of tumour cells and their relative ability to represent the
allelic stauts of the whole tumour, as well as conflicting AI from different portions of
the tumour resulting in relative allelic balance in plasma DNA. Previous studies have
postulated this mechanism as an explanation of discordance between plasma DNA
and tumour DNA alterations (420). A study of genetic heterogeneity and plasma DNA
LOH investigated 24 lung cancer cases and 26 colorectal cancer cases (337V This
study demonstrated the presence of non-matching LOH (which they termed alternate
AI) in the plasma of 25% of lung carcinomas, and in 54% of liver metastasis
compared to primary tumour (although plasma DNA analysis was not performed for
the CRC cases).
Alternatively suboptimal results may be a reflection of artefact inherent in
microsatellite analysis when performed on plasma DNA. Plasma DNA is a low copy
number template that is also subject to the action ofDNAse and the presence of
factors that may be inhibitory to PCR. Certainly there is evidence that plasma DNA is
degraded to some degree, with the majority being shorter than 181 bp (360) and
evidence that microsatellite markers enrich for smaller alleles in degraded DNA
(359). Therefore allelic proportions may not be truly reflected by microsatellite
analysis of plasma since larger alleles may be artefactually under represented.
Alternatively since the analysed aliquot of plasma DNA may contain very few alleles
and as such there is evidence from mathematical modelling that the sampling of
alleles within aliquots becomes subject to stochastic effects (421V a concept discussed
further in the following chapters. Data presented in this chapter do not support these
explanations for discordant LOH. Whilst complete allelic loss was observed in a few
cases which might be explained by allele degradation this was seen for both the larger
and the smaller allele. The data for plasma DNA concentration do not support
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discordant LOH being a function of lower copy number since there the mean
concentration for cases with discordant LOH was higher than that for cases with
concordant LOH, with no significant difference between the two.
The reasons for sensitivity being suboptimal are likely multifactorial. Firstly many
studies of plasma DNA have concluded that only some tumours release detectable
mutant DNA into the bloodstream, hence reducing the inherent sensitivity of plasma
DNA assays. Secondly any tumour derived DNA in plasma is for practical purposes
'diluted' by larger quantities of normal DNA. The exact contribution of tumour
derived DNA to the totality of plasma DNA remains debated and is discussed
elsewhere, and seems likely to be related in some degree to tumour load. Whilst
mutation enrichment techniques for specific mutations (e.g. K-ras) may obviate the
problem of tumour derived DNA being overwhelmed by normal DNA, this may be a
particular problem for the detection ofAI in plasma DNA, since analysis is dependent
on the maintenance of relative quantities present within the original sample. However
it has been suggested that fluorescent microsatellite analysis can detect DNA
alterations down to a ratio of tumour to normal DNA of 0.5% (316), or even 1 in 1000
(422). Additionally it seems likely that specific characteristics of individual markers
have relevance to differing sensitivity levels in detecting microsatcllite alterations
(301). Sensitivity levels are also affected by the defininiton used to classify LOH.
There remains no consensus as to the level of allelic ratio alteration that constitutes
LOH, with studies variously employing cut-offs of between 20-50% (306:318:337). In
this work sensitivity was marginally improved by using a less stringent cut-off of 30%
(by 4.3%) but at the expense of specificity , therefore 50% cut-offwas employed in
further analysis.
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Sensitivity levels for the whole cohort analysed in this chapter were reduced by the
proportion of cases that were not informative. Again this lack of informativity was
likely multifactorial including the number of cases that were homozygous at given
markers, and a few clinical samples that repeatedly yielded no detectable PCR
product or artefactual peaks interfering with analysis. The rates of LOH and hence
informativity in tumour samples were lower than might be predicted by the strategic
rationale behind this approach. This may partly reflect that tumours were not
microdissected and hence tumour samples are likely to contain a degree of
'contamination' from adjacent normal tissue that would reduce observed alterations in
allelic proportions. However the rates of LOH are in keeping with other published
studies.
Strategically reduced levels of sensitivity are potentially surmountable by increasing
the number of analysed markers that will result in increased informativity for the
whole cohort. Additionally currently employed screening methods have suboptimal
sensitivity estimated at around 50%.
Ofmore concern to the validity and potential clinical utility of the approach are the
poor levels of specificity presented in this chapter. As described previously the
applicability of assays to large sections of the population is dependent on a low false
positive rate, since false positives require further, invasive, investigation. Specificity
based on controls alone was 31.8%. A potential source of postive results for these
controls is the presence of other diseases resulting in plasma LOH. However control
recruitment was stringent to prevent this confounding effect, selecting controls with a
negative colonoscopy.
Further data for specificity were generated including tumours without LOH as
controls. The rationale behind their inclusion was that tumours without LOH would
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not be expected to result in plasma LOH, and hence lack of LOH in plasma might be
considered a true negative, whilst de novo LOH might be considered a false positive.
Using these criteria specificity was improved, but still suboptimal, at 37.5%. A
possible explanation for poor specificity within the cohort is artefact from low copy
number DNA within controls as discussed above, and would be expected to be more
of an issue for controls since plasma DNA concentration is lower than in cancer cases
(chapter 2). Evidence to support this from these results is the significant difference in
plasma DNA concentration between true negatives and false positives. This
constitutes a fundamental problem when considering applying these assays to
asymptomatic populations where plasma DNA concentrations are likely to be low,
and as a result analysis may be subject to inherent artefact resulting in high levels of
false positives.
Investigation of techniques that have potential to negate these problems, such as
whole genome amplification(423 ;424). seems inherently worthwhile given the
optimal sensitivity and the strategic potential of these approaches.
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CHAPTER 6
ASSESSMENT OF CHROMOSOME 5 LOH BY TAQMAN PCR
6.1 Introduction
Given the sub-optimal performance of fluorescence LOH detection described in the
previous chapter, other approaches were explored to determine if plasma DNA LOH
assessment might be a valuable biomarker. Real-time PCR has been shown to be
highly sensitive, and specificity for the target sequence is improved over conventional
PCR (425). Additionally post-amplification processing is not required to visualise and
interpret results, hence reducing the opportunity for errors and contamination.
Taqman probes may be utilised to visualise each cycle or allow relative quantification
of signal fluorescence at the end of the PCR reaction, an application designed for
allelic discrimination.
Taqman PCR has been employed in investigating the associations of plasma DNA,
although application has been limited to absolute quantification of plasma DNA, or
the detection ofmutant DNA sequences related to tumour derived DNA. The
detection of differing quantities of sequences that each occur in normal subjects had
yet to be described at the outset of this project. However in a normal subject that is
heterozygous for a given SNP, it might be expected that each allele would be present
in equal proportion in plasma DNA. If however an individual harbours a tumour that
is contributing more of one allele into the circulation, on account of LOH of the
region containing the other allele, there might be expected to be a relative excess of
that allele in the circulation. Whilst this hypothesis is also the basis for detecting LOH
in plasma by fluorescence electrophoresis, described in the previous chapter, the
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potentially increased accuracy of Taqman PCR might allow detection of smaller
variations in relative quantities.
Assay development was focused on a region of interest on chromosome 5. A segment
of chromosome 5q21 has been shown to be frequently deleted in colorectal cancer and
contains the APC gene. As described in the introduction (section 1.2.6a) the APC
gene is of fundamental importance to colorectal carcinogenesis. LOH affecting the
APC gene has been observed in a high proportion of colorectal cancers, and occurs at
an early stage, including in pre-malignant adenomas. As such an assay able to detect
small alterations in the relative quantities of chromosome 5q alleles would be an ideal
potential biomarker. The ability to infer the presence of curable neoplasia by detecting
tumour derived alterations in allelic ratio in plasma would allow targeted application
of invasive diagnostic and therapeutic modalities such as colonoscopy.
Also included within the frequently deleted region of chromosome 5q are thousands
of single nucleotide polymorphisms that can be exploited to identify one chromosome
from the other copy. As such there is potential for all cases to be heterozygous at one
of a few given SNPs, and hence for a small panel of taqman PCR markers to be
informative. Also included within the frequently deleted region are dinucleotide
repeat markers D5S346 and D5S82, which allow assessment of allelic loss within
samples by conventional means, as those described in the previous chapter, and hence
validation of novel assays.
Therefore a quantitative assay was designed to detect differing proportions of
heterozygous alleles. The assay's sensitivity was determined by artificially inducing
AI in plasma. The assay was validated using clinical samples derived from normal
and tumour tissue, and then applied to the plasma of colorectal cancer patients.
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6.2 Materials and methods
Assay design, primers, probes and reaction conditions are described in section 2.7, as
are the methods for experiments to investigate the limit of resolution of the assay and
the analysis of normal, tumour and plasma DNA
6.3 Results
6.3.1 Assay validation
a} Normal DNA samples
To determine the assay performance, analysis of normal DNA from buffy coat was
performed using standard reagent volumes and concentrations and cycling conditions
as indicated from manufacturer's product literature. Normal DNA from 45 colorectal























Graph depicting fluorescence results from normal DNA of colorectal cancer patients.
The x axis corresponds to arbitrary units ofVIC fluorescence, and similarly the y axis
to FAM fluorescence. Data points in black indicate no template controls, generating
small amounts of background FAM and VIC fluorescence. Blue data points indicate
samples that have generated FAM fluorescence only, and correspond to samples
homozygous for the allele to which the FAM probe specifically binds (CCA).
Similarly red data points indicate VIC fluorescence only and correspond to samples
homozygous for the CCG (VIC allele). Data points in green demonstrate FAM and
VIC fluorescence and correspond to samples heterozygous at the 15n SNP.
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The results shown in figure 6.2 demonstrate that the assay is able to clearly
discriminate the two different alleles at the '15n' locus. The absence of the alternative
fluorescent signal in homozygous samples indicates the presence ofminimal cross
interaction, and hence a high level of probe specificity.
These results were confirmed by sequencing of normal DNA from 10 cases,
confirming presence of only CCA allele (n=3), heterozygosity (n=5) or homozygosity
for CCG allele (n= 2)
6.3.2 Tumour and Normal DNA from Colorectal Cancer Cases
Having determined that the 15n assay was able to specifically discriminate between
alleles, the assay's utility in determining relative proportions of the two alleles, was
investigated. Assay performance was compared to the conventional LOH detection
method of fluorescent electrophoresis in the analysis of tumour and normal DNA
from a series of colorectal cancer cases.
i) Dinucleotide repeat analysis
Cases were deemed informative where PCR product was reproducible and two
different length alleles were detectable. The number of cases informative for each







Table 6.1 legend: number of cases informative at each of the 2 chromosome 5 short
tandem repeat markers.
Details of cases and total numbers exhibiting degrees of LOH are detailed in table 6.2.
LOH was classified as:
1) Clear cut LOH: reduction of relative peak intensity of one allele of greater than




Analysis of tumour and normal
DNA from case number 2488.
There is a reduction of the
smaller allele in tumour >50% of
that allele's signal amplitude
from normal DNA.
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2) Possible LOH: reduction of relative peak intensity of one allele of between 20-50%
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Fig 6.4 legend:
Analysis of tumour and normal
DNA from case number 2641.
There is a reduction of the
smaller allele in tumour by 25%
of that allele's signal amplitude
from normal DNA.
238
3) No LOH: reduction of relative peak intensity of one allele of less than 20%









Fig 6.5 legend: Analysis of tumour and normal DNA from case number 2645.
The allelic proportions are maintained in tumour and normal samples.
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4) Allelic Shift: Was identified on the basis of a different size allele in the tumour that
was not present in normal DNA. This was detected in only one case (2565) as
demonstrated in Figure 6.6.
Fig 6.6
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Figure 6.6 legend: Analysis of case 2565, showing the presence of an extra allele
(bottom trace), sized between the 2 normal allele sizes whichseen in the normal DNA
(top trace)
Summary data of the number of cases exhibiting evidence of differing degrees of
LOH in tumour are detailed in Table 6.2
Primary data for this chapter are presented in appendix 5.
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Table 6.2
ClearcutLOH PossibleLOH NoLOH Shift Notlnformative
D5S346 5 15 15 1 9
D5SS2 3 10 19 0 13
ii) 15n SNP analysis
Analysis of the same 45 colorectal cancer cases was performed using the taqman
'15n' assay. Standard reaction conditions were as described in the materials and
methods. Normal DNA was analysed to determine allele status and results are
provided in table 6.3.
Table 6.3:
CCA homozygotes CCGhomozygotes Heterozygotes
Number of cases 16 5 24
A total of 24 of 45cases (53.3%) were informative (heterozygous) at the 15n SNP.
The tumour and normal DNA from these cases was therefore analysed with the
Taqman '15n' assay, using standard conditions, in duplicate.
Fluorescent electrophoresis analysis of dinucleotide repeat markers described in the













Graph demonstrating the results of 15n assay analysis of tumour and normal DNA
from heterozygous cases (n=24). The x-axis exhibits units ofVIC fluorescence and
the Y axis units of FAM fluorescence. Red squares (■) indicate a positive control for
FAM fluorescence. Green squares (■) indicate a positive control for VIC
fluorescence. Green crosses (+) indicate no template controls. Dark blue diamonds (♦)
indicate normal DNA from cases. Light blue diamonds (♦) indicate tumour DNA from
cases exhibiting no evidence of LOH by fluorescence electrophoresis. Purple squares
(■) indicate tumour DNA from cases with clearcut LOH by fluorescence
electrophoresis. Yellow triangles ( ) indicate tumour DNA from cases with possible
LOH by fluorescence electrophoresis.
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Clearly those cases exhibiting some evidence of LOH by fluorescence electrophoresis
fall into 2 separate groups on analysis with the 15n assay, according to which allele






















Graph demonstrating the results of 15n assay analysis of tumour and normal DNA
from heterozygous cases (n=24). The x-axis exhibits units ofVIC fluorescence and
the Y axis units of FAM fluorescence. Red squares (■) indicate a positive control for
FAM fluorescence. Green squares (■) indicate a positive control for VIC
fluorescence. Green crosses (+) indicate no template controls. Dark blue diamonds (♦)
indicate normal DNA from cases. Light blue diamonds (♦) indicate tumour DNA from
cases exhibiting no evidence of LOH by fluorescence electrophoresis. Purple circles
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(•) indicate cases with loss of the CCG allele.Yellow circles ( ) indicate cases with
loss of the CCA allele
Generating an allelic ratio by dividing the FAM signal amplitude by the VIC signal
amplitude allows analysis of these results numerically. There is no overlap in allelic
ratio between those cases exhibiting some evidence of LOH (clearcut and possible),
and those with no evidence of LOH by fluorescence electrophoresis. Numerical




CCA Loss(n=5) 0.47 0.67
CCG loss(n=7) 2.50 37.8
Table 6.4 legend: Table presenting allelic ratios from tumour DNA analysis. Rows
represent cases with each of allelic balance (No LOH), loss of the CCA (FAM
labelled) allele and loss of the CCG (VIC labelled) allele. Columns demonstrate the










f 5 -0.5482 0.1713
n 12 0.4600 0.2163
V 7 1.6009 0.9488
A.11 24 0.5827 0.9294
Fig 6.9 Legend:
Data presented on a log scale, with data points corresponding to the allelic ratio from
each case given as a dot. The three rows indicate tumours with CCA allele loss (f), no
LOFI (n), and CCG allele loss (v). Numbers of cases, mean allelic ratio and standard
deviation for each group are given below.
These data demonstrate that the novel Taqman ' 15n' assay is able to quantify relative
allelic proportions within clinical samples of tumour DNA from colorectal cancer
cases. The assay is able to clearly categorise cases exhibiting LOH in the tumour,
including in those samples where conventional analysis provides ambiguous results.
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6.3.3 Application of 15n Assay to Plasma DNA
Having determined that the assay was able to determine relative proportions of alleles
within clinical samples of tumour DNA, its ability to detect AI in plasma DNA was
investigated.
a) Determining Sensitivity ofDetecting Allelic Imbalance Induced in Plasma
To delineate the sensitivity of the 15n assay at detecting AI within plasma DNA,
quantities ofDNA homozygous for the FAM allele was introduced into plasma from
heterozygous control subjects.
Normal DNA from the buffy coat of a control subject that was homozygous for the
FAM allele was extracted and quantified using spectrophotometry. Serial dilutions of
this DNA were added to 1ml of plasma from a healthy control heterozygous at the
15n SNP, and then the plasma DNA extracted as described. Analysis of these spiked
plasma DNA samples with the 15n assay were performed using standard reagent
concentrations and reaction conditions. Spiking, extraction and analysis were











0.2 0.4 0.6 0.8 1
VIC fluorescence
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Fig 6.10 legend
Graph demonstrating results of real-time analysis of plasma DNA where AI has been
introduced by spiking. VIC fluorescence is demonstrated on the x-axis and FAM
fluorescence on the y-axis. Data points shown are average results from replicates,
with vertical errorbars indicating 95% confidence intervals.
♦ Plasma DNA spiked with lOOng ofFAM homozygous DNA
■ Plasma DNA spiked with lOng of FAM homozygous DNA
Plasma DNA spiked with 5ng of FAM homozygous DNA
A Plasma DNA spiked with 3ng of FAM homozygous DNA
* Indicate all individual results from control (unspiked) samples








These results indicate that the 15n assay is able to discriminate, with statistical
significance, plasma DNA with an artificially induced AI down to a level of 5ng/ml of
plasma. These levels are consistent with those described in the literature for tumour
derived DNA in plasma, and indicate this assay is sufficiently sensitive to potentially
detect tumour derived AI in plasma.
b) Application of 15n assay to clinical plasma samples from Colorectal Cancer
Cases and Controls
Having established the level of sensitivity ofAI detection using the Taqman assay, the
abilityof theassay to detect AI in plasma DNA of colorectal cancer cases was tested,






















Graph demonstrating results of 15n assay analysis of plasma DNA from colorectal
cancer cases and controls.
♦ no template controls
♦ positive controls (VIC)




These results are presented in an alternative way in figure 6.12
Fig 6.12:
Contr, LOH n/a, p •"
Case, LOH no, p
_+ + f + + . +— log {ng_2
Case, LOH poss, p
Case, LOH yes, p
-3.6 -2.4 -1.2 0.0 1.2 2.4
Fig 6.12 legend: Data presented on a log scale, with data points corresponding to the
allelic ratio from each case given as a dot. The four rows indicate plasma results from
controls, tumours without LOH, those with ambiguous LOH and those with clear cut
LOH by microsatellite analysis.
As can be seen from figures 6.11 and 6.12 there is overlap in the allelic ratios between
all groups. Therefore using these methods, realtime PCR using the 15n assay is not
able to discriminate plasma DNA from cases with tumour LOH from cases without
tumour LOH or from controls.
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6.4 Discussion
The experiments in this chapter were designed to further develop the strategy to
exploit the near ubiquitous phenomenon of LOH in colorectal cancer. Given the
limitations of standard fluorescence electrophoresis described in the previous chapter,
an approach was developed to utilise the high performance characteristics of Taqman
PCR.
To this end a novel assay was designed and validated, with the ability to discriminate
different alleles of a commonly heterozygous SNP within exon 15 of the APC gene.
As part of assay validation the assay's performance was compared to that of
conventional LOH detection in detecting LOH resulting in AI in tumour tissue from
colorectal cancer cases. Previous studies of LOH in tumour tissue have used varying
definitions of what degree of loss is counted as demonstrating LOH. Classically LOH
has been scored as being present when the signal indicating one allele is reduced by
70% or more than that detectable in corresponding normal DNA. This stringent
classification is likely to result in few false positives, but may result in some tumours
being classified as not exhibiting LOH that do to lesser degrees. In order to meet these
stringent criteria studies have by necessity employed microdissection of tumour
samples to prevent inclusion of portions of normal DNA within the tumour sample.
This process is both time consuming and expensive, and was not performed in the
work presented in this thesis. Studies have also used smaller decreases in allele signal
to indicate LOH, including 50% or more, which was taken in this work to indicate
clear cut LOH. Less than 20% change in allele signal cannot be termed relevant to
LOH detection due to inherent variability and artefact within analysis by fluorescent
electrophoresis. However cases demonstrating between 20-50% alteration in allele
251
signal may indicate a level of LOH within the tumour, and in this work were
classified as possible LOH. These cases of possible LOH are of particular relevance to
the detection ofAI in plasma DNA, since within plasma DNA only a proportion can
be expected to be derived from the tumour, with the rest constituting 'contaminating'
normal DNA. As such stringent LOH criteria cannot be expected to detect subtle AI
in plasma caused by a tumour, and more accurate methods of quantifying allelic
proportions would be beneficial. The novel assay described in this chapter appear to
fulfil this requirement with the clear and statistically significant classification of
tumour DNA samples to exhibiting LOH, where conventional analysis is ambiguous.
This approach may also have application to studies investigating LOH in tumour
samples only, as it may obviate the need for tumour microdissection, and allows
single step, high throughput analysis of samples.The principal is applicable to
innumerate genetic loci, present on any given chromosomal region of interest.
In view of the assay's ability to discriminate lower levels ofAI in tumour tissue the
assay was then applied to plasma DNA. The results presented in this chapter indicate
that this approach is able to sensitively detect AI that has been artificially introduced
into plasma DNA. A level of sensitivity of 5ng of 'foreign' DNA per millilitre of
plasma is in keeping with levels of tumour DNA that have been described in plasma.
However the results in this chapter demonstrate that the inter-sample variability
increases when there is less plasma DNA available to act as template within a
reaction. This is indicated by the widening error bars with lower levels of spiked
DNA, with the largest confidence interval occurring for control plasma samples. This
is likely to be a reflection of the low quantities of plasma DNA expected in normal
controls, and was not negated by the high number of repeat samples from controls. As
such this approach will favour the detection ofAI in samples with higher
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concentrations of plasma DNA, and hence favour the detection of advanced cases,
where levels ofplasma DNA have been shown to be highest.
A further difficulty with artificially inducing AI in plasma by spiking is that the
introduced DNA has a high degree of integrity. Conversely plasma DNA has been
exposed to the milieu within plasma, including the action of endonucleases, and has
been shown to be largely composed of small, partially digested fragments. As such
the ability to detect low levels of intact DNA may have limited applicability to the
detection of native tumour derived DNA. However determining the level of
detectability of the assay is a necessary process in assessing assay performance and
indicated a high level of sensitivity. Additionally fragmentary DNA may be less of an
issue using a Taqman PCR assay such as the 15n assay, as the primers and probes are
targeted at a relatively short DNA sequence when compared to the longer sequences
involved in fluorescent microsatellite analysis.
Application of the assay using the same reaction conditions to plasma DNA from
cases and controls did not result in discrimination of cases with tumour LOH from
those with no tumour LOH or from controls. Therefore the assay using these methods
does not appear to have potential clinical utility. There are a number of possible
explanations for these negative results, some ofwhich are discussed above and in the
discussion of the previous chapter. However there are a number of technical
considerations that might explain the failure to detect any AI that might be present.
There was a wide variation in the allelic ratio from control plasma DNA, precluding
the generation of a narrow range of allelic ratio outside of which a sample might be
categorised as having AI. This coupled with the variability within cancer cases results
and within replicates of the same samples indicate that template plasma DNA
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introduced into the reactions was variable. A possible explanation of these results is
sampling error, whereby only a small number of plasma DNA alleles are included in
each well, on account of the low plasma DNA concentration. Therefore the numbers
of each allele in each well may vary sufficiently by chance, to result in a large
percentage change in generated signal and hence allelic ratio.
Approaches considered to address this possibility included the use of an initial round
of nested PCR to increase the template copies in the analysis reaction. However if the
initial round of PCR equally amplified both alleles, as would be desired, then the
template for the secondary PCR would simply contain an extrapolation of the
sampling error introduced in the primary PCR. An alternative approach is count a






An alternative approach to detecting AI is a modification of the assay described in the
previous chapter that allows counting of individual alleles within a sample. This
approach is able to address the possibility of sampling error as the cause for poor
discrimination of plasma DNA from cases and controls using the 15n assay, since
many alleles may be assessed by repeating reactions on a large scale.
In order to count alleles individually DNA template is diluted such that there is only
one DNA copy present in every other reaction well. This approach has previously
been employed to detect low levels of genetic changes that might otherwise be
undetectable within the signal from a large number of normal alleles (392).
With regard to allelic ratios, with the template diluted to this level each reaction well
is either empty or contains one or the other allele. Therefore positive wells can simply
be counted and reflect the relative quantities of either allele within the undiluted
template. This process can be repeated on a large scale, and hence allow sampling of
numerous alleles from a template. The description of this approach has been termed
digital SNP analysis (426). and has been applied to tumours (427). ascitic fluid (320)
and plasma DNA (52) to determine allelic ratios within samples. In the study ofDNA
extracted from malignant ascitic fluid associated with several intra-abdominal
malignancies, including colorectal cancer, digital SNP analysis was used to compare
allelic ratios from 20 cases to 20 controls. This study employed 7 SNP markers and
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counted around 100 alleles per sample, and was able to demonstrate AI in 95% of the
cytology proven malignant samples, compared to 5% of the cytology negative
samples.
The potential application of this technique to plasma DNA has been investigated with
respect to ovarian cancer, as a subset of a large study of controls and cases with a
variety of conditions. 330 plasma samples from cases with benign and malignant
diseases, as well as healthy controls, were assessed for plasma DNA concentration. Of
these 54 ovarian cancer cases and 31 controls, had a plasma DNA concentration
greater than 50ng/ml, and were assessed for AI by digital SNP analysis using 8 SNP
markers. An average of 200 individual alleles were counted per plasma DNA sample
and varying levels ofAI were used, from 55% to 95%, to generate receiver-operating
characteristic curves. Optimal performance was generated using an allelic ratio of 0.6,
giving an overall sensitivity of 93% (87% for stages I or II cancer) and a specificity of
100%. In 15 out of 17 matched tumour samples available the AI was concordant
between tumour and plasma (52). The authors of this study concluded that this
approach was a promising method for detecting cancer and should be tested more
extensively on ovarian and other cancers.
Therefore an allele counting approach was assessed in its ability to detect allelic
imbalance in clinical samples from a subset of the prospectively collected series of
cases and controls.
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7.2 Materials and methods
Reaction conditions, assay validation, study subjects and means of analysis are
presented in section 2.8.
7.3 Results
7.3.1 Validation
Allele counting of normal DNA from control heterozygote was performed to assess
whether this approach resulted in allelic balance in clinical samples. Triplicate data is
presented in table 7.1. There was no significant difference in expected compared to






Expected CCA Expected CCG
Replicate 1 521 512 516.5 516.5
Replicate 2 499 503 501 501
Replicate 3 507 502 504.5 504.5
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7.3.2 Test case
To test the approach, one case was selected from the cohort analysed using the 15n
assay, as described in the previous chapter, which had demonstrated clear cut LOH in
the tumour by microsatellite marker analysis and confirmed by analysis using the 15n
assay (case number MD 2530). This was a case of advanced cancer, with metastatic
disease, and a corresponding high plasma DNA concentration allowing sufficient
template for multiple reactions.
Allele counting in tumour DNA was performed at dilution of 1:50 stock tumour
DNA: dH20.
FAM alleles: 81
VICalleles 35 k=9A94, p<0.01
Serial dilution of plasma DNA from case 2530, to a level whereby 1 allele was
present in every other lul aliquot was performed (1 in 200), figures 7.1 and 7.2.









Detector:H 5n FAM Ptot:|ARn vs. Cycle 3 Threshold:fa2o"
Figure 7.1 legend: Raw amplification plot for test case (2530)
259
Figure 7.2:
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Figure 7.2 legend: Allelic discrimination plot for plasma from test case 2530. y axis =
FAM fluorescence, x axis = VIC fluorescence. Dilution of template plasma DNA has
been performed to detect individual alleles (FAM in blue, VIC in red), with only 3
wells containing a CCA and a CCG allele and hence registering as heterozygotes.
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The number of each allele present within each 384 well plate in analysis of plasma
DNA from case 2530 by allele counting is presented in table 7.2.
Table 7.2
CCA allele CCG allele Negative Both
Plate 1 67 65 238 14
Plate2 60 52 269 3
Plate3 108 49 216 11
Plate4 66 37 272 9
Plate5 61 70 234 19
Plate6 64 45 262 13
Plate7 85 56 223 20
Plate8 70 74 224 16
TOTAL 581 448
Comparing these allele totals to those expected if the sample were in allelic balance





Performing the Chi squared (x2) test (with Yates correction) on these values gives x2
8.38 (p=0.004) indicating that the plasma DNA from case 2530 has significant AI,
with a relative excess of the same allele observed in the tumour (FAM).
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Therefore using this allele counting approach it was possible to demonstrate matching
AI in plasma and tumour DNA.
7.3.2 Prospective cohort
Having demonstrated that allele counting is able to detect tumour derived AI in
plasma DNA from a colorectal cancer case, the principle was further investigated by
analysing a prospective cohort in a blinded fashion.
The ascertainment and enrolment of cases remained unchanged from earlier cases in
this study, but a larger volume of plasma was collected from cases and controls, to
allow counting of a large number of alleles. 13 cases and 7 controls with normal
colonoscopy were recruited. Blood was collected and processed, with plasma DNA
extracted, as described in materials and methods.
In all 8 patients (38%) were informative at this SNP, with 4 cancer cases (31%) and 4
controls (50%). These cases and controls underwent counting of over 1000 alleles
without prior knowledge of the allelic status in the 4 corresponding tumours.
Serial dilution of plasma DNA was performed to allow an individual allele in every
other well or less. Dilutions required are provided in chapter 2.
Total number of individual alleles counted in each plasma DNA sample, along with
the x2 value and significance of difference from allelic balance (total number ofFAM
and VIC alleles counted / 2) are provided in table 7.4:
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Table 7.4:
FAM VIC X2 p value
5011 571 565 0.01 0.920
5508 527 485 0.79 0.374
5509 480 484 0.00 1.0
6341 537 519 0.12 0.73
5504 539 547 0.01 0.92
5505 498 527 0.36 0.55
6335 511 512 0.00 1.0
6336 534 518 0.09 0.76
As can been seen from the above results neither the 4 controls or the 4 cases had a
plasma DNA allelic ratio that differed significantly from allelic balance. This would
suggest that this approach is unable to identify cases from controls within this small
cohort. It was however possible that these results simply reflected an un-informative
population sample. Therefore the paired tumours for the 4 informative cancer cases
were analysed for AI by counting >100 alleles at the 15n SNP, and the results
presented in the table below (7.5):
Table 7.5:
FAM VIC X2 pvalue
5011 105 75 2.19 0.14
5508 62 58 0.02 0.89
5509 82 70 0.33 0.57
6341 81 94 0.35 0.55
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As such none of the 4 informative cancer cases demonstrated AI in tumour tissue by
allele counting (>100 alleles), and hence none of the cohort was truly informative.
Additionally microsatellite analysis of these cases as described in chapter 5 did not
show evidence of LOH by assessment with the marker D5 S346.
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7.4 Discussion
There are a number of potential advantages to the allele counting approach described
in this chapter. As with other applications of the 15n assay, PCR products for each
allele are small and the same size, unlike in assessment with microsatellite markers
where there may be bias against detection of the larger allele due to DNA degradation
in plasma. Additionally any given number of alleles may be counted giving the ability
to increase sensitivity and specificity, and the potential to detect more subtle examples
ofAI. As described in the introduction in this chapter, promising results have been
described in ovarian cancer, but this approach had not been previously described in
relation to colorectal cancer.
9
The results described in this chapter investigate the potential of allele counting to
detect tumour derived AI within plasma. Analysis of case 2530 demonstrated that
matching AI in tumour and normal tissue is detectable using this approach. This case
was of advanced colorectal malignancy with a high plasma DNA concentration,
where tumour related AI might be expected to be more readily demonstrated than in
cases with earlier disease stage. Additionally plasma DNA analysis was performed
with prior knowledge of the allelic status of the tumour, which might constitute a
source of potential bias. However the allele counting approach is less susceptible to
interpretation bias on account of the simple nature of the generated results, whereby
samples are either negative (empty) or contain one or the other allele. As such results
are not generated within a continuous spectrum that could be open to interpretation.
The ability to detect only advanced colorectal cancer cases via a blood test would
have limited clinical utility and have no potential for disease screening, therefore
analysis was performed on a prospective cohort that included earlier stage disease.
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This series of 4 heterozygous cancer cases, from a range of cancer stages, did not
show significant plasma DNA AI by allele counting. However allele counting of
matched tumour DNA for these cases did not show AI, hence these tumours could not
be expected to result in plasma AI. Whilst the number of alleles counted from tumour
specimens was a degree smaller than for plasma DNA, analysis of a similar number of
alleles from case 2530 tumour DNA did demonstrate significant AI. Additionally it
seems unlikely that tumours that do not show appreciable AI, as would be detected by
analysing smaller numbers of alleles, would result in detectable levels of plasma DNA
AI in a background of normal DNA. It seems therefore that this small series of cases
and controls was simply not informative. Therefore although proof of principle is
demonstrated by case 2530, analysis of the further prospective cohort neither
disproves nor enhances the potential for detecting tumour derived AI within plasma
DNA of colorectal cancer cases.
Importantly however these cases and controls in plasma allelic balance demonstrate a
specificity for the approach whereby those individuals expected to have no AI were
observed to maintain allelic balance. This contrasts with the poor specificity of
microsatellite analysis described in chapter 5. As such this approach may negate a
technical difficulty relating to assessment of LOH in very low copy number samples,
where observed AI may be the result of artefact.
The previous reports of the allele counting approach discussed in the introduction to
this chapter used stastical modelling to determine how many alleles required to be
counted before it was possible to determine if the sample was in allelic balance or
imbalance, with an average number of 200 alleles counted per plasma DNA sample.
Whilst this method has potential to reduce the number of replicates required it
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assumes the use of a representative sample of alleles. However sampling error is
likely to remain an issue, as demonstrated by the variation in allelic ratios between
plates of the same sample as shown for case 2530 in table 7.1. The proof of principle
work in this chapter looked to circumvent this potential sampling error by performing
large numbers of replicates and hence giving a high probability of analysing samples
representative of the allelic content within the plasma DNA.
There are also a number of disadvantages to the allele counting approach. Having to
repeat very many replicates is inherently expensive. This is particularly the case since
by the nature of the dilution at least every other well is negative, resulting in non-
informative use of reagents. Previous studies have estimated the cost at over $200 per
test (52). Added to this are labour costs, with the technique being time consuming and
labour intensive. There is potential for these costs to be reduced with streamlining of
processing and high throughput technologies, that were employed in this work,
including the use of robots to prepare 384 well plates and automated analysis with
realtime PCR platforms such as ABI 7900 HT. Coupled to this is the need to take
relatively large amounts of plasma from patients to ensure a pool of sufficient alleles
to sample. Previous studies have drawn 3-5mls of plasma per patients (-7.5-12.5 mis
of blood), and in this work 40 mis of blood was taken for the allele counting cohort.
The principle of allele counting is applicable to innumerate SNP loci, which would
enable informativity for very nearly 100% of any cohort with analysis of a panel of
sufficient numbers ofmarkers. This work describes analysis of a cohort of 13 cases at
a commonly heterozygous SNP with a published high rate of LOH of the region in
which it is contained. However none of the 13 cases were informative, therefore it is
likely that a relatively large panel ofmarkers would be required to provide a
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sufficiently sensitive blood test. Given the financial and workload constraints this
would entail it seems unlikely that this approach will yield a viable and practical test
to identify tumour related AI in plasma DNA with clinical utility.
However since the completion of the laboratory work for this project a recent paper
examined low copy number APC mutations in plasma DNA from colorectal cancer
and adenoma patients (323). Whilst the intent was not to detect LOH per se, the
results looked to determine the relative contribution of tumour DNA in the
circulation. They utilised an elegant technique termed BEAMing, that utilises
microemulsions to count many alleles individually within a single reaction. This
approach clearly has advantages over manual dilution and allele counting in terms of
time, labour intensity and cost. BEAMing might therefore constitute the necessary
technological advance that facilitates the assessment of the allele counting strategy
into wider application. However the results from Diehl's paper suggest that the
relative contribution of tumour DNA to the totality of plasma DNA is low,
particularly in respect to early stage disease. These findings warrant further
investigation, since should they prove reproducibly true, then only approaches that
contain a considerable degree of mutation enrichment have the potential to be





In Chapter 1 I presented the rationale for this project. Colorectal cancer is
undeniably an important disease both in terms of the clinical implications of the
disease and the public health challenges it represents. As such further approaches to
influence the incidence and disease survival are a major focus of research interest.
One approach to influencing the effects of disease is to identify means by which to
detect disease at an early stage, when surgical treatment alone effects cure in the
majority of patients. This approach has been extensively tested with regard to
screening of asymptomatic populations for colorectal neoplasia using FOBT, and is
now adopted as a national screening programme for bowel cancer. This national
programme and review of the literature for FOBT establishes the rationale for
screening for bowel cancer, with real benefits within the screened arm of trials,
including an improved stage distribution of disease, improved cancer specific survival
and a reduced cancer incidence in the long term. FOBT screening therefore
constitutes a significant step forward in the management of colorectal cancer.
However there are a number of limitations to FOBT, as there are with other potential
methods of screening, including suboptimal test accuracy as well as limited
acceptability to populations offered screening, manifest as poor compliance rates.
There is therefore a need for the development of other markers of disease to
supplement or replace FOBT by enhancing the diagnostic accuracy of tests, and by
being more acceptable to screened populations and hence widening the net to the
potential benefits of being screened.
It remains the 'Holy Grail' of molecular biology in general, and genetics in
particular, to translate the vast expansion of knowledge ascertained in recent decades
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into increasing numbers of clinically useful tests. The development of biomarkers for
disease detection and monitoring would appear to be an ideal avenue in this regard.
As such there have been considerable efforts directed into this field over recent years.
The discovery and characterisation of free circulating nucleic acids has naturally
become a focus for this type of translational research. The development of clinically
relevant tests on the basis of tumour derived DNA are inherently attractive, not least
since such tests would be essentially non-invasive and hence likely to be highly
acceptable to at risk populations, but also potentially applicable to tumours at multiple
anatomical sites. This said there have published studies in the field of circulating
DNA in cancer patients for more than 15 years, but no tests that are in clinical
practice as yet, although there are encouraging data from head and neck cancer and
EBV circulating DNA that this approach may soon be of clinical use in the
monitoring of disease response and recurrence.
Certainly there is much that remains to be elucidated regarding the biology of
circulating tumour derived DNA. It is clear that not all tumours result in detectable
tumour derived DNA in circulation using currently available methods. With respect to
colorectal cancer it has been suggested that first pass metabolism from the portal
circulation has a role in clearing tumour derived DNA, and that this might explain the
negative results from some assays. It is counterintuitive however that the liver would
clear some mutant sequences whilst others are preserved, and tumour derived DNA
has been reproducibly detected using k-ras assays.
Additionally the source, characteristics, kinetics and clearance of plasma DNA remain
to be determined. It is evident that circulating DNA is a less than ideal template with
which to perform molecular genetic tests. There is evidence that DNA is low copy
number, fragmented, susceptible to inhibitors of assay performance, and that tumour
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derived template may be sparse amongst a relatively much larger quantity of normal
circulating DNA, all of which may have implications to the performance of assays
looking to detect mutant sequences as a surrogate of disease states.
In chapter 2 the generic materials and methods utilised in this project are
documented, with reference to experiment specific methods within individual
chapters.
Chapter 3 examined extraction and quantification ofplasma DNA, with correlation to
disease stage and survival. The technical difficulties ofworking with small volume
plasma DNA were manifest in the experiments of extraction of plasma DNA, and
there remains no consensus on optimal extraction methods in the literature. This
certainly constitutes a major hurdle for the field of circulating nucleic acids research,
limiting comparisons between studies on account of methodological differences.
However it appears to be too early to settle on any given method since technological
advances in extraction techniques and commercially available kits are likely to
continue to generate improving yields and quality templates with which to perform
analysis. That said a reproducible and widely employed commercial extraction kit was
employed and allowed generation of results presented throughout this work.
I subsequently quantified plasma DNA using a number of techniques, and
demonstrated the picogreen assay to be the most accurate of these for assessment of
quantity in relation to plasma DNA. Analysis of a prospective series of patients
employing this method demonstrated a significant difference in total plasma DNA
concentration between cases and controls. Subsequent to the completion of the
laboratory work for this project, a number of papers, examining smaller series of
cases, have demonstrated similar results, with a degree of variation in the sensitivity
and specificity of plasma DNA quantity as a marker of colorectal cancer. The ability
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of plasma DNA concentration alone to detect colorectal cancer was suboptimal, and
likely multifactorial. There remains to be sufficient work detailing the effects of
benign and inflammatory diseases on plasma DNA concentration which might inform
the selection of super controls and hence improve specificity of testing.
In this work there was not an association between disease stage or suvival and plasma
DNA quantity, although in subset analysis numbers were small. There was a trend to
poorer survival with the highest levels of plasma DNA, which may be a reflection of a
tendency for advanced disease to generate the highest concentrations. However this
trend was also observed in cases with early stage disease where survival would be
expected to be good. This association warrants further investigation with a view to
application clinically, as may be of relevance to disease states where clinical staging
is suboptimal such as polyp cancers. The potential ability of plasma DNA
quantification to augment current screening modalities such as FOB would require
assessment on large asymptomatic populations which might be accessed through
current screening programmes. Each of the potential applications of plasma DNA
assessment would again require further knowledge of plasma DNA levels in
asymptomatic populations, which may alter with other disease states or vary within
different demographic subsets of the population.
Chapter 4 details experiments designed to detect tumour specific mutations
within plasma DNA. Assays were developed to the poly A tract of the TGFBR II gene
and to a mutational hotspot of the K ras gene. Initial experiments to validate the
TGFB assay were hampered by technical difficulties that necessitated multiple
reagent changes, and ultimately a change of marker fluoresence. Subsequently I
demonstrated a limit of detectability of this assay to levels applicable to mutant
plasma DNA in spiking experiments using exogenous positive control DNA.
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However these experiments utilised DNA derived directly from cell culture, which is
likely to be non-fragmentary in nature. Application of the assay to clinical plasma
samples resulted in positive results for all samples likely reflecting an artefact from
the multiple numbers of replication cycles. This would suggest that this approach has
limited applicability to plasma DNA when assessing repetitive polyA tracts. Negative
results were also obtained from the assay designed to detect K-ras mutations.
Chapter 5 presents results of fluorescent microsatellite analysis, at 3
polymorphic markers on 3 chromosomes, in matched normal, tumour and plasma
DNA. Using this small panel of markers gave good levels of informativity for a
relatively large series of patients, with approaching two thirds of cases having LOH in
tumour tissue at one or more, highlighting the strategic rationale for this approach.
Analysing for changes in allelic ratio in plasma as a marker of the underlying tumour
had suboptimal sensitivity and low specificity. These findings have been previously
described in relation to LOH in plasma, although the maximal sensitivity of 67.3% is
encouraging. Ofmore concern for the applicability of this approach is the poor
specificity with a large number of controls exhibiting unexplained changes in plasma
allelic ratios. However further data from experiments quantifying plasma DNA
suggest that poor specificity may be partly a function of low copy number DNA, since
there was a significantly lower plasma DNA concentration from false positive
controls compared to true negative controls. This might suggest that the very low
copy number DNA in some controls results in artifact in this form of plasma DNA
analysis hampering the identification of normal subjects.
Experiments in chapter 6 looked to exploit the potentially increased accuracy
afforded by real time PCR, with the development of a SNP based real time PGR
chromosome 5 assay. A functioning assay was designed and validated to clearly
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discriminate homozygotes and heterozygotes. The assay was then assessed in its
ability to detect allelic imbalance within tumour samples from a series of colorectal
cancer patients. The assay was shown to clearly categorise tumours according to
allelic proportion, including in a subset of patients in whom fluorescent microsatellite
analysis was ambiguous. The assay was then assessed in its limit of detectability by
artificially introducing allelic imbalance in control plasma by the addition of
homozygous normal DNA, showing a limit of detectability of between 3-5ng /ml of
added exogenous DNA. The assay was then applied to a series of cancer cases and
controls, but was unable to discriminate between these plasmas using this approach.
Whilst the results of this assay in tumour samples and in artificially induced allelic
imbalance were encouraging, the assay was not sufficiently accurate to be
discriminatory in regard to plasma DNA. It appears that this approach, in itself, is not
sufficient to negate the difficulties of using plasma DNA substrates. A potential
explanation of these findings is a function of the low copy number DNA in plasma,
resulting in a non-proportional number of alleles being introduced into each reaction
well.
Therefore in Chapter 7 experiments were performed to try to obviate this
potential sampling error, by counting large numbers of individual alleles. This
approach was initially validated on normal control DNA, and then performed on a test
case, with high levels of plasma DNA and LOH in the tumour. This analysis
demonstrated matching allelic imbalance in plasma and tumour tissue, showing proof
of principle for this approach. On the basis of this allele counting was assessed in a
small series of heterozygous cases and controls. Plasma analysis was performed in a
blinded fashion in order to limit potential bias. All of these cases and controls
demonstrated allelic balance within plasma, but subsequent analysis showed allelic
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balance in the cases tumours also. In retrospect therefore it would have been better to
perform unblinded analysis to ensure that the series included cases demonstrating
allelic imbalance at the relevant locus, which might then be detected in the plasma.
That said this non-informativity of the series would be potentially circumvented by
assessment at further loci. These results also constitute an important negative, since
this approach demonstrated high specificity, in that assessment of each plasma
demonstrated allelic balance and hence the presence of no false positives. This would
suggest that assessing sufficient numbers of alleles for each plasma sample improves
test accuracy. This improved specificity was however hard fought, requiring labour
intensive and expensive methods that would not be practical to apply to clinical
practice. That said recent developments that allow examination of multiple individual
alleles by in a single reaction tube, or by chip based arrays, might circumvent some of
these limitations in the future. Pursuing these approaches seems worthwhile given the
strategic informativity of LOH at a panel ofmarkers both in colorectal and other
cancers.
At present it appears positive results from plasma DNA assays are to a large
degree dependent on steps that produce enrichment ofmutant sequences. Certainly the
wealth of literature regarding k-ras mutations in colorectal and other cancers, with
reasonable sensitivity and specificity, employ methods that select and amplify mutant
sequence. As such low copy number mutant template within an excess of normal
sequences may become detectable, but these assays have ability to be qualitative only
and provide little information regarding relative proportions of tumour derived DNA
within plasma. These difficulties may be obviated by technological advances that
allow the assessment ofmultiple alleles or markers in single experiments.
Alternatively techniques that enable improved extraction or quality of template such
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as whole genome amplification may result in more robust template with which to
assess quantitative assays.
There will remain however some important strategic questions, particularly since
assessments ofplasma based assays to date have been performed on subjects with
proven cancer detected by other means rather than on asymptomatic populations.
Many cancers have been shown to demonstrate genetic alterations the same genes,
such as p53. If an asymptomatic person was demonstrated to harbour such a mutation
in the plasma, much research remains to be done to inform how that patient might be
further investigated clinically to confirm or exclude any of these disease states. It is
likely that any test that comes to clinical utility will involve a panel of markers, and
some information as to likely disease process may be determined from the pattern of
changes across the panel, such as patterns of LOH at given chromosomal locations,
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Information Sheet:
Full project title
Development of techniques for detecting gene mutations in plasma of patients
undergoing investigation and treatment for benign or malignant colorectal
tumours
Short lay title
Gene mutations in plasma of patients undergoing investigation and treatment
for suspected bowel conditions
Principal Investigator
Professor MG Dunlop MD FRCS
Department of Surgery
Western General Hospital, Edinburgh EH4 2XU
Contact number 0131 537 1546 (or 467 8439 in event of any urgent problem relating to the
study)
Independent advisor (who is not involved in the research but can provide further information)
Mr IMC Macintyre FRCS
Department of Surgery
Western General Hospital, Edinburgh EH4 2XU
Tel 0131 537 1549
Clinical protocol
Detecting changes in DNA in the blood of patients undergoing investigation and treatment for
benign or malignant colorectal tumours
Invitation:
You are being invited to take part in a research study. Before you decide it is important for
you to understand why the research is being done and what it will involve. Please take time
to read the following information carefully and discuss it with others if you wish. Ask us if
there is anything that is not clear or if you would like more information. Take time to decide
whether or not you wish to take part.
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Consumers for Ethics in Research (CERES) publish a leaflet entitled 'Medical Research and You'.
This leaflet gives more information about medical research and looks at some questions you may want
to ask. A copy may be obtained from CERES, PO Box 1365, London N16 OBW.
Thank you for reading this.
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What is the purpose of this study?
Certain diseases of the large bowel result from changes in the genetic code (DNA) in the
cells lining the bowel. This study is designed to determine how often, and for which
diseases, the same genetic changes seen in the bowel can be detected in the blood. The
ultimate aim is to be able to detect bowel diseases, including growths in the bowel, by way of
performing a blood test.
Why have I been chosen?
We need to test people who are undergoing investigation and/or treatment for a suspected large bowel
condition. We also need to test people who do not have any known bowel condition in order to be
sure that our test results don't simply occur in everyone whether they have bowel disease or not.
Do I have to take part?
It is up to you to decide whether or not to take part. Ifyou do decide to take part you will be
given this information sheet to keep and be asked to sign a consent form. Ifyou decide to take part
you are stillfree to withdraw at any time and without giving a reason. A decision to withdraw at any
time, or a decision not to take part, will not affect the standard ofcare you receive.
What will happen if I take part?
The study will make no difference to how your condition is treated, or how often you are
followed up after treatment. If you agree to take part in the study you will be asked to sign a
form confirming your consent to be involved. We will then require a blood sample, which can
be taken at the same time as routine blood tests that occur as part of your tests or treatment
anyway. Similarly we would take a further blood test following your investigation or
treatment. Should you be found to have a disease of the large bowel during your tests, or
you are undergoing an operation for a known large bowel disease, then we would take a
portion of the diseased tissue. We will perform genetic tests on both the diseased tissue and
the blood samples. We also require to examine specific parts of your medical notes, namely
your operation and pathology reports, so that we can relate findings in these to the results of
your genetic tests.
What do I have to do?
Allow us to take two blood samples from you, and a piece of tissue at your operation or test.
There are no other requirements of this study, and you do not need to take any further
action.
What is the procedure being tested?
This is a study looking at a series of new tests, in order to determine if they might be able to
provide additional information about diseases of the large bowel. For example, it might be
possible to tell whether people have a benign or malignant tumour simply using a blood test.
Are there any side effects or risks of taking part?
There are no side effects or risks to taking part. You will have blood taken routinely as part of
your care, and the study only requires some additional samples.
What are the potential benefits of taking part?
There is no direct benefit to yourself for taking part in this study. The information we get from
this study may help us diagnose and treat future patients with large bowel diseases better.
What if something goes wrong?
It is not foreseen that you can come to any harm by taking part in this study, however if you
are harmed by taking part in this research project, there are no special compensation
arrangements. If you are harmed due to someone's negligence, then you may have
grounds for a legal action but you may have to pay for it. Regardless of this, if you wish to
complain, or have any concerns about any aspect of the way you have been approached or
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treated during the course of this study, the normal National Health Service complaints
mechanisms should be available to you.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be kept
strictly confidential. Any information about you which leaves the hospital/surgery will have
your name and address removed so that you cannot be recognised from it. Because your
participation has no implications for your clinical care, we will not inform your General
Practitioner of your participation in this study.
What will happen to the results of the research study?
You will not be informed of the results of the genetic tests. As this is a study of tests at an
early stage of their development, the results of them will not have a proven meaning that
would relate to your health or your treatment. Similarly doctors involved in your care will not
be informed of the results.
The results of the study may be published in medical journals, but it will not be possible to
identify you from these. Should you be interested in the collective results you may get details
of where they have been published (probably in 2003) from the contact person given below.
Who is Organising and Funding the Research?
The study is being undertaken by researchers employed by the University of Edinburgh.
The study is funded by grants from Cancer Research UK (formerly the Cancer Research
Campaign) and the Chief Scientists Office (CSO). The doctors involved in your care are not
paid for your inclusion into this study.
Who has reviewed the study?
This work forms part of a major project aimed at combating cancer of the large bowel and
funded to Professor Dunlop by the largest cancer charity in the UK, Cancer Research UK.
This work has been the subject of intensive peer review by Cancer Research UK and has
gone forward for funding for a further 5 years. The Lothian Research Ethics Committee has
also reviewed the ethical aspects of the study.
Contact for further information:
Dr Andrew Clark
Clinical Research Fellow
MRC Human Genetics Unit
Western General Hospital
Edinburgh
Tel: 0131 332 2471 Ext. 2106
You will be given a copy of this information sheet and a copy of the consent form to keep.
Centre Number:
Study Number:
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Development of techniques for detecting gene mutations in plasma of patients
undergoing investigation and treatment for benign or malignant colorectal
tumours
Short lay title
Gene mutations in plasma of patients with colorectal tumours
Clinical protocol
Detecting changes in DNA in the blood of patients undergoing investigation and treatment for




Prof. MG Dunlop MD FRCS, Department of
Western General Hospital, Edinburgh EH4
Tel. number 0131 537 1546
Independent advisor
Surgery
(a doctor not involved in the research
2XU
but able to provide further information)
Mr IMC Macintyre FRCS, Department of
Western General Hospital, Edinburgh EH4
Tel 0131 537 1549
I have read and understood this consent form and Information Sheet and had
opportunity to ask questions about them
I understand that my participation is voluntary and that I am free to withdraw at
any time, without giving any reason, without my medical care or legal rights being
affected.
I agree to participate in this study which requires taking a blood sample before
and after a bowel test or operation and for a tissue sample/biopsy to be collected
and analysed.
I agree to review of my medical and pathology records, as well as records held on
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174.4LOH 52.2LOH 17.4NOLOH 23.5NOLOH 2.3NOLOH 30.1NOLOH 14.3NOLOH n/a 13.7NOLOH 39.9NOLOH 13.4NOLOH 3.7NOLOH 10.3NOLOH Nl 120LOH 23.2NOLOH 6.4NOLOH 177.1LOH 15.1NOLOH 228.5LOH 6.8NOLOH 96.4LOH 291.5LOH 19.6NOLOH 65.3LOH 32.6NOLOH 19.5NOLOH 35.5NOLOH
2.268137848 2.690738474 1.7030185 1.603993776 1.88526373 0.633674255 homozygous 1.75148816 noamp 1.608733624 0.7219593 1.622454254 2.94084507 1.692772277 1.449419569 1.391712275 3.838178295 1.429275362 1.863082863 3.605813953 2.099423631 complete 1.24118229 noamp 1.948295455 0.990180033 1.87947736
NOLOH(C N) LOH(con) noLOH(dis) NOLOH(C N) NOLOH(C N) LOH(denovo) Nl NOLOH(C N) Nl Nl NOLOH(C N) LOH(denovo) NOLOH(C N) LOH(denovo) Nl noLOH(dis) NOLOH(C N) LOH(denovo) LOH(con) NOLOH(C N) noLOH(dis) LOH(denovo) noLOH(dis) LOH(con) NOLOH(C N) Nl NOLOH(C N) LOH(denovo) NOLOH(C N)
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noamp
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noamp n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
n/a complete n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
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Nl
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noamp /complete homozygous noamp 1.349431568 noamp noamp noamp noamp noamp 1.904458599 noamp noamp 0.586330935 noamp 1.558788362 noamp noamp 3.176340275 2.14412678 homozygous noamp 0.984050367 noamp noamp 2.063860493
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Page10


















































































































































































































































































































































appendix4 1.141019956noLOH(con; homozygousNI homozygousNI 2.920552677LOH(dis) 2.381093058noLOH(con; 1.667342799noLOH(dis) 3.01986755LOH(dis) 1.504751985noLOH(con;
NI






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.18875104.2046254130 65 13.5 9864 1.32615531.301386082 292416715 49
3mean






1.280620185 1.09763848 1.047018302 1.309284655 1.000500623 0.741874896 1.368642045 0.982847287
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yestovie
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2015
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2487
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